[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"\"}":3,"_public_publisher_byId_83289c5a-0e1a-4089-90d0-8447ef02c8ba":656,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"totalCitation\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:83289c5a-0e1a-4089-90d0-8447ef02c8ba,\"}":671},{"meta":4,"data":6},{"total":5},"117",[7,60,176,207,299,413,445,480,543,572],{"id":8,"createTime":9,"updateTime":10,"relativeEntities":11,"slug":12,"properties":13,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":29,"subjectFields":30,"manageAffiliations":31,"indexDatabases":32,"url":33,"thumbnailPath":34,"statistic":35,"gsStatistic":26,"type":26,"analyzePriority":26},"5a09599f-54d1-44c3-8f16-3847ac552024","2023-08-17T04:28:50.832+00:00","2025-10-13T23:58:52.517+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Truy%E1%BB%81n-nhi%E1%BB%85m-Vi%E1%BB%87t-Nam",{"country":14,"issn":16,"introduce":18,"title":21},{"VOID":15},"VN",{"VOID":17},"08667829",{"EN":19,"VI":20},"{\"ops\":[{\"insert\":\"Vietnam Journal of Infectious Diseases is a social - professional forum of the Vietnam Society for Infectious Diseases, whose responsibility is to introduce the researches, the scientific advances in Vietnam and from the world; to contribute to the improvement of knowledges for health care staffs about clinic, treatment, guideline, prevention, epidemiology for infectious diseases, HIV\u002FAIDS and community health care; to provide, exchange and publish scientific information to the public accurately and promptly.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Vietnam Journal of Infectious Diseases publishes in the whole country; serves the professional work for researchers, clinical staffs, administrators, undergraduate and postgraduate students who are working and studying in the infections, tropical diseases and HIV\u002FAIDS from central to local levels, also organizations and individuals in the world who are interested in infectious and tropical diseases and prevention for HIV\u002FAIDS.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Editor in Chief:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Kinh. - Chairman of Editorial Board\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Prof. Dr. Nguyen Van Mui.\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Headquarter:\"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Address:\"},{\"insert\":\" Level 6, National Hospital for Tropical Diseases, No. 78 Giai Phong Street, Dong Da District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tel:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913552672\"},\"insert\":\"0913552672\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"insert\":\".\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Bank account:\"},{\"insert\":\" 0021000275119, Vietcombank Hanoi Branch. Transaction office No. 7, 402 Tran Khat Chan, Hai Ba Trung District, Hanoi city, Vietnam.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Tạp chí Truyền nhiễm Việt Nam là cơ quan ngôn luận của Hội Truyền nhiễm Việt Nam, chịu sự lãnh đạo, chỉ đạo trực tiếp của Thường vụ Ban Chấp hành Hội Truyền nhiễm Việt Nam; sự kiểm tra, giám sát về nghiệp vụ báo chí của các cơ quan chức năng quản lý báo chí thuộc Bộ Thông tin và Truyền thông và Ban Tuyên giáo Trung ương Đảng.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí có trách nhiệm giới thiệu các công trình nghiên cứu khoa học, những tiến bộ khoa học trên thế giới và trong nước, góp phần nâng cao kiến thức khoa học cho cán bộ y tế về lâm sàng, điều trị, hướng dẫn, dự phòng, dịch tễ học các bệnh truyền nhiễm, HIV\u002FAIDS và chăm sóc sức khỏe cộng đồng; cung cấp, trao đổi, phổ biến các thông tin khoa học tới công chúng chính xác và kịp thời.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Tạp chí xuất bản 03 tháng\u002F01 kỳ và được phát hành qua Bưu điện và tự phát hành trong phạm vi toàn quốc.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Lãnh đạo Tạp chí: \"},{\"attributes\":{\"header\":4},\"insert\":\"\\n\"},{\"insert\":\"Tổng Biên tập: ThS.BSCKII Nguyễn Trung Cấp\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"Phó Tổng Biên tập:\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"insert\":\"            TS.BSCKII Phạm Ngọc Thạch\"},{\"attributes\":{\"align\":\"justify\",\"blockquote\":true},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Trụ sở tòa soạn:\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Địa chỉ: Tầng 6, Bệnh viện Bệnh Nhiệt đới Trung ương, 78 đường Giải Phóng, phường Phương Mai, quận Đống Đa, thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Điện thoại:\"},{\"insert\":\" \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:02435765464\"},\"insert\":\"02435765464\"},{\"insert\":\" - \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Ftel:0913228072\"},\"insert\":\"0913228072\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Email\"},{\"insert\":\": \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Findex\u002Fadmin\u002Fcontexts\u002Fmailto:tungphamvan52@gmail.com\"},\"insert\":\"tungphamvan52@gmail.com\"},{\"insert\":\"; \"},{\"attributes\":{\"color\":\"#008d45\",\"background\":\"transparent\",\"link\":\"https:\u002F\u002Fbvnd.vojs.vn\u002Findex.php\u002Fvjid\u002Fmanagement\u002Fsettings\u002Fcontext\u002Fmailto:tapchitruyennhiem@gmail.com\"},\"insert\":\"tapchitruyennhiem@gmail.com\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Tài khoản:\"},{\"insert\":\" Số 0021000275119 Ngân hàng Ngoại thương Việt Nam, chi nhánh Hà Nội (Vietcombank Hà Nội). Phòng giao dịch số 7, 402 Trần Khát Chân, quận Hai Bà Trưng, Thành phố Hà Nội.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":22,"VI":23},"Vietnam Journal of Infectious Diseases","Tạp chí Truyền nhiễm Việt Nam","PUBLISHER","VERIFIED",null,"Admin update database","PENDING",51,[],[],[],"https:\u002F\u002Ftruyennhiemvietnam.vn\u002Findex.php\u002Fvjid","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F5a09599f-54d1-44c3-8f16-3847ac552024\u002Fadb0e52bf25e0de580fd4289519cb8bf.jpg",{"impactFactor":36,"impactFactorByYear":37,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":41,"totalPublicationByYear":42,"totalCitation":48,"totalCitationByYear":49,"totalCitationPerPublication":54,"totalCitationPerPublicationByYear":55,"hindexLast5Year":59,"hindex":59},0,{"2022":38,"2023":39,"2024":40},0.01,0.03,0.13,315,{"2020":43,"2021":44,"2022":45,"2023":46,"2024":47},63,58,57,65,72,43,{"2020":50,"2021":51,"2022":52,"2023":53},8,15,9,11,0.14,{"2020":40,"2021":56,"2022":57,"2023":58},0.26,0.16,0.17,3,{"id":61,"createTime":62,"updateTime":63,"relativeEntities":64,"slug":65,"properties":66,"entityType":24,"verifyStatus":25,"verifyTime":78,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":79,"subjectFields":80,"manageAffiliations":81,"indexDatabases":136,"url":137,"thumbnailPath":26,"statistic":138,"gsStatistic":155,"type":175,"analyzePriority":26},"25b6bd10-676c-40c0-8dc3-356d1679a284","2023-05-19T02:22:33.430+00:00","2026-06-18T23:33:57.141+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Y-D%C6%B0%E1%BB%A3c-h%E1%BB%8Dc-C%E1%BA%A7n-Th%C6%A1",{"country":67,"issn":68,"introduce":70,"title":73,"gsId":76},{"VOID":15},{"VOID":69},"23541210",{"EN":71,"VI":72},"\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">04\u002F10\u002F2015 Ministry of Information and Communications allowed Can Tho journal of medicine and pharmacy to operate (102 \u002FGP-BTTTT)\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">07\u002F16\u002F2015 Can Tho journal of medicine and pharmacy is internationally recognized: ISSN 2354-1210\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">In 2016, The journal has been included in the list of medical science journals by The State Council for professorship which is awarded a work score of 0-0.5 points for a published article.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Can Tho Journal of Medicine and Pharmacy welcome original works that haven’t been submitted or published in other medical journals. Posts must contain content related to one of the journal’s categories.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The content published\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The journal is divided into 3 categories:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Scientific research article: are valuable scientific works, which have been researched and accepted.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Overview of medicine, biology and pharmacy: serving the objective of continuing training in the fields of medicine, biology and pharmacy; to systematize classical and modern knowledge.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Update information on new knowledge about medicine, biology, pharmacy in the country and in the world.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Scope\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Publication and introduction of scientific research in the fields:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Medicine (internal medicine, surgery, pediatrics, obstetrics and gynecology, odonto-stomatology, laboratory, oncology, traditional medicine, nursing).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Biology (genetics, biotechnology).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">+ Pharmacology (pharmaceutics, drug quality analysis-control, synthetic pharmaceutical chemistry, biochemistry, pharmacognosy, botany, clinical pharmacy).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- To enhance the quality of undergraduate, postgraduate education, scientifically researching and meet the necessary treatment in hospital.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Introducing the updated domestic and oversea information about science technology to promote scientific research and exchanging technology in local, other universities.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">- Exchanging pharmaceutical and medical information for social health developing in the Mekong Delta and Vietnam.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">The object\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Postgraduate students, student of Can Tho University of Medicine and Pharmacy, scientists from schools, research institutes, hospitals, health centers, pharmaceutical companies of the Mekong Delta; other provinces and regions in Vietnam and other country.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Address\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Headquarters of Can Tho Journal of Medicine and Pharmacy, located Scientific Research and International Cooperation Office: 179 Nguyen Van Cu Street, An Khanh Ward, Ninh Kieu District, Can Tho City, Vietnam.\u003C\u002Fspan>\u003C\u002Fp>","\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Ngày 16\u002F7\u002F2015, Tạp chí Y Dược học Cần Thơ được cấp chỉ số quốc tế: ISSN 2354-1210.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 4\u002F2016, Tạp chí đã được Hội đồng Giáo sư ngành Y đưa vào danh sách các tạp chí khoa học Y học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Năm 2020 Tạp chí Y Dược học Cần Thơ đã được phê duyệt vào danh mục của các Hội đồng Giáo sư ngành Dược học được tính điểm công trình 0-0,5 điểm cho một bài báo đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ ra 12 số\u002Fnăm, 180-200 trang\u002Fsố.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Từ tháng 12\u002F2022 Tạp chí Y Dược học Cần Thơ là thành viên của hệ thống Crossref và từ tháng 01\u002F2023 tạp chí thực hiện bình duyệt online kín 2 chiều nhằm tăng tính minh bạch, tin cậy của các công trình nghiên cứu khoa học và đảm bảo tốt nhất chất lượng khoa học của bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ, mục đích và phạm vi của tạp chí\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tôn chỉ và mục đích hoạt động của tạp chí: xuất bản nhằm mục đích phổ biến kết quả từ các đề tài nghiên cứu khoa học; giao lưu trao đổi khoa học, chia sẻ kinh nghiệm, học tập, đồng thời cập nhật thông tin khoa học mới trong các lĩnh vực y, sinh, dược học trong và ngoài nước.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phạm vi của tạp chí: Tạp chí xuất bản được chia thành 3 chuyên mục: (i) Bài báo nghiên cứu khoa học là kết quả công trình nghiên cứu khoa học có giá trị đã được triển khai nghiên cứu, (ii) Bài tổng quan y, sinh, dược học: phục vụ mục tiêu đào tạo liên tục trong lĩnh vực y, sinh, dược học; nhằm hệ thống hóa những kiến thức kinh điển và hiện đại; (iii) Thông tin cập nhật kiến thức mới về y, sinh, dược học trong nước và trên thế giới.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Chính sách truy cập mở\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ áp dụng chính sách truy cập mở đối với các bài báo đã xuất bản đến với độc giả, nhằm mở rộng cơ hội tiếp cận các kết quả nghiên cứu chất lượng cao và tăng cường trao đổi kiến thức. Tạp chí đăng tải trực tuyến (miễn phí) toàn văn các bài báo được công bố trên website của Tạp chí (https:\u002F\u002Ftapchi.ctump.edu.vn).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đạo đức xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ cam kết tuân thủ đạo đức xuất bản phù hợp với các hướng dẫn và tiêu chuẩn của the Committee on Publication Ethics (COPE), tuân thủ các nguyên tắc của COPE’s Core Practices, Best Practices Guidelines for Journal Editors và Guidelines on Good Publication Practices.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Bản thảo bài báo chỉ được chấp nhận khi được tác giả chịu trách nhiệm chính cam kết các nội dung sau: Các nội dung của bản thảo chưa được đăng tải toàn bộ hoặc một phần ở các tạp chí khác; Tất cả các tác giả đều có đóng góp một cách đáng kể vào quá trình nghiên cứu hoặc chuẩn bị bản thảo và cùng chịu trách nhiệm về các nội dung của bản thảo; Tuân thủ các biện pháp đảm bảo đạo đức nghiên cứu (ví dụ thỏa thuận đồng ý tham gia nghiên cứu).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Cam kết bảo mật\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí cam kết thực hiện và tuân thủ các quy định của luật và các văn bản hướng dẫn liên quan đến bảo mật thông tin cá nhân trên không gian mạng. Các thông tin mà người dùng (tác giả, độc giả, biên tập viên, người phản biện) nhập vào các biểu mẫu trên Hệ thống Quản lý xuất bản trực tuyến của tạp chí chỉ được sử dụng vào các mục đích đã được tuyên bố rõ ràng và sẽ không được cung cấp cho bất kỳ bên thứ ba nào khác, hay dùng vào bất kỳ mục đích nào khác.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Phí gửi bài\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng bài: 1.000.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Lệ phí gửi đăng nhanh: 1.500.000đ\u002Fbài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với tác giả là cán bộ viên chức thuộc Trường Đại học Y Dược Cần Thơ thì được hỗ trợ 50% lệ phí gửi đăng bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Đối với sinh viên thực hiện đề tài nghiên cứu khoa học cấp trường được hỗ trợ 100% lệ phí đăng bài ( Tác giả gửi đính kèm “ Quyết định về việc giao tổ chức thực hiện đề tài nghiên cứu khoa học cấp Trường của sinh viên”).\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Hình thức nộp lệ phí:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Tiền mặt:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Nộp trực tiếp tại Phòng Tài chính - Kế toán, Trường Đại học Y Dược Cần Thơ, số 179 Nguyễn Văn Cừ, P. An Khánh, Q. Ninh Kiều, thành phố Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Chuyển khoản:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tên Tài khoản: Trường ĐHYD Cần Thơ, Số TK: 0111000115668, tại ngân hàng Vietcombank chi nhánh Cần Thơ.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Thời gian: Áp dụng từ ngày 01\u002F02\u002F2023.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">* Phí gửi bài không được hoàn trả khi bài viết bị từ chối hoặc tác giả xin rút bài viết.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Quy trình phản biện bài báo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tạp chí Y Dược học Cần Thơ thực hiện quy trình phản biện kín hai chiều nghiêm ngặt. Danh tính của những người phản biện không được tiết lộ cho các tác giả và ngược lại. Quy trình thẩm định bài báo đăng gồm các bước sau:\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tiếp nhận bản thảo\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Tác giả liên hệ gửi bản thảo đến Tạp chí qua hệ thống trực tuyến tại website: https:\u002F\u002Ftapchi.ctump.edu.vn. Hướng dẫn về cách đăng ký, gửi bài và chuẩn bị bản thảo được cung cấp trên website của Tạp chí.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sàng lọc sơ bộ\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Sau khi Tòa soạn nhận được bài báo của tác giả, Ban Thư ký sẽ tiến hành kiểm tra sơ bộ bài báo (các yêu cầu về nội dung và hình thức). Những bài báo không đúng quy cách hoặc có nội dung không phù hợp hoặc vi phạm bản quyền sẽ bị từ chối (Ban Thư ký thông báo phản hồi đến tác giả trong vòng 1 tuần). Những bài báo đủ điều kiện, được Ban Thư ký tòa soạn chuyển đến Ban Biên tập có cùng chuyên môn với nội dung bài báo để đề xuất người phản biện. Thời gian kể từ khi Ban Biên tập nhận bài báo đến khi đề xuất người phản biện bài báo chậm nhất là 5 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Vòng phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký gửi bài và yêu cầu phản biện đến 02 phản biện độc lập.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Các phản biện gởi nhận xét cho Ban Thư ký. Thời gian từ khi gửi bài cho phản biện đến khi nhận ý kiến của phản biện tối đa là 20 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xử ký kết quả phản biện\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Nếu ý kiến đồng ý cho đăng và không cần chỉnh sửa, Ban Thư ký tiếp tục đăng bài theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Nếu ý kiến đồng ý đăng và cần chỉnh sửa, Ban Thư ký sẽ thông tin đến tác giả chỉnh sửa theo yêu cầu của người phản biện. Thời gian chỉnh sửa và gửi lại kéo dài không quá 2 tuần, từ khi tác giả bài báo nhận được thông tin (Quá trình này có thể lặp lại tối đa 2 lần\u002F1 bài báo). Khi có sự thống nhất, đồng ý của người phản biện; bài báo được tiếp tục đăng theo qui trình.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Những bài báo có chất lượng không đạt yêu cầu, cả 2 phản biện không đồng ý cho đăng sẽ bị Tòa soạn từ chối đăng.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">Xuất bản\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">1. Ban Thư ký tổng hợp các bản thảo đã được tác giả hoàn thiện sau thẩm định trình Ban Biên tập xem xét, Tổng Biên tập phê duyệt, quyết định bài đăng theo các tiêu chí: sự phù hợp nội dung với tôn chỉ và mục đích, thể loại bài viết (ưu tiên các bài có bài có nghiên cứu chuyên sâu, hàm lượng khoa học cao), đóng góp mới bài báo, bài báo được ưu tiên đăng trong số gần nhất của Tạp chí theo thứ tự: tính thời sự, chất lượng bài báo và thời gian gửi bài.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">2. Ban Biên tập và Ban Thư ký biên tập bản thảo, chế bản, đọc rà soát lỗi. Thời gian hoàn thành từ 10-15 ngày.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">3. Ban Thư ký có trách nhiệm thông báo cho tác giả bài báo (bằng e-mail) về tình hình phê duyệt bài báo, thời gian, số kỳ, tập xuất bản bài báo theo qui định.\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>\u003Cp>\u003Cspan style=\"color: rgb(0, 0, 0);\">4. Danh sách bài báo theo số Tạp chí được in ấn và phát hành trong năm định kỳ được công bố chính thức trên website: https:\u002F\u002Ftapchi.ctump.edu.vn\u003C\u002Fspan>\u003C\u002Fp>\u003Cp>\u003Cbr>\u003C\u002Fp>",{"EN":74,"VI":75},"Cantho Journal of Medicine and Pharmacy","Tạp chí Y Dược học Cần Thơ",{"VOID":77},"wcQ1uqwAAAAJ","2023-05-30T08:17:21.868+00:00",32,[],[82],{"id":83,"createTime":84,"updateTime":85,"relativeEntities":86,"slug":87,"properties":88,"entityType":98,"verifyStatus":25,"verifyTime":99,"verifyNote":26,"syncStatus":28,"languages":100,"translateLanguages":26,"viewCount":103,"url":104,"parentIds":105,"statistic":106},"6413896b-eca9-442b-a73f-182a58a0ce40","2023-06-12T14:59:13.446+00:00","2026-06-19T02:29:32.871+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Y-D%C6%B0%E1%BB%A3c-C%E1%BA%A7n-Th%C6%A1",{"country":89,"title":90,"address":93,"abbreviation":96},{"VOID":15},{"EN":91,"VI":92},"Can Tho University of Medicine and Pharmacy","Trường Đại học Y Dược Cần Thơ",{"VI":94,"EN":95},"Số 179, đường Nguyễn Văn Cừ, phường An Khánh, quận Ninh Kiều, thành phố Cần Thơ, Việt Nam","No 179, Nguyen Van Cu street, An Khanh ward, Ninh Kieu district, Can Tho city, Vietnam",{"VOID":97},"ctump","AFFILIATION","2023-08-01T14:07:27.977+00:00",[101,102],"VI","EN",12,"http:\u002F\u002Fwww.ctump.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":107,"i10Index":111,"i10IndexLast5Year":59,"totalPublication":112,"totalPublicationByYear":113,"totalCitation":122,"totalCitationByYear":123,"totalCitationPerPublication":128,"totalCitationPerPublicationByYear":129,"hindexLast5Year":135,"hindex":135},{"2022":108,"2023":109,"2024":110,"2025":38},0.1,0.05,0.07,4,1489,{"2013":114,"2014":115,"2015":115,"2016":111,"2017":115,"2018":59,"2019":114,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120,"2025":121,"2026":111},2,1,10,84,281,680,260,156,313,{"2013":59,"2014":114,"2018":124,"2021":125,"2022":126,"2023":127},17,36,123,132,0.21,{"2013":130,"2014":114,"2018":131,"2021":132,"2022":133,"2023":134},1.5,5.67,0.43,0.44,0.19,6,[],"https:\u002F\u002Ftapchi.ctump.edu.vn\u002Findex.php\u002Fctump",{"impactFactor":36,"impactFactorByYear":139,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":140,"totalPublicationByYear":141,"totalCitation":147,"totalCitationByYear":148,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":152,"hindexLast5Year":135,"hindex":135},{"2022":38,"2023":36,"2024":39,"2025":38},1956,{"0":114,"2019":114,"2020":50,"2021":142,"2022":143,"2023":144,"2024":145,"2025":146},76,403,789,305,371,524,{"0":114,"2019":135,"2021":124,"2022":149,"2023":150,"2024":111,"2025":114},287,206,0.27,{"0":115,"2019":59,"2021":153,"2022":154,"2023":56,"2024":38,"2025":38},0.22,0.71,{"impactFactor":26,"impactFactorByYear":26,"i10Index":114,"i10IndexLast5Year":114,"totalPublication":156,"totalPublicationByYear":157,"totalCitation":163,"totalCitationByYear":164,"totalCitationPerPublication":169,"totalCitationPerPublicationByYear":170,"hindexLast5Year":135,"hindex":135},461,{"0":158,"2019":114,"2021":159,"2022":160,"2023":161,"2024":158,"2025":162},7,37,296,107,5,419,{"2021":59,"2022":59,"2023":165,"2024":166,"2025":167,"2026":168},71,126,171,41,0.91,{"2021":171,"2022":38,"2023":172,"2024":173,"2025":174},0.08,0.66,18,34.2,"JOURNAL",{"id":177,"createTime":178,"updateTime":179,"relativeEntities":180,"slug":181,"properties":182,"entityType":24,"verifyStatus":25,"verifyTime":193,"verifyNote":26,"syncStatus":28,"languages":194,"translateLanguages":26,"viewCount":36,"subjectFields":195,"manageAffiliations":196,"indexDatabases":197,"url":198,"thumbnailPath":26,"statistic":26,"gsStatistic":199,"type":175,"analyzePriority":26},"f8d0bf97-8d89-482e-b58c-2fc481a0b79b","2025-10-27T06:27:08.591+00:00","2026-06-18T23:33:41.667+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-v%C3%A0-C%C3%B4ng-ngh%E1%BB%87-nhi%E1%BB%87t-%C4%91%E1%BB%9Bi",{"country":183,"introduce":184,"gsId":186,"title":188,"issn":191},{"VOID":15},{"EN":185},"\u003Cp style=\"text-align:justify;\">     Journal of Tropical Science and Engineering (JTSE) is a multidisciplinary scientific journal, licensed to operate as a print journal in 2012 and an electronic journal in 2024 (License No.1479\u002FGP-BTTTT dated August 20, 2012 and No.91\u002FGP-BTTTT dated April 9, 2024 issued by the Ministry of Information and Communications of Vietnam). The JTSE is headquartered in Hanoi.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">        The JTSE is published every 3 months (4 issues\u002Fyear), publishing research results and overview articles in 3 groups of fields: Tropical Ecology and Environment; Chemistry and Material Sciences; Biomedicine and Pharmacy. In 2022, the JTSE registered the international identifier Digital Object Identifier (DOI): 10.58334\u002Fvrtc.jtst and assigned DOI codes to all articles of the journal. The members of the Editorial Board of the JTSE are prestigious scientists and leading scientists from Vietnam and many countries in the world. The JTSE has been recognized by the Vietnam State Council for Professorship to score scientific articles in Chemistry, Medicine and Biology with scores ranging from 0-0.75 points.\u003C\u002Fp>\u003Cp style=\"text-align:justify;\">      Currently, the JTSE is building and perfecting a set of criteria and making efforts to join the List of prestigious  international journals with a roadmap to enter Scopus and SCIE in the coming time.\u003C\u002Fp>",{"VOID":187},"MS2_GJQAAAAJ",{"VI":189,"EN":190},"Tạp chí Khoa học và Công nghệ nhiệt đới","Journal of Tropical Science and Engineering",{"VOID":192},"08667535","2025-10-27T06:27:25.058+00:00",[101,102],[],[],[],"https:\u002F\u002Ftapchikhcnnd.com.vn",{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":200,"totalPublicationByYear":201,"totalCitation":161,"totalCitationByYear":203,"totalCitationPerPublication":153,"totalCitationPerPublicationByYear":205,"hindexLast5Year":114,"hindex":114},481,{"0":115,"2020":115,"2021":115,"2022":114,"2024":115,"2025":202,"2026":115},474,{"2017":114,"2018":115,"2019":111,"2020":162,"2021":162,"2022":116,"2023":50,"2024":162,"2025":204,"2026":52},52,{"2020":162,"2021":162,"2022":162,"2024":162,"2025":206,"2026":52},0.11,{"id":208,"createTime":209,"updateTime":210,"relativeEntities":211,"slug":212,"properties":213,"entityType":24,"verifyStatus":25,"verifyTime":221,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"subjectFields":223,"manageAffiliations":224,"indexDatabases":225,"url":226,"thumbnailPath":26,"statistic":227,"gsStatistic":276,"type":175,"analyzePriority":26},"a3d1e82a-57e2-40f9-940e-f5fa8b9ef64a","2023-06-01T07:11:26.039+00:00","2026-06-18T23:33:28.573+00:00",[],"VNU-Journal-of-Science-Earth-and-Environmental-Sciences",{"issn":214,"title":216,"country":218,"gsId":219},{"VOID":215},"26159279",{"EN":217},"VNU Journal of Science: Earth and Environmental Sciences",{"VOID":15},{"VOID":220},"UmXD8vEAAAAJ","2023-06-01T07:17:59.210+00:00",27,[],[],[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FEES",{"impactFactor":36,"impactFactorByYear":228,"i10Index":234,"i10IndexLast5Year":36,"totalPublication":235,"totalPublicationByYear":236,"totalCitation":246,"totalCitationByYear":247,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":262,"hindexLast5Year":103,"hindex":103},{"2010":229,"2012":40,"2013":230,"2014":230,"2015":231,"2016":54,"2017":171,"2018":109,"2019":110,"2020":57,"2021":232,"2022":233,"2023":151,"2024":58},0.02,0.04,0.09,0.31,0.4,19,656,{"2008":237,"2009":238,"2010":239,"2011":238,"2012":240,"2013":241,"2014":239,"2015":242,"2016":243,"2017":244,"2018":245,"2019":165,"2020":125,"2021":168,"2022":125,"2023":222,"2024":111},23,24,22,28,25,20,146,29,78,1038,{"2008":248,"2009":249,"2010":250,"2011":251,"2012":252,"2013":253,"2014":254,"2015":255,"2016":256,"2017":257,"2018":161,"2019":258,"2020":259,"2021":29,"2022":260},119,64,66,86,38,73,59,31,129,39,97,53,26,1.58,{"2008":263,"2009":264,"2010":59,"2011":265,"2012":266,"2013":267,"2014":268,"2015":269,"2016":270,"2017":271,"2018":272,"2019":272,"2020":273,"2021":274,"2022":275},5.17,2.67,3.58,1.36,2.92,2.68,1.55,0.88,1.34,1.37,1.47,1.24,0.72,{"impactFactor":26,"impactFactorByYear":26,"i10Index":173,"i10IndexLast5Year":135,"totalPublication":277,"totalPublicationByYear":278,"totalCitation":279,"totalCitationByYear":280,"totalCitationPerPublication":288,"totalCitationPerPublicationByYear":289,"hindexLast5Year":158,"hindex":298},113,{"2007":114,"2008":103,"2009":173,"2010":116,"2011":51,"2012":239,"2013":103,"2014":162,"2015":53,"2016":135},616,{"2009":162,"2010":114,"2011":52,"2012":124,"2013":222,"2014":255,"2015":48,"2016":44,"2017":281,"2018":282,"2019":259,"2020":283,"2021":284,"2022":285,"2023":286,"2024":257,"2025":287,"2026":59},54,60,49,47,34,44,33,5.45,{"2009":290,"2010":291,"2011":292,"2012":293,"2013":294,"2014":295,"2015":296,"2016":297},0.28,0.2,0.6,0.77,2.25,6.2,3.91,9.67,14,{"id":300,"createTime":301,"updateTime":302,"relativeEntities":303,"slug":304,"properties":305,"entityType":24,"verifyStatus":25,"verifyTime":316,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":234,"subjectFields":317,"manageAffiliations":318,"indexDatabases":388,"url":389,"thumbnailPath":390,"statistic":391,"gsStatistic":409,"type":175,"analyzePriority":26},"a7166325-6c9e-4db3-8a59-7c879701a372","2023-07-31T04:28:49.231+00:00","2026-06-18T23:33:22.428+00:00",[],"VNU-Journal-of-Science-Policy-and-Management-Studies",{"country":306,"issn":307,"eissn":309,"title":311,"gsId":314},{"VOID":15},{"VOID":308},"26159295",{"VOID":310},"25881116",{"EN":312,"VI":313},"VNU Journal of Science: Policy and Management Studies","Tạp chí Nghiên cứu Chính sách và Quản lý",{"VOID":315},"xKW2E_cAAAAJ","2023-08-01T03:23:46.688+00:00",[],[319],{"id":320,"createTime":321,"updateTime":322,"relativeEntities":323,"slug":324,"properties":325,"entityType":98,"verifyStatus":25,"verifyTime":335,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":336,"url":337,"parentIds":338,"statistic":339},"12466116-8f60-4b01-8faf-2411483a0977","2023-05-30T09:37:38.472+00:00","2026-06-19T02:14:28.352+00:00",[],"Vietnam-National-University",{"country":326,"title":327,"abbreviation":330,"address":332},{"VOID":15},{"EN":328,"VI":329},"Vietnam National University, Hanoi","Đại học Quốc gia Hà Nội",{"VOID":331},"VNU",{"VI":333,"EN":334},"Số 144 Xuân Thủy, Phường Dịch Vọng Hậu, Quận Cầu Giấy, Hà Nội, Việt Nam","No. 144 Xuan Thuy Street, Dich Vong Hau Ward, Cau Giay District, Hanoi, Vietnam","2023-08-02T13:58:17.029+00:00",16,"http:\u002F\u002Fwww.vnu.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":340,"i10Index":285,"i10IndexLast5Year":162,"totalPublication":344,"totalPublicationByYear":345,"totalCitation":354,"totalCitationByYear":355,"totalCitationPerPublication":368,"totalCitationPerPublicationByYear":369,"hindexLast5Year":336,"hindex":336},{"2014":109,"2015":231,"2016":231,"2017":206,"2018":341,"2019":110,"2020":342,"2021":343,"2022":171,"2023":231,"2024":110,"2025":39},0.06,0.18,0.35,1247,{"2003":115,"2004":115,"2005":114,"2006":59,"2007":111,"2008":162,"2009":59,"2010":50,"2011":124,"2012":336,"2013":260,"2014":244,"2015":250,"2016":281,"2017":346,"2018":347,"2019":348,"2020":349,"2021":350,"2022":351,"2023":352,"2024":353,"2025":255,"2026":50},94,88,83,67,176,185,187,93,1644,{"2004":111,"2005":115,"2006":52,"2007":298,"2008":356,"2009":298,"2010":286,"2011":357,"2012":244,"2013":358,"2014":359,"2015":360,"2016":361,"2017":362,"2018":363,"2019":364,"2020":365,"2021":366,"2022":367,"2023":367,"2024":162},13,81,48,70,151,115,109,259,174,181,121,101,1.32,{"2004":111,"2005":370,"2006":59,"2007":371,"2008":372,"2009":373,"2010":374,"2011":375,"2012":376,"2013":377,"2014":378,"2015":379,"2016":380,"2017":381,"2018":382,"2019":383,"2020":384,"2021":385,"2022":386,"2023":387,"2024":109},0.5,3.5,2.6,4.67,5.5,4.76,1.81,1.85,2.41,2.29,2.13,1.16,2.94,2.1,2.7,0.69,0.55,0.54,[],"https:\u002F\u002Fjs.vnu.edu.vn\u002FPaM","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002Fa7166325-6c9e-4db3-8a59-7c879701a372\u002Fecfe83f4bcc60c7023ae04d8900fe0ac.jpg",{"impactFactor":36,"impactFactorByYear":392,"i10Index":111,"i10IndexLast5Year":36,"totalPublication":394,"totalPublicationByYear":395,"totalCitation":399,"totalCitationByYear":400,"totalCitationPerPublication":293,"totalCitationPerPublicationByYear":403,"hindexLast5Year":158,"hindex":158},{"2018":109,"2019":171,"2020":393,"2021":108,"2022":54,"2023":206,"2024":54},0.23,320,{"2015":50,"2016":239,"2017":286,"2018":396,"2019":397,"2020":159,"2021":398,"2022":168,"2023":79,"2024":255},30,35,40,247,{"2015":115,"2016":242,"2017":401,"2018":222,"2019":402,"2020":79,"2021":239,"2022":50,"2023":116},77,50,{"2015":404,"2016":169,"2017":405,"2018":406,"2019":407,"2020":408,"2021":386,"2022":291,"2023":232},0.12,1.75,0.9,1.43,0.86,{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":103,"totalPublicationByYear":410,"totalCitation":234,"totalCitationByYear":411,"totalCitationPerPublication":261,"totalCitationPerPublicationByYear":412,"hindexLast5Year":114,"hindex":59},{"2015":114,"2016":116},{"2016":115,"2017":114,"2018":114,"2019":59,"2020":114,"2021":59,"2022":114,"2023":114,"2024":115,"2026":115},{"2016":108},{"id":414,"createTime":415,"updateTime":416,"relativeEntities":417,"slug":418,"properties":419,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":238,"subjectFields":428,"manageAffiliations":429,"indexDatabases":430,"url":431,"thumbnailPath":26,"statistic":432,"gsStatistic":438,"type":175,"analyzePriority":26},"16e65a3f-d274-47dd-8691-56d76eb58c3d","2023-05-30T09:10:06.062+00:00","2026-06-18T23:33:17.679+00:00",[],"Vietnam-Journal-of-Otorhinolaryngology-Head-and-Neck-Surgery",{"country":420,"issn":421,"title":423,"gsId":426},{"VOID":15},{"VOID":422},"18593704",{"EN":424,"VI":425},"Vietnam Journal of Otorhinolaryngology - Head and Neck Surgery","Tạp chí Tai Mũi Họng Việt Nam",{"VOID":427},"L78B_eIAAAAJ",[],[],[],"https:\u002F\u002Ftapchitaimuihong.vn\u002Findex.php\u002Ftmh",{"impactFactor":36,"impactFactorByYear":433,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":434,"totalPublicationByYear":435,"totalCitation":111,"totalCitationByYear":436,"totalCitationPerPublication":230,"totalCitationPerPublicationByYear":437,"hindexLast5Year":115,"hindex":115},{"2024":229},95,{"2022":52,"2023":286,"2024":255,"2025":53},{"2023":111},{"2023":231},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":240,"totalPublicationByYear":439,"totalCitation":234,"totalCitationByYear":440,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":442,"hindexLast5Year":114,"hindex":114},{"2023":53,"2024":116,"2025":135,"2026":115},{"2024":59,"2025":298,"2026":114},0.68,{"2024":443,"2025":444,"2026":114},0.3,2.33,{"id":446,"createTime":447,"updateTime":448,"relativeEntities":449,"slug":450,"properties":451,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":396,"subjectFields":460,"manageAffiliations":461,"indexDatabases":462,"url":463,"thumbnailPath":464,"statistic":465,"gsStatistic":472,"type":175,"analyzePriority":26},"25988add-c322-4eda-afda-63b1559bb824","2023-04-07T03:49:55.817+00:00","2026-06-18T23:32:23.776+00:00",[],"T%E1%BA%A1p%20ch%C3%AD%20Y%20-%20D%C6%B0%E1%BB%A3c%20h%E1%BB%8Dc%20qu%C3%A2n%20s%E1%BB%B1",{"country":452,"issn":453,"title":455,"gsId":458},{"VOID":15},{"VOID":454},"18590748",{"EN":456,"VI":457},"Journal of Military Pharmaco-medicine","Tạp chí Y - Dược học quân sự",{"VOID":459},"_pmQ8IEAAAAJ",[],[],[],"https:\u002F\u002Fjmpm.vn\u002Findex.php\u002Fjmpm","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F25988add-c322-4eda-afda-63b1559bb824\u002F09c6bc42157cf5ece95edc971ccddb52.jpg",{"impactFactor":36,"impactFactorByYear":466,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":467,"totalPublicationByYear":468,"totalCitation":135,"totalCitationByYear":470,"totalCitationPerPublication":38,"totalCitationPerPublicationByYear":471,"hindexLast5Year":115,"hindex":115},{"2023":229,"2024":38},475,{"2022":168,"2023":365,"2024":469,"2025":124},236,{"2022":114,"2023":111},{"2022":109,"2023":229},{"impactFactor":26,"impactFactorByYear":26,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":277,"totalPublicationByYear":473,"totalCitation":401,"totalCitationByYear":474,"totalCitationPerPublication":441,"totalCitationPerPublicationByYear":475,"hindexLast5Year":59,"hindex":59},{"2015":115,"2018":114,"2019":115,"2020":115,"2021":59,"2022":103,"2023":159,"2024":287,"2025":237},{"2020":115,"2021":115,"2022":115,"2023":52,"2024":237,"2025":79,"2026":116},{"2020":115,"2021":476,"2022":171,"2023":477,"2024":478,"2025":479},0.33,0.24,0.7,1.39,{"id":481,"createTime":482,"updateTime":483,"relativeEntities":484,"slug":485,"properties":486,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":496,"translateLanguages":26,"viewCount":45,"subjectFields":497,"manageAffiliations":498,"indexDatabases":525,"url":526,"thumbnailPath":527,"statistic":528,"gsStatistic":26,"type":26,"analyzePriority":26},"2b8d7b12-2d20-4777-be98-077f44f03c69","2023-09-07T07:40:58.286+00:00","2025-07-13T21:21:00.542+00:00",[],"VNU-Journal-of-Social-Sciences-and-Humanities",{"country":487,"issn":488,"introduce":490,"title":493},{"VOID":15},{"VOID":489},"23541172",{"EN":491,"VI":492},"{\"ops\":[{\"insert\":\"VNU Journal of Social Sciences and Humanities (ISSN 2354-1172) is a double-blind peer-reviewed journal published by University of Social Sciences and Humanities, Vietnam National University, Hanoi, Vietnam, under the publication permit no. 155\u002FGP-BTTTT, issued on 11\"},{\"attributes\":{\"script\":\"super\"},\"insert\":\"th \"},{\"insert\":\"May, 2015 by Ministry of Information and Communications. The journal publishes four Vietnamese issues and two English issues per year.\\nCurrently, there are 35 reputable professors in the editorial board. The main objectives of the journal include: providing an intellectual platform for Vietnamese and international scholars; promoting interdisciplinary studies in social sciences and humanities; becoming the leading journal in social sciences and humanities in Vietnam; being indexed by worldwide databases and having academic recognition internationally in the near future.\\nThe journal is currently indexed by Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services and Vietnam National University’s digital archive.\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Journal of Social Sciences and Humanities-Vietnam\"},{\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"ISSN 2354-1172, email: tapchikhxhnv@gmail.com, tckhxhnv@vnu.edu.vn\"},{\"insert\":\"\\n\"}]}","{\"ops\":[{\"insert\":\"Được thành lập ngày 31\u002F8\u002F2015 (giấy phép hoạt động số 155\u002FGP-BVHTT ngày 11 tháng 5 năm 2015 của Bộ Thông tin và Truyền thông, mã số tiêu chuẩn quốc tế ISSN 2354-1172), Tạp chí Khoa học Xã hội và Nhân văn (Journal of Social Sciences and Humanities) là ấn phẩm khoa học chính thức, duy nhất của Trường Đại học Khoa học Xã hội và Nhân văn, ĐHQG Hà Nội, phát triển và kế thừa Chuyên san Khoa học Xã hội và Nhân văn, Tạp chí Khoa học, ĐHQG Hà Nội.\\nTạp chí xuất bản định kỳ (04 số tiếng Việt\u002Fnăm và 02 số tiếng Anh\u002Fnăm), có nhiệm vụ \"},{\"attributes\":{\"italic\":true},\"insert\":\"công bố, giới thiệu các công trình nghiên cứu khoa học khoa học xã hội và nhân văn của các tác giả là các nhà khoa học trong và ngoài nước, phục vụ giảng dạy, học tập và nghiên cứu khoa học\"},{\"insert\":\". Hội đồng biên tập của Tạp chí hiện bao gồm 33 nhà khoa học có uy tín trong nước và quốc tế. Tạp chí tập trung và ưu tiên đăng tải những bài báo theo định hướng của tinh thần cởi mở, sáng tạo, nhanh chóng vươn lên để tiếp cận và sánh ngang với các tạp chí có uy tín hàng đầu của khu vực và trên thế giới. Nội dung chính của Tạp chí bao gồm các Bài nghiên cứu (khoảng 6000 đến 15000 từ), các bài điểm sách, thông tin khoa học (khoảng 300 đến 1500 từ) được trình bày theo đúng cấu trúc và chuẩn mực của một tạp chí khoa học.\\nCác bài viết của Tạp chí hiện đang được trích dẫn bởi Google Scholar, WorldCat, Open Archives, Cosmos Impact Factor, Advanced Sciences Index, Scientific Indexing Services, CrossRef, EBSCO Information Services.\\nMọi thông tin xin liên hệ: \"},{\"attributes\":{\"italic\":true},\"insert\":\"Phòng Tạp chí, 701 - E, Trường Đại học Khoa học Xã hội và Nhân văn, 336 Nguyễn Trãi, Thanh Xuân, Hà Nội. ĐT: 024.35581984; email: tckhxhnv@vnu.edu.vn \"},{\"insert\":\"hoặc \"},{\"attributes\":{\"italic\":true},\"insert\":\"tapchikhxhnv@gmail.com \"},{\"insert\":\"\\n\"}]}",{"EN":494,"VI":495},"VNU Journal of Social Sciences and Humanities","Tạp chí Khoa học Xã hội và Nhân văn",[101,102],[],[499],{"id":500,"createTime":501,"updateTime":502,"relativeEntities":503,"slug":504,"properties":505,"entityType":98,"verifyStatus":25,"verifyTime":509,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":222,"url":26,"parentIds":510,"statistic":511},"8b6e349b-0daf-4895-9c3f-85f30f1bfd42","2023-07-31T12:55:58.430+00:00","2026-06-19T02:30:07.899+00:00",[],"Tr%C6%B0%E1%BB%9Dng-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Khoa-h%E1%BB%8Dc-X%C3%A3-h%E1%BB%99i-v%C3%A0-Nh%C3%A2n-v%C4%83n-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-H%C3%A0-N%E1%BB%99i",{"title":506},{"EN":507,"VI":508},"VNU University of Social Sciences and Humanities","Trường Đại học Khoa học Xã hội và Nhân văn, Đại học Quốc gia Hà Nội","2023-08-02T15:28:49.057+00:00",[],{"impactFactor":36,"impactFactorByYear":512,"i10Index":59,"i10IndexLast5Year":115,"totalPublication":514,"totalPublicationByYear":515,"totalCitation":518,"totalCitationByYear":519,"totalCitationPerPublication":520,"totalCitationPerPublicationByYear":521,"hindexLast5Year":162,"hindex":162},{"2016":229,"2017":230,"2018":229,"2021":230,"2022":58,"2023":513,"2024":38},0.15,365,{"2013":115,"2014":158,"2015":125,"2016":252,"2017":44,"2018":516,"2019":286,"2020":396,"2021":259,"2022":517,"2023":396,"2024":115,"2025":59,"2026":115},21,42,169,{"2015":283,"2016":135,"2017":52,"2018":50,"2019":298,"2020":53,"2021":359,"2022":115,"2023":115},0.46,{"2015":266,"2016":57,"2017":57,"2018":522,"2019":523,"2020":524,"2021":368,"2022":229,"2023":39},0.38,0.32,0.37,[],"http:\u002F\u002Fjournal.ussh.vnu.edu.vn\u002Findex.php\u002Fvjossh","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F2b8d7b12-2d20-4777-be98-077f44f03c69\u002F0bd0751202944a4b4165b482e6e623e4.png",{"impactFactor":36,"impactFactorByYear":529,"i10Index":162,"i10IndexLast5Year":115,"totalPublication":530,"totalPublicationByYear":531,"totalCitation":537,"totalCitationByYear":538,"totalCitationPerPublication":343,"totalCitationPerPublicationByYear":540,"hindexLast5Year":135,"hindex":135},{"2016":341,"2017":39,"2018":229,"2019":38,"2020":110,"2021":231,"2022":231,"2023":341,"2024":39},764,{"2015":255,"2016":245,"2017":532,"2018":259,"2019":533,"2020":534,"2021":535,"2022":536,"2023":534,"2024":254,"2025":50},111,106,68,92,89,265,{"2015":539,"2016":241,"2017":168,"2018":51,"2019":349,"2020":260,"2021":244,"2022":298,"2023":114},46,{"2015":541,"2016":523,"2017":524,"2018":290,"2019":542,"2020":522,"2021":523,"2022":57,"2023":39},1.48,0.63,{"id":544,"createTime":545,"updateTime":546,"relativeEntities":547,"slug":548,"properties":549,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":558,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":50,"subjectFields":559,"manageAffiliations":560,"indexDatabases":561,"url":562,"thumbnailPath":563,"statistic":564,"gsStatistic":26,"type":26,"analyzePriority":26},"6ec01bd0-15c0-469a-86ac-41339076ae0a","2023-08-10T07:08:33.153+00:00","2026-01-31T21:19:06.362+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Da-li%E1%BB%85u-h%E1%BB%8Dc-Vi%E1%BB%87t-Nam",{"country":550,"issn":551,"introduce":553,"title":555},{"VOID":15},{"VOID":552},"18594824",{"VI":554},"{\"ops\":[{\"insert\":\"Tạp chí “Da liễu học Việt Nam” (Tiếng Anh: Vietnamese Journal of Dermatology and Venereology) thuộc Hội Da liễu Việt Nam, xuất bản 4 số mỗi năm bằng tiếng Việt hoặc tiếng Anh.\\nTạp chí Da liễu học Việt Nam hoạt động với mục đích, tôn chỉ là phổ biến, trao đổi thông tin trong lĩnh vực chuyên ngành da liễu; đăng tải các công trình nghiên cứu khoa học; chuyển giao công nghệ - kinh tế và khoa học kỹ thuật liên quan đến lĩnh vực da liễu.\\nPhạm vi của tạp chí là tất cả các bài báo khoa học, bài tổng quan, giới thiệu ca lâm sàng, … có liên quan tới chuyên ngành da liễu trong và ngoài nước. Tạp chí công bố các công trình nghiên cứu liên quan đến mô hình bệnh tật, các phương pháp chẩn đoán, điều trị, dự phòng và phục hồi chức năng các bệnh thuộc chuyên ngành da liễu. Ngoài ra, tạp chí còn đăng tải các bài tổng quan, cập nhật thông tin, kiến thức, hướng dẫn chẩn đoán, điều trị trong chuyên ngành da liễu trong nước và quốc tế; đăng tải các bài ca lâm sàng đặc biệt trong chuyên ngành da liễu.\\nTạp chí Da liễu học Việt Nam được biết tới là một tạp chí chuyên ngành có uy tín trong lĩnh vực da liễu. Các bài báo về nghiên cứu khoa học đăng trong Tạp chí được bình duyệt một cách nghiêm ngặt bởi ít nhất 2 chuyên gia. Hội đồng biên tập tạp chí bao gồm các nhà khoa học có uy tín (Giáo sư, Phó Giáo sư, Tiến sĩ, Bác sĩ…) trong chuyên ngành da liễu nhằm đảm bảo chất lượng và tính khách quan, khoa học cho các bài viết đăng trên Tạp chí.\\n\"}]}",{"EN":556,"VI":557},"Vietnamese Journal of Dermatology and Venereology","Tạp chí Da liễu học Việt Nam","Admin Import",[],[],[],"https:\u002F\u002Fvjdv.vn\u002Findex.php\u002Fvjdv","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F6ec01bd0-15c0-469a-86ac-41339076ae0a\u002F3cbc81720e58429dc7b1c4d7ab1935ca.jpg",{"impactFactor":36,"impactFactorByYear":565,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":566,"totalPublicationByYear":567,"totalCitation":116,"totalCitationByYear":570,"totalCitationPerPublication":109,"totalCitationPerPublicationByYear":571,"hindexLast5Year":115,"hindex":115},{"2023":38,"2024":230},182,{"2022":568,"2023":45,"2024":569},69,56,{"2022":52,"2023":115},{"2022":40,"2023":229},{"id":573,"createTime":574,"updateTime":575,"relativeEntities":576,"slug":577,"properties":578,"entityType":24,"verifyStatus":25,"verifyTime":26,"verifyNote":27,"syncStatus":28,"languages":587,"translateLanguages":26,"viewCount":283,"subjectFields":588,"manageAffiliations":589,"indexDatabases":647,"url":648,"thumbnailPath":649,"statistic":650,"gsStatistic":26,"type":26,"analyzePriority":26},"19221551-7519-47ff-a892-331d1139c64b","2023-09-12T07:03:05.744+00:00","2026-01-24T20:54:40.144+00:00",[],"T%E1%BA%A1p-ch%C3%AD-Khoa-h%E1%BB%8Dc-S%E1%BB%A9c-kho%E1%BA%BB-%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":579,"issn":580,"introduce":582,"title":584},{"VOID":15},{"VOID":581},"27349446",{"EN":583},"{\"ops\":[{\"attributes\":{\"bold\":true},\"insert\":\"1. History\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"Science and Technology Development Journal\"},{\"insert\":\" (STDJ) (ISSN 2734-9446), Vietnam National University - Ho Chi Minh City (VNU-HCM) was established in 1997. And the first issue was published in January 1998 with ISSN 1859-0128. Since then, STDJ has become the most important scientific forum of scientists from VNU-HCM as well as other universities. The magazine has undergone 20 years of development and has become a bridge for scientific exchanges, as well as enriching reference materials for the faculty, doctoral students, students of VNU-HCM in particular and other universities, institutes...\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Science and Technology Development Journal - Health Sciences (STDJ-HS) is a subjournal of Science and Technology Development Journal since 2020.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\" \"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"attributes\":{\"bold\":true},\"insert\":\"2. Focus and Scope\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Publishing articles with contents on healthcare, research projects in the field of health, advanced directions in health education and management. Therefore, STDJ-HS will accept articles from doctors, administrators, teachers, researchers, graduate students and fellows. The authors will be responsible for the accuracy of the data, opinions, opinions and material cited in the article.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"Facilitating the exchange of scientific and technological information and act as a bridge between theory and practice in the community of educators, scientists, managers, policy makers and enterprises in and out of the country.\"},{\"attributes\":{\"align\":\"justify\"},\"insert\":\"\\n\"},{\"insert\":\"\\n\"}]}",{"EN":585,"VI":586},"VNUHCM JOURNAL OF HEALTH SCIENCES","Tạp chí Khoa học Sức khoẻ Đại học Quốc gia Thành phố Hồ Chí Minh",[101,102],[],[590],{"id":591,"createTime":592,"updateTime":593,"relativeEntities":594,"slug":595,"properties":596,"entityType":98,"verifyStatus":25,"verifyTime":606,"verifyNote":26,"syncStatus":28,"languages":607,"translateLanguages":26,"viewCount":608,"url":609,"parentIds":610,"statistic":611},"fc4c2560-868c-4677-acb1-8686bef88727","2023-06-26T04:48:23.774+00:00","2026-06-19T01:46:17.248+00:00",[],"%C4%90%E1%BA%A1i-h%E1%BB%8Dc-Qu%E1%BB%91c-gia-Th%C3%A0nh-ph%E1%BB%91-H%E1%BB%93-Ch%C3%AD-Minh",{"country":597,"title":598,"abbreviation":601,"address":603},{"VOID":15},{"EN":599,"VI":600},"Vietnam National University Ho Chi Minh City","Đại học Quốc gia Thành phố Hồ Chí Minh",{"VOID":602},"VNUHCM",{"VI":604,"EN":605},"khu phố 6, Phường Linh Trung, Thành phố Thủ Đức, Thành phố Hồ Chí Minh, Việt Nam","Quarter 6, Linh Trung Ward, Thu Duc City, Ho Chi Minh City, Vietnam","2023-08-16T14:13:07.134+00:00",[101,102],45,"https:\u002F\u002Fvnuhcm.edu.vn\u002F",[],{"impactFactor":36,"impactFactorByYear":612,"i10Index":285,"i10IndexLast5Year":51,"totalPublication":613,"totalPublicationByYear":614,"totalCitation":624,"totalCitationByYear":625,"totalCitationPerPublication":634,"totalCitationPerPublicationByYear":635,"hindexLast5Year":124,"hindex":124},{"2014":36,"2015":38,"2016":109,"2017":39,"2018":229,"2019":38,"2020":110,"2021":171,"2022":110,"2023":110,"2024":171,"2025":229},3708,{"2005":115,"2006":115,"2007":115,"2008":135,"2009":111,"2010":53,"2011":52,"2012":568,"2013":615,"2014":351,"2015":616,"2016":469,"2017":617,"2018":127,"2019":618,"2020":619,"2021":620,"2022":621,"2023":622,"2024":623,"2025":159,"2026":50},164,266,177,226,603,931,314,246,74,2399,{"2006":115,"2008":50,"2010":162,"2011":242,"2012":222,"2013":43,"2014":626,"2015":627,"2016":628,"2017":629,"2018":258,"2019":630,"2020":631,"2021":632,"2022":633,"2023":353,"2024":115},250,124,157,162,152,385,559,128,0.65,{"2006":115,"2008":636,"2010":637,"2011":638,"2012":639,"2013":522,"2014":640,"2015":641,"2016":642,"2017":643,"2018":644,"2019":642,"2020":645,"2021":292,"2022":646,"2023":522,"2024":38},1.33,0.45,2.22,0.39,1.35,0.47,0.67,0.92,0.73,0.64,0.41,[],"http:\u002F\u002Fstdjhs.scienceandtechnology.com.vn\u002Findex.php\u002Fstdjhs","\u002Fapi\u002Fpublic\u002Ffile\u002Fpublisher\u002F19221551-7519-47ff-a892-331d1139c64b\u002F2e10768b7d1e380c36a25ed0c714dd7e.png",{"impactFactor":36,"impactFactorByYear":651,"i10Index":36,"i10IndexLast5Year":36,"totalPublication":652,"totalPublicationByYear":653,"totalCitation":516,"totalCitationByYear":654,"totalCitationPerPublication":151,"totalCitationPerPublicationByYear":655,"hindexLast5Year":59,"hindex":59},{"2022":57,"2023":108,"2024":39},79,{"2020":116,"2021":240,"2022":239,"2023":52,"2024":162,"2025":162},{"2020":59,"2021":51,"2022":59},{"2020":443,"2021":387,"2022":54},{"code":657,"data":658,"meta":26},"SUCCESS",{"id":659,"createTime":660,"updateTime":660,"relativeEntities":661,"slug":662,"properties":663,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":668,"manageAffiliations":669,"indexDatabases":670,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},"83289c5a-0e1a-4089-90d0-8447ef02c8ba","2023-12-05T06:03:54.978+00:00",[],"EMC-Ginecolog%C3%ADa-Obstetricia",{"issn":664,"title":666},{"VOID":665},"1283081X",{"EN":667},"EMC - Ginecología-Obstetricia",[],[],[],{"meta":672,"data":674},{"total":673},"233",[675,773,879,937,1097,1143,1188,1248,1332,1426],{"id":676,"createTime":677,"updateTime":678,"relativeEntities":679,"slug":680,"properties":681,"entityType":688,"verifyStatus":25,"verifyTime":689,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":691,"fullTextUrl":26,"authors":692,"publicationType":747,"publisherRelationship":748,"citationCount":36,"citationInfo":762,"publishDate":764,"publishYear":765,"citationAnalyzeStatus":766,"lastCitationAnalyze":767,"indexDatabases":26,"openAccess":26,"references":768,"isForceReanalyzing":772},"2e0022d8-691d-47c1-805b-2646aae83a4e","2024-01-24T08:55:54.986+00:00","2026-06-10T12:40:31.574+00:00",[],"Tratamiento-de-la-f%C3%ADstula-rectovaginal-y-de-las-secuelas-obst%C3%A9tricas",{"title":682,"doi":684,"gsPaper":686},{"ES":683},"Tratamiento de la fístula rectovaginal y de las secuelas obstétricas",{"VOID":685},"10.1016\u002Fs1283-081x(20)43720-8",{"VOID":687},"[\"8941905162942479020\"]","PUBLICATION","2024-05-03T00:37:56.136+00:00","Auto Verify","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X20437208",[693,709,721,733],{"id":694,"sortIndex":59,"researcher":26,"roles":695,"affiliations":697,"properties":706},"39888c05-cf30-4eaf-ab45-faf3ce88e0b8",[696],"AUTHOR",[698],{"id":26,"sortIndex":36,"affiliation":699,"properties":26},{"id":700,"createTime":701,"updateTime":701,"relativeEntities":702,"slug":26,"properties":703,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"d4d18b5e-933d-4c7a-8252-f956d23d19a2","2024-01-24T08:55:55.012+00:00",[],{"title":704},{"VI":705},"Service de chirurgie gynécologique, Hôpital Jeanne-de-Flandre, CHU de Lille, avenue Eugène-Avinée, 59037 Lille cedex, France",{"title":707},{"VI":708},"S. Delplanque",{"id":710,"sortIndex":114,"researcher":26,"roles":711,"affiliations":712,"properties":718},"a42857fa-931d-4443-b6a7-eeb4d3d287d4",[696],[713],{"id":26,"sortIndex":36,"affiliation":714,"properties":26},{"id":700,"createTime":701,"updateTime":701,"relativeEntities":715,"slug":26,"properties":716,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":717},{"VI":705},{"title":719},{"VI":720},"E. Declas",{"id":722,"sortIndex":115,"researcher":26,"roles":723,"affiliations":724,"properties":730},"cf770415-864d-4750-a611-abe739471221",[696],[725],{"id":26,"sortIndex":36,"affiliation":726,"properties":26},{"id":700,"createTime":701,"updateTime":701,"relativeEntities":727,"slug":26,"properties":728,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":729},{"VI":705},{"title":731},{"VI":732},"G. Giraudet",{"id":734,"sortIndex":36,"researcher":26,"roles":735,"affiliations":736,"properties":742},"08fc2047-379d-421d-a1db-869f3b3936fd",[696],[737],{"id":26,"sortIndex":36,"affiliation":738,"properties":26},{"id":700,"createTime":701,"updateTime":701,"relativeEntities":739,"slug":26,"properties":740,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":741},{"VI":705},{"title":743,"gsAuthor":745},{"VI":744},"M. Cosson",{"VOID":746},"[\"mra9H5MAAAAJ\"]","ARTICLE",{"url":691,"publisher":749,"properties":757},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":750,"slug":662,"properties":751,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":754,"manageAffiliations":755,"indexDatabases":756,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":752,"title":753},{"VOID":665},{"EN":667},[],[],[],{"volume":758,"pages":760},{"VOID":759},"56",{"VOID":761},"1-12",{"total":36,"publishYear":36,"statisticByYear":763},{},"2020-05-01",2020,"ERROR_IN_ANALYZE_CITATION","2026-06-10T12:40:31.573+00:00",[769],{"id":26,"text":770,"url":26,"identifiers":771},"Cosson, 2011",{},false,{"id":774,"createTime":775,"updateTime":776,"relativeEntities":777,"slug":778,"properties":779,"entityType":688,"verifyStatus":25,"verifyTime":776,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":786,"fullTextUrl":26,"authors":787,"publicationType":747,"publisherRelationship":863,"citationCount":26,"citationInfo":26,"publishDate":877,"publishYear":878,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"02a8e3ee-d8d6-41d8-86f5-5144853a9b0a","2024-01-11T06:50:21.574+00:00","2024-12-12T00:55:43.470+00:00",[],"Estrategia-de-diagn%C3%B3stico-prenatal-y-tratamiento-de-las-enfermedades-relacionadas-con-los-embarazos-m%C3%BAltiples",{"references":780,"title":782,"doi":784},{"VOID":781},"Evans, 2010, Screening and testing in multiples, Clin Lab Med, 30, 643, 10.1016\u002Fj.cll.2010.05.005\nVayssiere, 2010, Twin pregnancies: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF), Eur J Obstet Gynecol Reprod Biol, 156, 12, 10.1016\u002Fj.ejogrb.2010.12.045\nCuckle, 1998, Down's syndrome screening in twins, J Med Screen, 5, 3, 10.1136\u002Fjms.5.1.3\nSebire, 1997, The prevalence and consequences of missed abortion in twin pregnancies at 10 to 14 weeks of gestation, Br J Obstet Gynaecol, 104, 847, 10.1111\u002Fj.1471-0528.1997.tb12033.x\nSebire, 1996, Screening for trisomy 21 in twin pregnancies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation, Br J Obstet Gynaecol, 103, 999, 10.1111\u002Fj.1471-0528.1996.tb09550.x\nOdibo, 2003, Screening for aneuploidy in twins and higher-order multiples: is first-trimester nuchal translucency the solution?, Obstet Gynecol Surv, 58, 609, 10.1097\u002F01.OGX.0000082369.30519.A8\nGlinianaia, 2008, Congenital anomalies in twins: a register-based study, Hum Reprod, 23, 1306, 10.1093\u002Fhumrep\u002Fden104\nBryan, 1987, Congenital anomalies in twins, Baillieres Clin Obstet Gynaecol, 1, 697, 10.1016\u002FS0950-3552(87)80012-3\nLewi, 2008, The outcome of monochorionic diamniotic twin gestations in the era of invasive fetal therapy: a prospective cohort study, Am J Obstet Gynecol, 199, 514, 10.1016\u002Fj.ajog.2008.03.050\nSepulveda, 2005, Discordant lower urinary tract obstruction in early twin gestations: management and outcome, Obstet Gynecol, 106, 797, 10.1097\u002F01.AOG.0000175833.65983.ee\nWeber, 2010, Genetics and developmental pathology of twinning, Semin Fetal Neonatal Med, 15, 313, 10.1016\u002Fj.siny.2010.06.002\nWeisz, 2004, Tailored management of twin reversed arterial perfusion (trap) sequence, Ultrasound Obstet Gynecol, 23, 451, 10.1002\u002Fuog.1040\nNakata, 2008, Fetoscopic laser photocoagulation of placental communicating vessels for twin-reversed arterial perfusion sequence, J Obstet Gynaecol Res, 34, 649, 10.1111\u002Fj.1447-0756.2008.00901.x\nDiehl, 2007, Selective cord coagulation in acardiac twins, Semin Fetal Neonatal Med, 12, 458, 10.1016\u002Fj.siny.2007.06.008\nRossi, 2008, Laser therapy and serial amnioreduction as treatment for twin-twin transfusion syndrome: a meta-analysis and review of literature, Am J Obstet Gynecol, 198, 147, 10.1016\u002Fj.ajog.2007.09.043\nRoman, 2010, Selective reduction in complicated monochorionic pregnancies: radiofrequency ablation vs. bipolar cord coagulation, Ultrasound Obstet Gynecol, 36, 37, 10.1002\u002Fuog.7567\nDelabaere, 2013, Suivi pédiatrique de 30 grossesses gémellaires monochoriales consécutives traitées par foeticide sélectif, Gynecol Obstet Fertil, 41, 85, 10.1016\u002Fj.gyobfe.2012.12.007\nYamamoto, 2005, Incidence and impact of perioperative complications in 175 fetoscopy-guided laser coagulations of chorionic plate anastomoses in fetofetal transfusion syndrome before 26 weeks of gestation, Am J Obstet Gynecol, 193, 1110, 10.1016\u002Fj.ajog.2005.07.003\nQuintero, 1999, Staging of twin-twin transfusion syndrome, J Perinatol, 19, 550, 10.1038\u002Fsj.jp.7200292\nQuintero, 2003, Stage-based treatment of twin-twin transfusion syndrome, Am J Obstet Gynecol, 188, 1333, 10.1067\u002Fmob.2003.292\nHuber, 2006, Stage-related outcome in twin-twin transfusion syndrome treated by fetoscopic laser coagulation, Obstet Gynecol, 108, 333, 10.1097\u002F01.AOG.0000225945.17022.6b\nHarkness, 2005, Twin-twin transfusion syndrome: where do we go from here?, Semin Perinatol, 29, 296, 10.1053\u002Fj.semperi.2005.10.001\nRoberts, 2008, Interventions for twin-twin transfusion syndrome: a Cochrane review, Ultrasound Obstet Gynecol, 31, 701, 10.1002\u002Fuog.5328\nDelabaere, 2011, Résultats favorables d’une équipe émergente dans le traitement du syndrome transfuseur–transfusé par photocoagulation-laser, Gynecol Obstet Fertil, 39, 482, 10.1016\u002Fj.gyobfe.2011.02.016\nSlaghekke, 2010, Twin anemia-polycythemia sequence: diagnostic criteria, classification, perinatal management and outcome, Fetal Diagn Ther, 27, 181, 10.1159\u002F000304512\nLopriore, 2008, Fetal and neonatal haematological complications in monochorionic twins, Semin Fetal Neonatal Med, 13, 231, 10.1016\u002Fj.siny.2008.02.002\nLopriore, 2009, Residual anastomoses in twin-to-twin transfusion syndrome treated with selective fetoscopic laser surgery: localization, size, and consequences, Am J Obstet Gynecol, 201, 66, 10.1016\u002Fj.ajog.2009.01.010\nRobyr, 2006, Prevalence and management of late fetal complications following successful selective laser coagulation of chorionic plate anastomoses in twin-to-twin transfusion syndrome, Am J Obstet Gynecol, 194, 796, 10.1016\u002Fj.ajog.2005.08.069\nLewi, 2006, Pregnancy and infant outcome of 80 consecutive cord coagulations in complicated monochorionic multiple pregnancies, Am J Obstet Gynecol, 194, 782, 10.1016\u002Fj.ajog.2005.09.013\nHabli, 2009, Incidence of complications in twin-twin transfusion syndrome after selective fetoscopic laser photocoagulation: a single-center experience, Am J Obstet Gynecol, 201, 417, 10.1016\u002Fj.ajog.2009.07.046\nRussell, 2007, Intrauterine growth restriction in monochorionic twins, Semin Fetal Neonatal Med, 12, 439, 10.1016\u002Fj.siny.2007.06.004\nChang, 2009, Clinical outcome and placental territory ratio of monochorionic twin pregnancies and selective intrauterine growth restriction with different types of umbilical artery Doppler, Prenat Diagn, 29, 253, 10.1002\u002Fpd.2193\nDenbow, 2000, Placental angioarchitecture in monochorionic twin pregnancies: relationship to fetal growth, fetofetal transfusion syndrome, and pregnancy outcome, Am J Obstet Gynecol, 182, 417, 10.1016\u002FS0002-9378(00)70233-X\nLeduc, 2005, Persistance of adverse obstetric and neonatal outcomes in monochorionic twins after exclusion of disorders unique to monochorionic placentation, Am J Obstet Gynecol, 193, 1670, 10.1016\u002Fj.ajog.2005.04.007\nAcosta-Rojas, 2007, Twin chorionicity and the risk of adverse perinatal outcome, Int J Gynaecol Obstet, 96, 98, 10.1016\u002Fj.ijgo.2006.11.002\nGratacos, 2004, Prevalence of neurological damage in monochorionic twins with selective intrauterine growth restriction and intermittent absent or reversed end-diastolic umbilical artery flow, Ultrasound Obstet Gynecol, 24, 159, 10.1002\u002Fuog.1105\nIshii, 2009, Perinatal outcome of monochorionic twins with selective intrauterine growth restriction and different types of umbilical artery Doppler under expectant management, Fetal Diagn Ther, 26, 157, 10.1159\u002F000253880\nValsky, 2010, Selective intrauterine growth restriction in monochorionic twins: pathophysiology, diagnostic approach and management dilemmas, Semin Fetal Neonatal Med, 15, 342, 10.1016\u002Fj.siny.2010.07.002\nGratacos, 2007, A classification system for selective intrauterine growth restriction in monochorionic pregnancies according to umbilical artery Doppler flow in the smaller twin, Ultrasound Obstet Gynecol, 30, 28, 10.1002\u002Fuog.4046\nAxt, 1999, Maternal and neonatal outcome of twin pregnancies complicated by single fetal death, J Perinat Med, 27, 221, 10.1515\u002FJPM.1999.031\nLee, 2008, Twin chorionicity and the risk of stillbirth, Obstet Gynecol, 111, 301, 10.1097\u002FAOG.0b013e318160d65d\nOng, 2006, Prognosis for the co-twin following single-twin death: a systematic review, Bjog, 113, 992, 10.1111\u002Fj.1471-0528.2006.01027.x\nWoo, 2000, Single foetal death in twin pregnancies: review of the maternal and neonatal outcomes and management, Hong Kong Med J, 6, 293\nvan Heteren, 1998, Risk for surviving twin after fetal death of co-twin in twin-twin transfusion syndrome, Obstet Gynecol, 92, 215, 10.1016\u002FS0029-7844(98)00159-8\nBejar, 1990, Antenatal origin of neurologic damage in newborn infants. II. Multiple gestations, Am J Obstet Gynecol, 162, 1230, 10.1016\u002F0002-9378(90)90024-2\nNicolini, 1999, Single intrauterine death in monochorionic twin pregnancies, Ultrasound Obstet Gynecol, 14, 297, 10.1046\u002Fj.1469-0705.1999.14050297.x\nSchinzel, 1979, Monozygotic twinning and structural defects, J Pediatr, 95, 921, 10.1016\u002FS0022-3476(79)80278-4\nMoore, 1969, Intrauterine disseminated intravascular coagulation: a syndrome of multiple pregnancy with a dead twin fetus, J Pediatr, 74, 523, 10.1016\u002FS0022-3476(69)80034-X\nWeisz, 2005, Invasive diagnostic procedures in twin pregnancies, Prenat Diagn, 25, 751, 10.1002\u002Fpd.1263\nNieuwint, 1999, “Identical” twins with discordant karyotypes, Prenat Diagn, 19, 72, 10.1002\u002F(SICI)1097-0223(199901)19:1\u003C72::AID-PD465>3.0.CO;2-V\nToth-Pal, 2004, Genetic amniocentesis in multiple pregnancy, Fetal Diagn Ther, 19, 138, 10.1159\u002F000075138\nMujezinovic, 2007, Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review, Obstet Gynecol, 110, 687, 10.1097\u002F01.AOG.0000278820.54029.e3\nDommergues, 1991, Embryo reduction in multifetal pregnancies after infertility therapy: obstetrical risks and perinatal benefits are related to operative strategy, Fertil Steril, 55, 805, 10.1016\u002FS0015-0282(16)54252-6\nEvans, 1994, Transabdominal versus transcervical and transvaginal multifetal pregnancy reduction: international collaborative experience of more than one thousand cases, Am J Obstet Gynecol, 170, 902, 10.1016\u002FS0002-9378(94)70306-X\nWapner, 1990, Selective reduction of multifetal pregnancies, Lancet, 335, 90, 10.1016\u002F0140-6736(90)90550-O\nSentilhes, 2008, Multifetal pregnancy reduction: indications, technical aspects and psychological impact, Presse Med, 37, 295, 10.1016\u002Fj.lpm.2007.05.016\nSenat, 2002, Funipuncture for fetocide in late termination of pregnancy, Prenat Diagn, 22, 354, 10.1002\u002Fpd.290\nBhide, 2002, Comparison of feticide carried out by cordocentesis versus cardiac puncture, Ultrasound Obstet Gynecol, 20, 230, 10.1046\u002Fj.1469-0705.2002.00797.x\nSenat, 2003, The use of lidocaine for fetocide in late termination of pregnancy, Bjog, 110, 296, 10.1046\u002Fj.1471-0528.2003.02217.x\nNielsen, 1991, Analgesic efficacy of low doses of intravenously administered lidocaine on experimental laser-induced pain: a placebo controlled study, Reg Anesth, 16, 28\nRossi, 2009, Umbilical cord occlusion for selective feticide in complicated monochorionic twins: a systematic review of literature, Am J Obstet Gynecol, 200, 123, 10.1016\u002Fj.ajog.2008.08.039\nDelabaere, 2013, Suivi pédiatrique de 30 grossesses gémellaires monochoriales consécutives traitées par fœticide sélectif, Gynecol Obstet Fertil, 41, 85, 10.1016\u002Fj.gyobfe.2012.12.007",{"ES":783},"Estrategia de diagnóstico prenatal y tratamiento de las enfermedades relacionadas con los embarazos múltiples",{"VOID":785},"10.1016\u002Fs1283-081x(13)65365-5","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X13653655",[788,803,815,827,839,851],{"id":789,"sortIndex":36,"researcher":26,"roles":790,"affiliations":791,"properties":800},"a6572e51-5aa5-4115-a749-b8be236a9f71",[696],[792],{"id":26,"sortIndex":36,"affiliation":793,"properties":26},{"id":794,"createTime":795,"updateTime":795,"relativeEntities":796,"slug":26,"properties":797,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3677a859-5b95-42dd-85d4-27d0c50a01c8","2024-01-11T06:50:21.681+00:00",[],{"title":798},{"VI":799},"Pôle gynéco-obstétrique-reproduction humaine, Centre hospitalier universitaire de Clermont-Ferrand, Centre hospitalier universitaire Estaing, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand cedex 1, France",{"title":801},{"VI":802},"A. Delabaere",{"id":804,"sortIndex":111,"researcher":26,"roles":805,"affiliations":806,"properties":812},"96b7792f-c31e-4cf1-a02e-3f39936930c8",[696],[807],{"id":26,"sortIndex":36,"affiliation":808,"properties":26},{"id":794,"createTime":795,"updateTime":795,"relativeEntities":809,"slug":26,"properties":810,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":811},{"VI":799},{"title":813},{"VI":814},"D. Lémery",{"id":816,"sortIndex":114,"researcher":26,"roles":817,"affiliations":818,"properties":824},"caa7839d-08a4-44d3-8caf-161f5aa1e31b",[696],[819],{"id":26,"sortIndex":36,"affiliation":820,"properties":26},{"id":794,"createTime":795,"updateTime":795,"relativeEntities":821,"slug":26,"properties":822,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":823},{"VI":799},{"title":825},{"VI":826},"F. Desvignes",{"id":828,"sortIndex":59,"researcher":26,"roles":829,"affiliations":830,"properties":836},"ded6f25d-5999-4755-a55e-a0f662dd5de9",[696],[831],{"id":26,"sortIndex":36,"affiliation":832,"properties":26},{"id":794,"createTime":795,"updateTime":795,"relativeEntities":833,"slug":26,"properties":834,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":835},{"VI":799},{"title":837},{"VI":838},"H. Laurichesse-Delmas",{"id":840,"sortIndex":115,"researcher":26,"roles":841,"affiliations":842,"properties":848},"4755ec38-4344-4dc0-a5a3-5afcef6f72f5",[696],[843],{"id":26,"sortIndex":36,"affiliation":844,"properties":26},{"id":794,"createTime":795,"updateTime":795,"relativeEntities":845,"slug":26,"properties":846,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":847},{"VI":799},{"title":849},{"VI":850},"S. Curinier",{"id":852,"sortIndex":162,"researcher":26,"roles":853,"affiliations":854,"properties":860},"444c2686-0290-4423-852c-e0810bccc815",[696],[855],{"id":26,"sortIndex":36,"affiliation":856,"properties":26},{"id":794,"createTime":795,"updateTime":795,"relativeEntities":857,"slug":26,"properties":858,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":859},{"VI":799},{"title":861},{"VI":862},"D. Gallot",{"url":786,"publisher":864,"properties":872},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":865,"slug":662,"properties":866,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":869,"manageAffiliations":870,"indexDatabases":871,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":867,"title":868},{"VOID":665},{"EN":667},[],[],[],{"volume":873,"pages":875},{"VOID":874},"49",{"VOID":876},"1-11","2013-09-01",2013,{"id":880,"createTime":881,"updateTime":882,"relativeEntities":883,"slug":884,"properties":885,"entityType":688,"verifyStatus":25,"verifyTime":882,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":892,"fullTextUrl":26,"authors":893,"publicationType":747,"publisherRelationship":921,"citationCount":26,"citationInfo":26,"publishDate":935,"publishYear":936,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"50ebf169-0831-451c-8f10-6e009a7bb777","2024-01-18T02:06:57.968+00:00","2024-12-25T07:10:31.921+00:00",[],"S%C3%ADndrome-de-dolor-vesical-cistitis-intersticial",{"references":886,"title":888,"doi":890},{"VOID":887},"Gillenwater, 1988, Summary of the national institute of arthritis, diabetes, digestive and kidney diseases workshop on interstitial cystitis. Bethesda, Maryland, August 28-29, 1987, J Urol, 140, 203, 10.1016\u002FS0022-5347(17)41529-1\nHanno, 1999, The diagnosis of interstitial cystitis revisited: lessons learned from the National Institutes of Health interstitial cystitis data base study, J Urol, 161, 553, 10.1016\u002FS0022-5347(01)61948-7\nAbrams, 2002, The standardisation of terminology of lower urinary tract function: report from the standardization subcommittee of the International Continence Society, Neurourol Urodyn, 21, 167, 10.1002\u002Fnau.10052\nDenson, 2000, Comparison of cystoscopic and histological findings in patients with suspected interstitial cystitis, J Urol, 164, 1908, 10.1016\u002FS0022-5347(05)66915-7\nDundore, 1996, Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis, J Urol, 155, 885, 10.1016\u002FS0022-5347(01)66334-1\nBade, 2003, Future research needs for the definition\u002Fdiagnosis of interstitial cystitis, Int J Urol, 10, S31, 10.1046\u002Fj.1442-2042.10.s1.9.x\nFuruya, 2007, Glomerulation observed during transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia is a common finding but no predictor of clinical outcome, Urology, 70, 922, 10.1016\u002Fj.urology.2007.06.1153\nVan De Merwe, 2008, Diagnostic criteria, classification and nomenclature for painful bladder syndrome\u002Finterstitial cystitis: an Essic proposal, Eur Urol, 53, 60, 10.1016\u002Fj.eururo.2007.09.019\nMoldwin, 2007, Rational approaches to the treatment of patients with interstitial cystitis, Urology, 69, 73, 10.1016\u002Fj.urology.2006.08.1105\nClauw, 1997, The relationship between fibromyalgia and interstitial cystitis, J Psychiatry Res, 31, 125, 10.1016\u002FS0022-3956(96)00051-9\nAlagiri, 1997, Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes, Urology, 49, 52, 10.1016\u002FS0090-4295(99)80332-X\nWarren, 2009, Antecedent nonbladder syndromes in case-control study of interstitial cystitis\u002Fpainful bladder syndrome, Urology, 73, 52, 10.1016\u002Fj.urology.2008.06.031\nKoziol, 1993, The natural history of interstitial cystitis: a survey of 374 patients, J Urol, 149, 465, 10.1016\u002FS0022-5347(17)36120-7\nSadhukhan, 2002, Sodium pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism, J Urol, 168, 289, 10.1016\u002FS0022-5347(05)64909-9\nMulholland, 1990, Pentosan polysulfate sodium therapy for interstitial cystitis, Urology, 35, 552, 10.1016\u002F0090-4295(90)80116-5\nParsons, 1993, A quantitatively controlled method to study prospectively interstitial cystitis and demonstrate the efficacy of pentosan polysulfate, J Urol, 150, 845, 10.1016\u002FS0022-5347(17)35629-X\nNickel, 2008, Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement, Urology, 71, 57, 10.1016\u002Fj.urology.2007.09.013\nHanno, 1994, Amitriptyline in the treatment of interstitial cystitis, Urol Clin North Am, 21, 89, 10.1016\u002FS0094-0143(21)00596-6\nSasaki, 2001, Oral Gabapentin (Neurontin) treatment of refractory genitourinary tract pain, Tech Urol, 7, 47\nSeshadri, 1994, Cimetidine in the treatment of interstitial cystitis, Urology, 44, 614, 10.1016\u002FS0090-4295(94)80074-X\nLewi, 1998, Cimetidine in the treatment of interstitial cystitis: 30-month follow-up, Br J Urol, 81, 42a\nThilagarajah, 2001, Oral cimetidine gives effective symptom relief in painful bladder disease: a prospective, randomized, double-blind placebo-controlled Trial, BJU Int, 87, 207, 10.1046\u002Fj.1464-410x.2001.02031.x\nSairanen, 2005, Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study, J Urol, 174, 2235, 10.1097\u002F01.ju.0000181808.45786.84\nParkin, 1997, Intravesical Dimethyl Sulfoxide (DMSO) for interstitial cystitis: a practical approach, Urology, 49, 105, 10.1016\u002FS0090-4295(97)00181-7\nGhoniem, 1993, Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy, World J Urol, 11, 178, 10.1007\u002FBF00211416\nParsons, 1994, Treatment of interstitial cystitis with intravesical heparin, Br J Urol, 73, 504, 10.1111\u002Fj.1464-410X.1994.tb07634.x\nPropert, 2008, Interstitial cystitis clinical trials group. followup of patients with interstitial cystitis responsive to treatment with intravesical bacillus calmette-guerin or placebo, J Urol, 179, 552, 10.1016\u002Fj.juro.2007.09.035\nPayne, 2005, Intravesical resiniferatoxin for the treatment of interstitial cystitis: a randomized, doubleblind, placebo controlled trial, J Urol, 173, 1590, 10.1097\u002F01.ju.0000154631.92150.ef\nChenTY, 2005, Prospective, Randomized, Double-Blind Study Of SafetyAnd Tolerability Of Intravesical Resiniferatoxin (Rtx) In Interstitial Cystitis (Ic), Int Urogynecol J Pelvic Floor Dysfunct, 16, 293, 10.1007\u002Fs00192-005-1307-4\nSmith, 2004, Botulinum Toxin A has antinociceptive effects in treating interstitial cystitis, Urology, 64, 871, 10.1016\u002Fj.urology.2004.06.073\nKuo, 2005, Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis, Urol Int, 75, 170, 10.1159\u002F000087173\nHsin-Tzu, 2007, Intravesical Botulinum Toxin A Injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis, Urology, 70, 463, 10.1016\u002Fj.urology.2007.04.038\nWhitmore, 2003, Sacral Neuromodulation In Patients With Interstitial Cystitis: A Multicenter Clinical Trial, Int Urogynecol J Pelvic Floor Dysfunct, 14, 305, 10.1007\u002Fs00192-003-1080-1\nVan Ophoven, 2002, Long-term results of trigonepreserving orthotopic substitution enterocystoplasty for interstitial cystitis, J Urol, 167, 603, 10.1016\u002FS0022-5347(01)69094-3",{"ES":889},"Síndrome de dolor vesical\u002Fcistitis intersticial",{"VOID":891},"10.1016\u002Fs1283-081x(12)61924-9","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X12619249",[894,909],{"id":895,"sortIndex":115,"researcher":26,"roles":896,"affiliations":897,"properties":906},"690c7ff2-4a45-432e-bf96-dbfed8b717cd",[696],[898],{"id":26,"sortIndex":36,"affiliation":899,"properties":26},{"id":900,"createTime":901,"updateTime":901,"relativeEntities":902,"slug":26,"properties":903,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"8037e446-6235-4fc4-9808-2be815c43781","2024-01-18T02:06:57.991+00:00",[],{"title":904},{"VI":905},"Service d’urologie, Nouvel hôpital civil, Université de Strasbourg, 1, place de l’Hôpital, 67091 Strasbourg, France",{"title":907},{"VI":908},"C. Saussine",{"id":910,"sortIndex":36,"researcher":26,"roles":911,"affiliations":912,"properties":918},"c7874190-5a9a-4581-8275-1725571c424e",[696],[913],{"id":26,"sortIndex":36,"affiliation":914,"properties":26},{"id":900,"createTime":901,"updateTime":901,"relativeEntities":915,"slug":26,"properties":916,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":917},{"VI":905},{"title":919},{"VI":920},"P. Mouracadé",{"url":892,"publisher":922,"properties":930},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":923,"slug":662,"properties":924,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":927,"manageAffiliations":928,"indexDatabases":929,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":925,"title":926},{"VOID":665},{"EN":667},[],[],[],{"volume":931,"pages":933},{"VOID":932},"48",{"VOID":934},"1-8","2012-04-01",2012,{"id":938,"createTime":939,"updateTime":940,"relativeEntities":941,"slug":942,"properties":943,"entityType":688,"verifyStatus":25,"verifyTime":940,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":950,"fullTextUrl":26,"authors":951,"publicationType":747,"publisherRelationship":1081,"citationCount":26,"citationInfo":26,"publishDate":1095,"publishYear":1096,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"a7721f00-3f8a-47c7-8f1c-a4449b687442","2024-01-03T14:07:46.155+00:00","2024-12-25T06:10:31.985+00:00",[],"Tratamiento-del-c%C3%A1ncer-de-mama-infiltrante-localizado-nuevos-desaf%C3%ADos",{"references":944,"title":946,"doi":948},{"VOID":945},"Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 - Volume 1 : Tumeurs solides : Étude à partir des registres des cancers du réseau Francim [Internet]. 2019. Disponible sur : https:\u002F\u002Fwww.santepubliquefrance.fr\u002Fmaladies-et-traumatismes\u002Fcancers\u002Fcancer-du-sein\u002Fdocuments\u002Frapport-synthese\u002Festimations-nationales-de-l-incidence-et-de-la-mortalite-par-cancer-en-france-metropolitaine-entre-1990-et-2018-volume-1-tumeurs-solides-etud.\nEl-Tamer, 2009, Surgical options as quality of care indicators in breast cancer, J Surg Oncol, 99, 393, 10.1002\u002Fjso.21148\nSakorafas, 2001, Breast cancer surgery--historical evolution, current status and future perspectives, Acta Oncol, 40, 5, 10.1080\u002F028418601750070984\nBuchholz, 2014, Margins for breast-conserving surgery with whole-breast irradiation in stage I and II invasive breast cancer: American Society of Clinical Oncology Endorsement of the Society of Surgical Oncology\u002FAmerican Society for Radiation Oncology Consensus Guideline, J Clin Oncol, 32, 1502, 10.1200\u002FJCO.2014.55.1572\nVincent, 2017, Synthèse des recommandations nationales et internationales concernant les indications de la technique du ganglion sentinelle et du curage axillaire complémentaire après ganglion sentinelle positif dans la prise en charge des cancers du sein, Bull Cancer, 104, 356, 10.1016\u002Fj.bulcan.2017.01.001\nAFSOS. Prise en charge du lymphœdème secondaire du membre supérieur après cancer du sein. Mars 2014.\nGiuliano, 2017, Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial, JAMA, 318, 918, 10.1001\u002Fjama.2017.11470\nGalimberti, 2013, Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial, Lancet Oncol, 14, 297, 10.1016\u002FS1470-2045(13)70035-4\nSolá, 2013, Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\u002F13\u002F2000, Ann Surg Oncol, 20, 120, 10.1245\u002Fs10434-012-2569-y\nDonker, 2014, Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial, Lancet Oncol, 15, 1303, 10.1016\u002FS1470-2045(14)70460-7\nSávolt, 2017, Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: a randomized, single centre, phase III, non-inferiority trial, Eur J Surg Oncol, 43, 672, 10.1016\u002Fj.ejso.2016.12.011\nGradishar, 2017, NCCN guidelines insights: breast cancer, version 1.2017, J Natl Compr Canc Netw, 15, 433, 10.6004\u002Fjnccn.2017.0044\nLyman, 2017, Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Update, J Clin Oncol, 35, 561, 10.1200\u002FJCO.2016.71.0947\nGnant, 2017, St. Gallen\u002FVienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment, Breast Care, 12, 102, 10.1159\u002F000475698\nCostaz, 2019, Stratégies en cas de positivité du ganglion sentinelle dans les cancers du sein, Bull Cancer\nFisher, 1997, Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18, J Clin Oncol, 15, 2483, 10.1200\u002FJCO.1997.15.7.2483\nVila, 2014, Conservative surgery for ipsilateral breast tumor recurrence, J Surg Oncol, 110, 62, 10.1002\u002Fjso.23629\nGentilini, 2012, Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates, Ann Surg Oncol, 19, 3771, 10.1245\u002Fs10434-012-2404-5\nHannoun-Levi, 2013, Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group, Radiother Oncol, 108, 226, 10.1016\u002Fj.radonc.2013.03.026\nOr Z. Variations des pratiques chirurgicales dans la prise en charge des cancers du sein en France. 2017.\nBailey, 2017, Quality-of-life outcomes improve with nipple-sparing mastectomy and breast reconstruction, Plast Reconstr Surg, 140, 219, 10.1097\u002FPRS.0000000000003505\nMota, 2016, Nipple- and areola-sparing mastectomy for the treatment of breast cancer, Cochrane Database Syst Rev, CD008932\nWeber, 2018, Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy, Breast Cancer Res Treat, 172, 523, 10.1007\u002Fs10549-018-4937-1\nEssai clinique cancer Sein\u002FSein clos aux inclusions [Internet]. [cité 19 nov 2019]. Disponible sur : https:\u002F\u002Fwww.e-cancer.fr\u002FProfessionnels-de-sante\u002FLe-registre-des-essais-cliniques\u002FLe-registre-des-essais-cliniques\u002FEtudes-cliniques\u002FEtude-MAPAM-01-Etude-de-chirurgie-evaluant-l-efficacite-d-une-mastectomie-avec-conservation-de-l-etui-cutane-et-de-la-plaque-areolomamelonnaire-MCPAM-chez-des-patientes-ayant-un-carcinome-mammaire.-essai-clos-aux-inclusions.\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2011, Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials, Lancet, 378, 1707, 10.1016\u002FS0140-6736(11)61629-2\nHennequin, 2016, Radiothérapie du cancer du sein, Cancer Radiother, 20, S139, 10.1016\u002Fj.canrad.2016.07.025\nStrnad, 2016, Lancet, 387, 229, 10.1016\u002FS0140-6736(15)00471-7\nVeronesi, 2013, Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial, Lancet Oncol, 14, 1269, 10.1016\u002FS1470-2045(13)70497-2\nVaidya, 2014, Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Lancet, 383, 603, 10.1016\u002FS0140-6736(13)61950-9\nVicini, 2019, Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial, Lancet, 394, 2155, 10.1016\u002FS0140-6736(19)32514-0\nWhelan, 2019, External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial, Lancet, 394, 2165, 10.1016\u002FS0140-6736(19)32515-2\nRivera, 2019, Hypofractionated radiation therapy for invasive breast cancer: from moderate to extreme protocols, Cancer Radiother, 23, 874, 10.1016\u002Fj.canrad.2019.09.002\nOffersen, 2016, ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1, Radiother Oncol, 118, 205, 10.1016\u002Fj.radonc.2015.12.027\nBartelink, 2007, Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial, J Clin Oncol, 25, 3259, 10.1200\u002FJCO.2007.11.4991\nSTART Trialists’ Group, 2008, The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet Oncol, 9, 331, 10.1016\u002FS1470-2045(08)70077-9\nSTART Trialists’ Group, 2008, The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial, Lancet, 371, 1098, 10.1016\u002FS0140-6736(08)60348-7\nGiraud, 2012, Contribution of respiratory gating techniques for optimization of breast cancer radiotherapy, Cancer Invest, 30, 323, 10.3109\u002F07357907.2012.657818\nBalic, 2019, St. Gallen\u002FVienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment, Breast Care, 14, 103, 10.1159\u002F000499931\nJagsi, 2018, Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction, J Natl Cancer Inst, 110, 10.1093\u002Fjnci\u002Fdjx148\nKrug, 2019, Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials, Ann Surg Oncol, 26, 3892, 10.1245\u002Fs10434-019-07635-x\nNational Surgical Adjuvant Breast and Bowel Project (NSABP) [Internet]. [cité 21 févr 2020]. Disponible sur : http:\u002F\u002Fwww.nsabp.pitt.edu\u002FB-51.asp.\nFourquet, 1994, Les résultats à long terme des traitements conservateurs du cancer du sein. Résultats à long terme, Trait Conserv Cancer Sein, 4, 40\nFitzgibbons, 2000, Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999, Arch Pathol Lab Med, 124, 966, 10.5858\u002F2000-124-0966-PFIBC\nAdami, 1986, The relation between survival and age at diagnosis in breast cancer, N Engl J Med, 315, 559, 10.1056\u002FNEJM198608283150906\nAnonyme. Facteurs pronostiques de l’évolution de la maladie loco-régionale ou métastatique et facteurs prédictifs de la réponse au traitement. Cancers du sein non métastatiques. Standards, Options et Recommandations. 1996. (FNCLCC).\nCarter, 1989, Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, 63, 181, 10.1002\u002F1097-0142(19890101)63:1\u003C181::AID-CNCR2820630129>3.0.CO;2-H\nde Mascarel, 1992, Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: reevaluation with longer follow-up, Br J Cancer, 66, 523, 10.1038\u002Fbjc.1992.306\nvan der Heiden-van der Loo, 2013, Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes, Ann Oncol, 24, 2794, 10.1093\u002Fannonc\u002Fmdt243\nEllis, 1992, Pathological prognostic factors in breast cancer. II. Histological type. Relationship with survival in a large study with long-term follow-up, Histopathology, 20, 479, 10.1111\u002Fj.1365-2559.1992.tb01032.x\nElston, 1991, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, 19, 403, 10.1111\u002Fj.1365-2559.1991.tb00229.x\nAndre, 2005, Mitotic index and benefit of adjuvant anthracycline-based chemotherapy in patients with early breast cancer, J Clin Oncol, 23, 2996, 10.1200\u002FJCO.2005.08.046\nBollet, 2006, Pathological response to preoperative concurrent chemo-radiotherapy for breast cancer: results of a phase II study, Eur J Cancer, 42, 2286, 10.1016\u002Fj.ejca.2006.03.026\nChakravarthy, 2006, Neoadjuvant concurrent paclitaxel and radiation in stage II\u002FIII breast cancer, Clin Cancer Res, 12, 1570, 10.1158\u002F1078-0432.CCR-05-2304\nde Mascarel, 1998, Obvious peritumoral emboli: an elusive prognostic factor reappraised. Multivariate analysis of 1320 node-negative breast cancers, Eur J Cancer, 34, 58, 10.1016\u002FS0959-8049(97)00344-4\n1999, [Recommendations for the immunohistochemistry of the hormonal receptors on paraffin sections in breast cancer. Update 1999. Group for Evaluation of Prognostic Factors using Immunohistochemistry in Breast Cancer (GEFPICS-FNCLCC)], Ann Pathol, 19, 336\nFisher, 1988, Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06, J Clin Oncol, 6, 1076, 10.1200\u002FJCO.1988.6.7.1076\nMcGuire, 1992, Prognostic factors and treatment decisions in axillary-node-negative breast cancer, N Engl J Med, 326, 1756, 10.1056\u002FNEJM199206253262607\nClark, 1994, Prognostic factors: rationale and methods of analysis and integration, Breast Cancer Res Treat, 32, 105, 10.1007\u002FBF00666211\n1992, Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group, Lancet, 339, 71\nPenault-Llorca, 2014, 2014 update of the GEFPICS’ recommendations for HER2 status determination in breast cancers in France, Ann Pathol, 34, 352, 10.1016\u002Fj.annpat.2014.08.018\nWolff, 2018, Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\u002FCollege of American Pathologists Clinical Practice Guideline Focused Update, Arch Pathol Lab Med, 142, 1364, 10.5858\u002Farpa.2018-0902-SA\nLuporsi, 2012, Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review, Breast Cancer Res Treat, 132, 895, 10.1007\u002Fs10549-011-1837-z\nde Azambuja, 2007, Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients, Br J Cancer, 96, 1504, 10.1038\u002Fsj.bjc.6603756\nViale, 2008, Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole, J Clin Oncol, 26, 5569, 10.1200\u002FJCO.2008.17.0829\nCheang, 2009, Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer, J Natl Cancer Inst, 101, 736, 10.1093\u002Fjnci\u002Fdjp082\nViale, 2008, Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer, J Natl Cancer Inst, 100, 207, 10.1093\u002Fjnci\u002Fdjm289\nPenault-Llorca, 2009, Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer, J Clin Oncol, 27, 2809, 10.1200\u002FJCO.2008.18.2808\nSalgado, 2015, The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, Ann Oncol, 26, 259, 10.1093\u002Fannonc\u002Fmdu450\nLoi, 2019, Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers, J Clin Oncol, 37, 559, 10.1200\u002FJCO.18.01010\nLook, 2002, Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients, J Natl Cancer Inst, 94, 116, 10.1093\u002Fjnci\u002F94.2.116\nPerou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038\u002F35021093\nCardoso, 2016, 70-Gene signature as an aid to treatment decisions in early-stage breast cancer, N Engl J Med, 375, 717, 10.1056\u002FNEJMoa1602253\nSparano, 2018, Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, 379, 111, 10.1056\u002FNEJMoa1804710\nYann C. Haute Autorité de santé. 2019.\nLehmann, 2011, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, 121, 2750, 10.1172\u002FJCI45014\nPlanes-Laine, 2019, PD-1\u002FPD-L1 targeting in breast cancer: the first clinical evidences are emerging: a literature review, Cancers, 11, 10.3390\u002Fcancers11071033\nValagussa, 1978, Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients, Cancer, 41, 1170, 10.1002\u002F1097-0142(197803)41:3\u003C1170::AID-CNCR2820410355>3.0.CO;2-I\nChia, 2008, Locally advanced and inflammatory breast cancer, J Clin Oncol, 26, 786, 10.1200\u002FJCO.2008.15.0243\n2018, Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials, Lancet Oncol, 19, 27, 10.1016\u002FS1470-2045(17)30777-5\nvon Minckwitz, 2012, Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes, J Clin Oncol, 30, 1796, 10.1200\u002FJCO.2011.38.8595\nBonnefoi, 2014, Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994\u002FBIG 1-00 phase III trial, Ann Oncol, 25, 1128, 10.1093\u002Fannonc\u002Fmdu118\nCortazar, 2014, Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, Lancet, 384, 164, 10.1016\u002FS0140-6736(13)62422-8\nCardoso, 2019, Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†, Ann Oncol, 30, 1194, 10.1093\u002Fannonc\u002Fmdz173\n1998, Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group, Lancet, 352, 930, 10.1016\u002FS0140-6736(98)03301-7\n2005, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 365, 1687, 10.1016\u002FS0140-6736(05)66544-0\nMartin, 2003, Ann Oncol, 14, 833, 10.1093\u002Fannonc\u002Fmdg260\nFumoleau, 2003, Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial, J Clin Oncol, 21, 298, 10.1200\u002FJCO.2003.04.148\nBria, 2006, Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients, Cancer, 106, 2337, 10.1002\u002Fcncr.21886\nFerguson, 2007, Taxanes for adjuvant treatment of early breast cancer, Cochrane Database Syst Rev, CD004421\nJacquin, 2012, Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials, Breast Cancer Res Treat, 134, 903, 10.1007\u002Fs10549-011-1933-0\nDe Laurentiis, 2008, Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials, J Clin Oncol, 26, 44, 10.1200\u002FJCO.2007.11.3787\nQin, 2011, Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients, PLoS One, 6, e26946, 10.1371\u002Fjournal.pone.0026946\nEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG), 2012, Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials, Lancet, 379, 432, 10.1016\u002FS0140-6736(11)61625-5\nShao, 2012, Sequential versus concurrent anthracyclines and taxanes as adjuvant chemotherapy of early breast cancer: a meta-analysis of phase III randomized control trials, Breast, 21, 389, 10.1016\u002Fj.breast.2012.03.011\nSparano, 2008, Weekly paclitaxel in the adjuvant treatment of breast cancer, N Engl J Med, 358, 1663, 10.1056\u002FNEJMoa0707056\nNitz, 2017, Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression, Ann Oncol, 28, 2899, 10.1093\u002Fannonc\u002Fmdw349\n2019, Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials, Lancet, 393, 1440, 10.1016\u002FS0140-6736(18)33137-4\nLohrisch, 2006, Impact on survival of time from definitive surgery to initiation of adjuvant chemotherapy for early-stage breast cancer, J Clin Oncol, 24, 4888, 10.1200\u002FJCO.2005.01.6089\nBurstein, 2019, Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019, Ann Oncol, 30, 1541, 10.1093\u002Fannonc\u002Fmdz235\nSparano, 2015, Prospective validation of a 21-gene expression assay in breast cancer, N Engl J Med, 373, 2005, 10.1056\u002FNEJMoa1510764\nSparano, 2019, Clinical outcomes in early breast cancer with a high 21-gene recurrence score of 26 to 100 assigned to adjuvant chemotherapy plus endocrine therapy: a secondary analysis of the TAILORx randomized clinical trial, JAMA Oncol, 6, 367, 10.1001\u002Fjamaoncol.2019.4794\nSparano, 2019, Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer, N Engl J Med, 380, 2395, 10.1056\u002FNEJMoa1904819\nCurigliano, 2017, De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017, Ann Oncol, 28, 1700, 10.1093\u002Fannonc\u002Fmdx308\nFrancis, 2018, Tailoring adjuvant endocrine therapy for premenopausal breast cancer, N Engl J Med, 379, 122, 10.1056\u002FNEJMoa1803164\nGnant, 2015, Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12, Ann Oncol, 26, 313, 10.1093\u002Fannonc\u002Fmdu544\nBlum, 2017, Anthracyclines in early breast cancer: The ABC Trials-USOR 06-090, NSABP B-46-I\u002FUSOR 07132, and NSABP B-49 (NRG Oncology), J Clin Oncol, 35, 2647, 10.1200\u002FJCO.2016.71.4147\nNitz, 2019, West German Study PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2-negative early breast cancer, J Clin Oncol, 37, 799, 10.1200\u002FJCO.18.00028\nEjlertsen, 2017, Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, Phase III, randomized trial, J Clin Oncol, 35, 2639, 10.1200\u002FJCO.2017.72.3494\nSpring, 2016, Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis, JAMA Oncol, 2, 1477, 10.1001\u002Fjamaoncol.2016.1897\nSemiglazov, 2007, Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer, Cancer, 110, 244, 10.1002\u002Fcncr.22789\nAlba, 2012, Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM\u002F2006-03, a multicenter, randomized, phase-II study, Ann Oncol, 23, 3069, 10.1093\u002Fannonc\u002Fmds132\nPalmieri, 2014, NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer, Breast Cancer Res Treat, 148, 581, 10.1007\u002Fs10549-014-3183-4\nEiermann, 2001, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study, Ann Oncol, 12, 1527, 10.1023\u002FA:1013128213451\nCataliotti, 2006, Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative « Arimidex » Compared to Tamoxifen (PROACT) trial, Cancer, 106, 2095, 10.1002\u002Fcncr.21872\nSmith, 2005, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial, J Clin Oncol, 23, 5108, 10.1200\u002FJCO.2005.04.005\nLeal, 2015, Neoadjuvant endocrine therapy for resectable breast cancer: a systematic review and meta-analysis, Breast, 24, 406, 10.1016\u002Fj.breast.2015.03.004\nMasuda, 2017, Adjuvant capecitabine for breast cancer after preoperative chemotherapy, N Engl J Med, 376, 2147, 10.1056\u002FNEJMoa1612645\nEllis, 2008, Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics, J Natl Cancer Inst, 100, 1380, 10.1093\u002Fjnci\u002Fdjn309\nPoggio, 2018, Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis, Ann Oncol, 29, 1497, 10.1093\u002Fannonc\u002Fmdy127\nLitton, 2018, Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+), J Clin Oncol, 36\nSchmid, 2017, Pembrolizumab (pembro) + chemotherapy (chemo) as neoadjuvant treatment for triple negative breast cancer (TNBC): preliminary results from KEYNOTE-173, J Clin Oncol, 35\nCameron, 2017, 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial, Lancet, 389, 1195, 10.1016\u002FS0140-6736(16)32616-2\nPerez, 2014, Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831, J Clin Oncol, 32, 3744, 10.1200\u002FJCO.2014.55.5730\nSlamon, 2011, Adjuvant trastuzumab in HER2-positive breast cancer, N Engl J Med, 365, 1273, 10.1056\u002FNEJMoa0910383\nvon Minckwitz, 2017, Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer, N Engl J Med, 377, 122, 10.1056\u002FNEJMoa1703643\nTolaney, 2019, Seven-year follow-up analysis of adjuvant paclitaxel and trastuzumab trial for node-negative, human epidermal growth factor receptor 2-positive breast cancer, J Clin Oncol, 37, 1868, 10.1200\u002FJCO.19.00066\nGoldhirsch, 2013, 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial, Lancet, 382, 1021, 10.1016\u002FS0140-6736(13)61094-6\nPivot, 2013, 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial, Lancet Oncol, 14, 741, 10.1016\u002FS1470-2045(13)70225-0\nJoensuu, 2018, Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: The SOLD Randomized Clinical Trial, JAMA Oncol, 4, 1199, 10.1001\u002Fjamaoncol.2018.1380\nConte, 2017, 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian study Short-HER, J Clin Oncol, 35\nEarl, 2019, 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial, Lancet, 393, 2599, 10.1016\u002FS0140-6736(19)30650-6\nMartin, 2017, Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 18, 1688, 10.1016\u002FS1470-2045(17)30717-9\nBuzdar, 2007, Clin Cancer Res, 13, 228, 10.1158\u002F1078-0432.CCR-06-1345\nPierga, 2010, A multicenter randomized phase II study of sequential epirubicin\u002Fcyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients, Breast Cancer Res Treat, 122, 429, 10.1007\u002Fs10549-010-0939-3\nGianni, 2010, Lancet, 375, 377, 10.1016\u002FS0140-6736(09)61964-4\nvan Ramshorst, 2018, Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial, Lancet Oncol, 19, 1630, 10.1016\u002FS1470-2045(18)30570-9\nSchneeweiss, 2013, Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA), Ann Oncol, 24, 2278, 10.1093\u002Fannonc\u002Fmdt182\nvon Minckwitz, 2019, Trastuzumab emtansine for residual invasive HER2-positive breast cancer, N Engl J Med, 380, 617, 10.1056\u002FNEJMoa1814017\nUntch, 2012, Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial, Lancet Oncol, 13, 135, 10.1016\u002FS1470-2045(11)70397-7\nGuarneri, 2012, Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study, J Clin Oncol, 30, 1989, 10.1200\u002FJCO.2011.39.0823\nBaselga, 2012, Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial, Lancet, 379, 633, 10.1016\u002FS0140-6736(11)61847-3\nRobidoux, 2013, Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial, Lancet Oncol, 14, 1183, 10.1016\u002FS1470-2045(13)70411-X\nBonnefoi, 2015, Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study, Ann Oncol, 26, 325, 10.1093\u002Fannonc\u002Fmdu551\nCarey, 2016, Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib, J Clin Oncol, 34, 542, 10.1200\u002FJCO.2015.62.1268\nGianni, 2016, 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial, Lancet Oncol, 17, 791, 10.1016\u002FS1470-2045(16)00163-7\nHurvitz, 2018, Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial, Lancet Oncol, 19, 115, 10.1016\u002FS1470-2045(17)30716-7\n2015, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, 386, 1353, 10.1016\u002FS0140-6736(15)60908-4\nBurstein, 2018, Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: ASCO Clinical Practice Guideline Focused Update, J Clin Oncol, 37, 423, 10.1200\u002FJCO.18.01160\nCuzick, 2010, Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial, Lancet Oncol, 11, 1135, 10.1016\u002FS1470-2045(10)70257-6\nRegan, 2011, Evaluating letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomized clinical trial at 8.1 years median follow-up, Lancet Oncol, 12, 1101, 10.1016\u002FS1470-2045(11)70270-4\nVelde, 2011, Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial, Lancet, 377, 321, 10.1016\u002FS0140-6736(10)62312-4\n2015, Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials, Lancet, 386, 1341, 10.1016\u002FS0140-6736(15)61074-1\nViale, 2011, Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial, Ann Oncol, 22, 2201, 10.1093\u002Fannonc\u002Fmdq738\nCoombes, 2007, Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, Lancet, 369, 559, 10.1016\u002FS0140-6736(07)60200-1\nBoccardo, 2005, Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial, J Clin Oncol, 23, 5138, 10.1200\u002FJCO.2005.04.120\nJakesz, 2005, Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial, Lancet, 366, 455, 10.1016\u002FS0140-6736(05)67059-6\nSestak, 2015, Markers for the identification of late breast cancer recurrence, Breast Cancer Res, 17, 10, 10.1186\u002Fs13058-015-0516-0\nJakesz, 2007, Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a, J Natl Cancer Inst, 99, 1845, 10.1093\u002Fjnci\u002Fdjm246\nMamounas, 2008, Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 Trial, J Clin Oncol, 26, 1965, 10.1200\u002FJCO.2007.14.0228\nJin, 2011, Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 Trial: analyses adjusting for treatment crossover, J Clin Oncol, 30, 718, 10.1200\u002FJCO.2010.34.4010\nMore on the ABCSG-16 Trial - The ASCO Post [Internet]. [cité 3 févr 2020]. Disponible sur : https:\u002F\u002Fwww.ascopost.com\u002Fissues\u002Fapril-10-2018\u002Fmore-on-the-abcsg-16-trial\u002F.\n2011, Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials, Lancet, 378, 771, 10.1016\u002FS0140-6736(11)60993-8\nFisher, 2001, Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 Randomized Trial, JNCI J Natl Cancer Inst, 93, 684, 10.1093\u002Fjnci\u002F93.9.684\nStewart, 2001, Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years, J Natl Cancer Inst, 93, 456, 10.1093\u002Fjnci\u002F93.6.456\nTormey, 1996, Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer, J Natl Cancer Inst, 88, 1828, 10.1093\u002Fjnci\u002F88.24.1828\nDavies, 2013, Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial, Lancet, 381, 805, 10.1016\u002FS0140-6736(12)61963-1\nGray, 2013, aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer, J Clin Oncol, 31\nAl-Mubarak, 2014, Extended adjuvant tamoxifen for early breast cancer: a meta-analysis, PLoS ONE, 9, 10.1371\u002Fjournal.pone.0088238\nBartlett, 2019, Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial, Ann Oncol, 30, 1776, 10.1093\u002Fannonc\u002Fmdz289\nPagani, 2020, Absolute improvements in freedom from distant recurrence to Tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT, J Clin Oncol, 38, 1293, 10.1200\u002FJCO.18.01967\nKorde, 2010, Multidisciplinary meeting on male breast cancer: summary and research recommendations, J Clin Oncol, 28, 2114, 10.1200\u002FJCO.2009.25.5729\nCardoso, 2018, Characterization of male breast cancer: results of the EORTC 10085\u002FTBCRC\u002FBIG\u002FNABCG International Male Breast Cancer Program, Ann Oncol, 29, 405, 10.1093\u002Fannonc\u002Fmdx651\nSousa, 2013, An update on male breast cancer and future directions for research and treatment, Eur J Pharmacol, 717, 71, 10.1016\u002Fj.ejphar.2013.03.037\nEggemann, 2013, Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients, Breast Cancer Res Treat, 137, 465, 10.1007\u002Fs10549-012-2355-3",{"ES":947},"Tratamiento del cáncer de mama infiltrante localizado: nuevos desafíos",{"VOID":949},"10.1016\u002Fs1283-081x(21)45718-8","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X21457188",[952,969,984,1009,1028,1043,1062],{"id":953,"sortIndex":59,"researcher":26,"roles":954,"affiliations":955,"properties":966},"7bfa269a-ec8d-49b3-bb6b-8801d2a76bf7",[696],[956],{"id":26,"sortIndex":36,"affiliation":957,"properties":26},{"id":958,"createTime":959,"updateTime":960,"relativeEntities":961,"slug":962,"properties":963,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"02f55f68-9e66-474d-acc8-74ccef7eb103","2024-01-03T14:07:46.219+00:00","2025-06-11T16:19:54.162+00:00",[],"D%C3%A9partement-de-radioth%C3%A9rapie-Centre-Georges-Fran%C3%A7ois-Leclerc-1-rue-Pr-Marion-21000-Dijon-France",{"title":964},{"VI":965},"Département de radiothérapie, Centre Georges François Leclerc, 1, rue Pr Marion, 21000 Dijon, France",{"title":967},{"VI":968},"K. Peignaux",{"id":970,"sortIndex":111,"researcher":26,"roles":971,"affiliations":972,"properties":981},"f02bc45d-23b3-49d7-8a44-3d289fbb36b3",[696],[973],{"id":26,"sortIndex":36,"affiliation":974,"properties":26},{"id":975,"createTime":976,"updateTime":976,"relativeEntities":977,"slug":26,"properties":978,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"a87a1def-e0a5-4bda-99d3-3c58b13a05d8","2024-01-03T14:07:46.228+00:00",[],{"title":979},{"VI":980},"Département de biologie et de pathologie des tumeurs, Centre Georges François Leclerc, 1, rue Pr Marion, 21000 Dijon, France",{"title":982},{"VI":983},"L. Arnould",{"id":985,"sortIndex":115,"researcher":26,"roles":986,"affiliations":987,"properties":1006},"cedc7ed2-7f52-4873-9100-3c6e2fc9bac6",[696],[988,998],{"id":989,"sortIndex":115,"affiliation":990,"properties":997},"866672d3-fe48-488d-ba6c-9b4dc5106f1b",{"id":991,"createTime":992,"updateTime":992,"relativeEntities":993,"slug":26,"properties":994,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4fba1af7-1d23-4c64-9dbc-54e5a547d646","2024-01-03T14:07:46.242+00:00",[],{"title":995},{"VI":996},"UFR des sciences de santé, 7, boulevard Jeanne d’Arc, 21000 Dijon, France",{},{"id":26,"sortIndex":36,"affiliation":999,"properties":26},{"id":1000,"createTime":1001,"updateTime":1001,"relativeEntities":1002,"slug":26,"properties":1003,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"3299e841-c1e6-4e42-a052-16461bcc4bc6","2024-01-03T14:07:46.180+00:00",[],{"title":1004},{"VI":1005},"Département d’oncologie médicale, Centre Georges François Leclerc, 1, rue Pr Marion, 21000 Dijon, France",{"title":1007},{"VI":1008},"J.-D. Fumet",{"id":1010,"sortIndex":114,"researcher":26,"roles":1011,"affiliations":1012,"properties":1025},"4d5dadb1-bbc4-4c77-9cf5-d96f34550324",[696],[1013,1018],{"id":26,"sortIndex":36,"affiliation":1014,"properties":26},{"id":1000,"createTime":1001,"updateTime":1001,"relativeEntities":1015,"slug":26,"properties":1016,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1017},{"VI":1005},{"id":1019,"sortIndex":115,"affiliation":1020,"properties":1024},"3bc84a86-2e77-48f8-89a2-38b5fc9f77db",{"id":991,"createTime":992,"updateTime":992,"relativeEntities":1021,"slug":26,"properties":1022,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1023},{"VI":996},{},{"title":1026},{"VI":1027},"C. Kaderbhai",{"id":1029,"sortIndex":36,"researcher":26,"roles":1030,"affiliations":1031,"properties":1040},"5f6354a5-5796-4539-9ac8-19a1eef3f503",[696],[1032],{"id":26,"sortIndex":36,"affiliation":1033,"properties":26},{"id":1034,"createTime":1035,"updateTime":1035,"relativeEntities":1036,"slug":26,"properties":1037,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"e19d8151-be85-4534-802b-2629da7c6ace","2024-01-03T14:07:46.254+00:00",[],{"title":1038},{"VI":1039},"Département de chirurgie oncologique, Centre Georges François Leclerc, 1, rue Pr Marion, 21000 Dijon, France",{"title":1041},{"VI":1042},"C. Jankowski",{"id":1044,"sortIndex":162,"researcher":26,"roles":1045,"affiliations":1046,"properties":1059},"bf20e707-ea48-40c1-bdc3-077ca7a31435",[696],[1047,1052],{"id":26,"sortIndex":36,"affiliation":1048,"properties":26},{"id":1000,"createTime":1001,"updateTime":1001,"relativeEntities":1049,"slug":26,"properties":1050,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1051},{"VI":1005},{"id":1053,"sortIndex":115,"affiliation":1054,"properties":1058},"92ba4466-cda0-4e86-be6c-fd691891c471",{"id":991,"createTime":992,"updateTime":992,"relativeEntities":1055,"slug":26,"properties":1056,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1057},{"VI":996},{},{"title":1060},{"VI":1061},"S. Ladoire",{"id":1063,"sortIndex":135,"researcher":26,"roles":1064,"affiliations":1065,"properties":1078},"a7cfdd9f-f5d4-42a1-b01c-b05d9d11bfda",[696],[1066,1073],{"id":1067,"sortIndex":115,"affiliation":1068,"properties":1072},"fcadd45c-fccf-4729-adb2-141858fadaaa",{"id":991,"createTime":992,"updateTime":992,"relativeEntities":1069,"slug":26,"properties":1070,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1071},{"VI":996},{},{"id":26,"sortIndex":36,"affiliation":1074,"properties":26},{"id":1034,"createTime":1035,"updateTime":1035,"relativeEntities":1075,"slug":26,"properties":1076,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1077},{"VI":1039},{"title":1079},{"VI":1080},"C. Coutant",{"url":950,"publisher":1082,"properties":1090},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":1083,"slug":662,"properties":1084,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1087,"manageAffiliations":1088,"indexDatabases":1089,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":1085,"title":1086},{"VOID":665},{"EN":667},[],[],[],{"volume":1091,"pages":1093},{"VOID":1092},"57",{"VOID":1094},"1-20","2021-10-01",2021,{"id":1098,"createTime":1099,"updateTime":1100,"relativeEntities":1101,"slug":1102,"properties":1103,"entityType":688,"verifyStatus":25,"verifyTime":1100,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1110,"fullTextUrl":26,"authors":1111,"publicationType":747,"publisherRelationship":1127,"citationCount":26,"citationInfo":26,"publishDate":1141,"publishYear":1142,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"e3b7365d-5885-47a7-aa82-8792121ec984","2024-01-27T19:53:28.745+00:00","2025-02-09T05:10:41.900+00:00",[],"Anestesia-y-analgesia-fetales",{"references":1104,"title":1106,"doi":1108},{"VOID":1105},"Deprest, 2008, Fetal surgery for anesthesiologists, Curr. Opin. Anaesthesiol., 21, 298, 10.1097\u002FACO.0b013e3282ff8607\nDe Buck, 2008, Anesthesia for fetal surgery, Curr. Opin. Anaesthesiol., 21, 293, 10.1097\u002FACO.0b013e3282fe6e70\nFarmer, 1998, Fetal surgery: a brief review, Pediatr. Radiol., 28, 409, 10.1007\u002Fs002470050372\nMagner, 2005\nBronstein, 1986, Visceral nociception in developing rats, Dev. Psychobiol., 19, 473, 10.1002\u002Fdev.420190508\nFitzgerald, 1985, The post-natal development of cutaneous afferent fibre input and receptive field organization in the rat dorsal horn, J. Physiol., 364, 1, 10.1113\u002Fjphysiol.1985.sp015725\nFitzgerald, 1988, The development of activity evoked by fine diameter cutaneous fibres in the spinal cord of the newborn rat, Neurosci. Lett., 86, 161, 10.1016\u002F0304-3940(88)90564-2\nFitzgerald, 1991, A physiological study of the prenatal development of cutaneous sensory inputs to dorsal horn cells in the rat, J. Physiol., 432, 473, 10.1113\u002Fjphysiol.1991.sp018395\nSmith, 2000, Pain and stress in the human fetus, Eur. J. Obstet. Gynecol. Reprod. Biol., 92, 161, 10.1016\u002FS0301-2115(00)00441-3\nSemba, 1982, Ontogeny of the peptidergic system in the rat spinal cord: immunohistochemical analysis, J. Comp. Neurol., 208, 54, 10.1002\u002Fcne.902080105\nLeong, 1984, Localizing spinal cord projecting neurons in neonatal and immature albino rats, J. Comp. Neurol., 228, 18, 10.1002\u002Fcne.902280104\nFitzgerald, 1987, The postnatal development of the ventral root reflex in the rat; a comparative in vivo and in vitro study, Neurosci. Lett., 78, 41, 10.1016\u002F0304-3940(87)90558-1\nPickel, 1982, Early prenatal development of substance P and enkephalin-containing neurons in the rat, J. Comp. Neurol., 210, 411, 10.1002\u002Fcne.902100407\nAnand, 1987, Pain and its effects in the human neonate and fetus, N. Engl. J. Med., 317, 1321, 10.1056\u002FNEJM198711193172105\nLecanuet, 1989, Sensorialité fœtale. Ontogenèse des systèmes sensoriels, conséquences de leur fonctionnement fœtal, 201\nLee, 2005, Fetal pain: a systematic multidisciplinary review of the evidence, JAMA, 294, 947, 10.1001\u002Fjama.294.8.947\nLowery, 2007, Neurodevelopmental changes of fetal pain, Semin. Perinatol., 31, 275, 10.1053\u002Fj.semperi.2007.07.004\nGiannakoulopoulos, 1994, Fetal plasma cortisol and β-endorphin response to intrauterine needling, Lancet, 344, 77, 10.1016\u002FS0140-6736(94)91279-3\nSulmasy, 1999, The rule of double effect: clearing up the double talk, Arch. Intern. Med., 159, 545, 10.1001\u002Farchinte.159.6.545\nGerdin, 1990, Transplacental transfer of morphine in man, J. Perinat. Med., 18, 305, 10.1515\u002Fjpme.1990.18.4.305\nSpielman, 1984, Anesthesia for fetal surgery, Anesthesia, 39, 756, 10.1111\u002Fj.1365-2044.1984.tb06517.x\nSpencer, 1994, The effect of neuromuscular blockade on human fetal heart rate and its variation, Br. J. Obstet. Gynaecol., 101, 121, 10.1111\u002Fj.1471-0528.1994.tb13076.x\nDaffos, 1988, Fetal curarization for prenatal magnetic resonance imaging, Prenat. Diagn., 8, 312, 10.1002\u002Fpd.1970080412\nWilliamson, 1989, Magnetic resonance imaging of anomalous fetuses, Obstet. Gynecol., 73, 952\nRevel, 1993, Magnetic resonance imaging of the fetus: a study of 20 cases performed without curarization, Prenat. Diagn., 13, 775, 10.1002\u002Fpd.1970130902\nMyers, 2004, Fetal endoscopic surgery: indications and anaesthetic management, Best Pract. Res. Clin. Anaesthesiol., 18, 231, 10.1016\u002Fj.bpa.2004.01.001\nMyers, 2004, Epidural versus general anesthesia for twin-twin transfusion syndrome requiring fetal surgery, Fetal Diagn. Ther., 19, 286, 10.1159\u002F000076713\nFisk, 2001, Effect of direct fetal opioid analgesia on fetal hormonal and hemodynamic stress response to intrauterine needling, Anesthesiology, 95, 828, 10.1097\u002F00000542-200110000-00008\nHaram, 1980, Diazepam as an induction agent for caesarean section: a clinical and pharmacological study of fetal exposure, Br. J. Obstet. Gynaecol., 87, 506, 10.1111\u002Fj.1471-0528.1980.tb04587.x\nJauniaux, 1996, In-vivo study of diazepam transfer across the first trimester human placenta, Hum. Reprod., 11, 889, 10.1093\u002Foxfordjournals.humrep.a019272\nMissant, 2004, Remifentanil for foetal immobilisation and maternal sedation during endoscopic treatment of twin-to-twin transfusion syndrome: a preliminary dose-finding study, Acta Anaesthesiol. Belg., 55, 239\nMoise, 1989, Intravenous pancuronium bromide for fetal neuromuscular blockade during intrauterine transfusion for red-cell alloimmunization, Obstet. Gynecol., 74, 905\nNatori M, Ishimoto H, Myazaki T. Intervention in the fetuses with pleural effusion. [Abstract]. 2nd World congress of Perinatal Medicine, Rome, 1993.\nNakano, 1991, Anesthesia for cesarean section in patients with fetal anomaly, Masui, 40, 738\nHanley, 1994, Fetal cardiac surgery, Adv. Card. Surg., 5, 47\nHarrison, 1990, Antenatal intervention for congenital cystic adenomatoid malformation, Lancet, 336, 965, 10.1016\u002F0140-6736(90)92420-M\nEsteve, 1992, Bilan de cinq années de chirurgie expérimentale in utero pour la réparation des hernies diaphragmatiques, Ann. Fr. Anesth. Reanim., 11, 193, 10.1016\u002FS0750-7658(05)80012-7\nRychik, 2004, Acute cardiovascular effects of fetal surgery in the human, Circulation, 110, 1549, 10.1161\u002F01.CIR.0000142294.95388.C4\nGoodman, 1997, Changing tactics in the abortion argument: does a fetus feel pain?, Br. J. Hosp. Med., 58, 550\nMcMahan, 2006, Paradoxes of abortion and prenatal injury, Ethics, 116, 625, 10.1086\u002F504621\nWenger, 2006, Fetal pain legislation. Subordinating sound medical findings to moral and political agendas, J. Leg. Med., 27, 459, 10.1080\u002F01947640601021089\n2005, Respecting women's rights and fetal value: reflections on the question of fetal anesthesia, Conscience, 26, 39\nPreston, 2004, NY US Court in New York rejects partial-birth abortion ban, Times, A12\nGupta, 2007, On the nature, assessment, and treatment of fetal pain: neurobiological bases, pragmatic issues, and ethical concerns, Pain Phys, 10, 525\nSenat, 2002, Funipuncture for fetocide in late termination of pregnancy, Prenat. Diagn., 22, 354, 10.1002\u002Fpd.290\nNielsen, 1991, Analgesic efficacy of low doses of intravenously administered lidocaine on experimental laser-induced pain: a placebo controlled study, Reg. Anesth., 16, 28\nSenat, 2003, The use of lidocaine for fetocide in late termination of pregnancy, BJOG, 110, 296, 10.1046\u002Fj.1471-0528.2003.02217.x",{"ES":1107},"Anestesia y analgesia fetales",{"VOID":1109},"10.1016\u002Fs1283-081x(09)70784-2","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X09707842",[1112],{"id":1113,"sortIndex":36,"researcher":26,"roles":1114,"affiliations":1115,"properties":1124},"11214995-34e8-4643-9bd6-5f5854c6190d",[696],[1116],{"id":26,"sortIndex":36,"affiliation":1117,"properties":26},{"id":1118,"createTime":1119,"updateTime":1119,"relativeEntities":1120,"slug":26,"properties":1121,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"14238574-459e-4dc0-8c5c-1e270f52bbe8","2024-01-27T19:53:28.757+00:00",[],{"title":1122},{"VI":1123},"Service de réanimation et médecine néonatale, Centre hospitalier de Poissy-Saint-Germain-en-Laye, 10, rue du Champ-Gaillard, 78303 Poissy, France",{"title":1125},{"VI":1126},"R. Lenclen",{"url":1110,"publisher":1128,"properties":1136},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":1129,"slug":662,"properties":1130,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1133,"manageAffiliations":1134,"indexDatabases":1135,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":1131,"title":1132},{"VOID":665},{"EN":667},[],[],[],{"volume":1137,"pages":1139},{"VOID":1138},"45",{"VOID":1140},"1-6","2009-01-01",2009,{"id":1144,"createTime":1145,"updateTime":1146,"relativeEntities":1147,"slug":1148,"properties":1149,"entityType":688,"verifyStatus":25,"verifyTime":1146,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1156,"fullTextUrl":26,"authors":1157,"publicationType":747,"publisherRelationship":1173,"citationCount":26,"citationInfo":26,"publishDate":1186,"publishYear":1187,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"f8e1d282-8f4d-49e0-906f-f07294e992de","2024-01-26T09:42:18.150+00:00","2024-12-27T09:24:44.506+00:00",[],"Fibromas-uterinos",{"references":1150,"title":1152,"doi":1154},{"VOID":1151},"Abbas, 1997, Uterine rupture during labour after hysteroscopic myomectomy, Cynaecol Endose, 6, 245, 10.1046\u002Fj.1365-2508.1997.970505.x\nAcien, 1996, Abdominal myomectomy: results of a simple operative technique, Fertil Sterin, 65, 41, 10.1016\u002FS0015-0282(16)58025-X\nAharoni, 1988, Uterine myomas and pregnancy, Br I Obstet Gynaecol, 95, 510, 10.1111\u002Fj.1471-0528.1988.tb12807.x\nAndersen, 1998, Factors in fibroid growth, Baillieres Clin Obstet Cynaecol, 12, 225\nAndersen, 1995, Leiomyoma primary cultures have elevated transcriptional response to estrogen compared with autologous myometrial cultures, J Soc Gynecol Invest, 2, 542, 10.1016\u002F1071-5576(94)00053-4\nBaggish, 1989, Hysteroscopic treatment of symptomatic submucous myomata uterine with the Nd:YAG laser, J Gynecol Surg, 15, 17\nBarbot, 1994, Échecs et\u002Fou récidives après myomectomy par voie hystéroscopique, 67\nBernard, 1997, Saline contrastsonohysterography as first-fine investigation for women with uterine bleeding, Ultrasound Obstet Gynecol, 10, 121, 10.1046\u002Fj.1469-0705.1997.10020121.x\nCarr, 1993, An evaluation of the effects of gonadotropin-releasing hormone analoguesand medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double-blind, placebo-controlled, cross-over trial, J Clin Endocrinol Metab, 76, 1217, 10.1210\u002Fjc.76.5.1217\nChegini, 1994, Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF betal ),TGF beta 2, TGF beta 3, and TGF beta type bll receptor messenger ribonucleic acid and protein and contain [125] TGF betal-binding sites, Endocrinology, 135, 439, 10.1210\u002Fen.135.1.439\nCicinelli, 1997, Topical anesthesia for diagnostic hysteroscopy and endometrial biopsy in post menopausal women: a randomised placebo-controlled double-blind study, Br J Obstet Cynaecol, 104, 316, 10.1111\u002Fj.1471-0528.1997.tb11460.x\nCicinelli, 1995, Transabdominal sonohysterography transvaginal sonography and hysteroscopy in the evaluation of submucous myomas, Obstet Gynecol, 85, 42, 10.1016\u002F0029-7844(94)00298-R\nColeman, 1988, Transvaginal and transabdominal sonography: prospective comparison, Radiology, 168, 639, 10.1148\u002Fradiology.168.3.3043545\nCorson, 1991, Resectoscopic myomectomy, Fertil Steril, 55, 1041, 10.1016\u002FS0015-0282(16)54349-0\nCravello, 1995, Hysteroscopic treatment of uterine fibroids, J Gynecol Surg, 11, 227, 10.1089\u002Fgyn.1995.11.227\nDe Aloysio, 1998, Bleeding patterns in recent postmenopausal outpatients with uterine myomas: comparison between two regimens of HRT, Maturitas, 29, 261, 10.1016\u002FS0378-5122(98)00014-0\nDerman, 1991, The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas, Obstet Gynecol, 77, 591\nDonnez, 1990, Neodymium: YAG laser hysteroscopy in large submucous fibroids, Fertil Steril, 54, 999, 10.1016\u002FS0015-0282(16)53994-6\nDonnez, 2000, Laparoscopie myolysis, Hum Reprod Update, 6, 609, 10.1093\u002Fhumupd\u002F6.6.609\nDubuisson, 1996, Fertility after laparoscopic myomectomy of large intramural myomas: preliminary results, Hum Reprod, 11, 518, 10.1093\u002FHUMREP\u002F11.3.518\nDubuisson, 1997, Laparoscopic myomectomy and myolysis, Curr Opin Obstet Gynecol, 9, 233, 10.1097\u002F00001703-199708000-00004\nDubuisson, 2000, Laparoscopic myomectomy: a current view, Hum Reprod Update, 6, 588, 10.1093\u002Fhumupd\u002F6.6.588\nDubuisson, 1998, Second look after laparoscopic myomectomy, Hum Reprod, 13, 2102, 10.1093\u002Fhumrep\u002F13.8.2102\nDubuisson, 2000, Pregnancy outcome and deliveries following laparoscopic myomectomy, Hum Reprod, 15, 869, 10.1093\u002Fhumrep\u002F15.4.869\nDudiak, 1988, Uterine leiomyomas in the infertile patient: preoperative localization with MR imaging versus US and hystero-salpingography, Radiology, 167, 627, 10.1148\u002Fradiology.167.3.3283833\nEldar-Geva, 1998, Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted reproductive technology treatment, Fertil Steril, 70, 687, 10.1016\u002FS0015-0282(98)00265-9\nEnglund, 1998, Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment, J Clin Endocrinol Metab, 83, 4092, 10.1210\u002Fjc.83.11.4092\nFarhi, 1995, Effect of uterine leiomyomata on the results of in-vitro fertilization treatment, Hum Reprod, 10, 2576, 10.1093\u002Foxfordjournals.humrep.a135748\nFriedman, 1995, Does low-dose combination oral contraceptive use affect uterine size or menstrual flow ín premenopausal women with leiomyomas, Obstet Gynecol, 85, 631, 10.1016\u002F0029-7844(95)00007-E\nFriedmann, 1996, Uterine rupture after laparoscopic myomectomy, Acta Obstet Gynecol Scand, 75, 683, 10.3109\u002F00016349609054700\nGiatras, 1999, Fertility after hysteroscopic resection of submucous myomas, J Am Assoc Gynecol Laparosc, 6, 155, 10.1016\u002FS1074-3804(99)80094-2\nGoldenberg, 1995, Outcome of hysteroscopic resection of submucous myomas for infertility, Fertil Steril, 64, 714, 10.1016\u002FS0015-0282(16)57844-3\nGoodwin, 1997, Preliminary experience with uterine artery embolization for uterine fibroids, J Vase Interv Radiol, 8, 517, 10.1016\u002FS1051-0443(97)70603-1\nGoodwin, 1998, Uterine artery embolization for the treatment of uterine fibroids, Curr Opin Obstet Gynecol, 10, 315, 10.1097\u002F00001703-199808000-00006\nGraves, 1933, Tumors of the uterus\nGreogoriou, 1997, Effect of tibolone on posmenopausal women with myoma, Maturitas, 27, 187, 10.1016\u002FS0378-5122(97)00036-4\nHallez, 1995, Single stage total hysteroscopic myomectomies: indications, techniques, and results, Fertil Steril, 63, 703, 10.1016\u002FS0015-0282(16)57469-X\nHofmann, 1984, Binding sites for epidermal growth factor in human uterine tissues and leiomyomas, J Clin Endocrinol Metab, 58, 880, 10.1210\u002Fjcem-58-5-880\nHowe, 1996, Presence of an insulin-like growth factor I autocrine loop predicts uterine fibroid responsiveness to tamoxifen, Cancer Res, 56, 4049\nHucke, 1992, Hysteroscopic resection of submucous myoma, Geburtshilfe Frauenheilkd, 52, 214, 10.1055\u002Fs-2007-1026132\nKarasick, 1992, Imaging of uterine leiomyomas, AJR Am J Roentgenol, 158, 799, 10.2214\u002Fajr.158.4.1546595\nKjerulff, 1996, Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis, J Reprod Med, 41, 483\nLee, 1985, The uterus: in vitro MR-anatomic correlation of normal and abnormal specimens, Radiology, 157, 175, 10.1148\u002Fradiology.157.1.4034962\nLoffer, 1990, Removal of large symptomatic intrauterine growths by the hysteroscopic resectoscope, Obstet Gynecol, 76, 836, 10.1097\u002F00006250-199011000-00023\nLumbiganon, 1995, Protective effect of depolmedroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study, Br J Obstet Cynaecol, 103, 909, 10.1111\u002Fj.1471-0528.1996.tb09911.x\nMais, 1996, Laparoscopie versus abdominal myomectomy: a prospective, randomized trial to evaluate benefits in early outcome, Am J Obstet Gynecol, 174, 654, 10.1016\u002FS0002-9378(96)70445-3\nMarugo, 1989, Estrogen and progesterone receptors in uterine leiomyomas, Acta Obstet Gynecol Scand, 68, 731, 10.3109\u002F00016348909006147\nMatsua, 1997, Increased expression of Bcl2 protein in human uterine leiomyoma and its up-regulation by progesterone, J Clin Endocrinol Metab, 82, 293, 10.1210\u002Fjc.82.1.293\nMayer, 1995, Ultrasonography and MRI of uterine fibroids, Obstet Gynecol Clin North Am, 22, 667, 10.1016\u002FS0889-8545(21)00660-4\nMencaglia, 1986, Diagnostic hysteroscopy today, Acta Eur fertill, 17, 431\nMergui, 1993, Hystéroscopie opératoire et fibromes, Gynécologie, 1, 325\nMurphy, 1993, Regression of uterine leiomyomata in response to the anti-progesterone RU486, J Clin Endocrinol Metab, 76, 513, 10.1210\u002Fjc.76.2.513\nMurphy, 1995, Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect, Fertil Steril, 64, 187, 10.1016\u002FS0015-0282(16)57678-X\nNagele, 1997, Randomized placebo controlled trial of mefenamic acid for premedication at outpatient hysteroscopy: a pilotstudy, Br J Obstet Cynaecol, 104, 842, 10.1111\u002Fj.1471-0528.1997.tb12031.x\nNarayan, 1994, Treatment of submucous fibroid and outcome of assisted conception, J Am Assoc Gynecol Laparosc, 1, 307, 10.1016\u002FS1074-3804(05)80793-5\nParazzini, 1988, Epidemiologie characteristics of women with uterine fibroids: a case control study, Obstet Gynecol, 72, 853, 10.1097\u002F00006250-198812000-00008\nParazzini, 1992, Oral contraceptive useand riskofuterinefibroids, Obstet Gynecol, 79, 430, 10.1097\u002F00006250-199203000-00021\nParazzini, 1996, Uterine myomas and smoking results from Italian study, J Reprod Med, 41, 316\nPreutthipan, 1998, Hysteroscopic resection of submucous myoma: a results of 50 procedures, J Med Assoc Thailand, 81, 190\nRamzy, 1998, Uterine myomata and outcome of assisted reproduction, Hum Reprod, 13, 198, 10.1093\u002Fhumrep\u002F13.1.198\nRavina, 1997, Recourse to particular arterial embolization in the treatment of some uterine leiomyoma, Bull Acad Natl, 181, 233\nRavina, 1995, Arterial embolisation to treat uterine myomata, Lancet, 346, 671, 10.1016\u002FS0140-6736(95)92282-2\nRavina, 1994, Embolisation préopératoire des fibromes utérins, Presse Méd, 23, 1540\nReich, 1992, A simple method for ligation with straight and curved needle in operative laparoscopy, Obstet Gynecol, 79, 143\nReidy, 1998, Uterine artery embolization for fibroid disease, Cardiovasc Intervent Radiol, 21, 357, 10.1007\u002Fs002709900280\nRein, 1995, Progesterone: a critical role in the pathogenesis of uterine myomas, Am J Obstet Gynecol, 172, 14, 10.1016\u002F0002-9378(95)90077-2\nSato, 1998, Body fat distribution and uterine leiomyomas, J Epidemiol, 8, 176, 10.2188\u002Fjea.8.176\nSchwarzler, 1998, An evaluation of sonohysterography and diagnostic hysteroscopy for the assessment of intrauterine pathology, Ultrasound Obstet Gynecol, 11, 337, 10.1046\u002Fj.1469-0705.1998.11050337.x\nStovall, 1998, Uterine leiomyomas reduce the efficacy of assisted reproduction cycles: results of a matched follow-up study, Hum Reprod, 13, 192, 10.1093\u002Fhumrep\u002F13.1.192\nTulandi, 1993, Adhesion formation and reproductive outcome after myomectomy and secondlook laparoscopy, Obstei Gynecol, 82, 213\nUgur, 1996, Laparoscopy for adhesion prevention following myomectomy, Int J Gynecol Obstet, 53, 145, 10.1016\u002F0020-7292(95)02644-4\nValle, 1990, Hysteroscopic removal of submucous leiomyomas, J Gynecol Surg, 6, 89, 10.1089\u002Fgyn.1990.6.89\nVan Roessel, 1987, Sonographic investigation of the uterus during artificial uterine cavity distention, JCU J Clin Ultrasound, 15, 439, 10.1002\u002Fjcu.1870150703\nVarasteh, 1999, Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women, Obstet Gynecol, 94, 168, 10.1016\u002FS0029-7844(99)00278-1\nVercellini, 1998, Abdominal myomectomy for infertility: a comprehensive review, Hum Reprod, 13, 873, 10.1093\u002Fhumrep\u002F13.4.873\nVercellini, 1999, Determinants of reproductive outcome after abdominal myomectomy for infertility, Fertil Steril, 72, 109, 10.1016\u002FS0015-0282(99)00200-9\nVercellini, 1999, Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility, Obstet Gynecol, 94, 341, 10.1016\u002FS0029-7844(99)00346-4\nVerkauf, 1992, Myomectomy for fertility enhancement and preservation, Fertil Steril, 58, 1, 10.1016\u002FS0015-0282(16)55128-0\nVij, 1990, Progestin and antiprogestin interactions with progesterone receptors in human myomas, Int J Gynaecol Obstet, 31, 347, 10.1016\u002F0020-7292(90)90913-6\nVikhlyaeva, 1995, Familial predisposition to uterine leiomyomas, Int J Gynaecol Obstet, 51, 127, 10.1016\u002F0020-7292(95)02533-I\nViville, 1997, Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium, Hum Reprod, 12, 815, 10.1093\u002Fhumrep\u002F12.4.815\nVollenhoven, 1998, Introduction: the epidemiology of uterine leiomyomas, Baillieres Clin Obstet Gynecol, 12, 169, 10.1016\u002FS0950-3552(98)80059-X\nVollenhoven, 1993, Messenger ribonucleic acid expression of the insulin like growth factors and their binding proteins in uterines fibroids and myometrium, J Clin Endocrinol Metab, 76, 1106, 10.1210\u002Fjc.76.5.1106\nVollenhoven, 1990, Uterine fibroids: a clinical review, Br J Obstet Cynaecol, 97, 285, 10.1111\u002Fj.1471-0528.1990.tb01804.x\nWallach, 1992, Myomectomy, 647\nWamsteker, 1993, Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension, Obstet Gynecol, 82, 736\nWeissman, 1996, Transvaginal ultrasonography in nonpregnant and postmenopausal women, Am Fam Physician, 53, 2065\nZaloudek, 1994, Mesenchymal tumors of the uterus, 487",{"ES":1153},"Fibromas uterinos",{"VOID":1155},"10.1016\u002Fs1283-081x(02)71897-3","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X02718973",[1158],{"id":1159,"sortIndex":36,"researcher":26,"roles":1160,"affiliations":1161,"properties":1170},"0866e30c-27d7-43b6-99de-ef755098efae",[696],[1162],{"id":26,"sortIndex":36,"affiliation":1163,"properties":26},{"id":1164,"createTime":1165,"updateTime":1165,"relativeEntities":1166,"slug":26,"properties":1167,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"164636f5-d903-43bc-8aaa-c5f01cc19780","2024-01-21T05:33:12.399+00:00",[],{"title":1168},{"VI":1169},"Professeur des Universités, praticien hospitalier",{"title":1171},{"VI":1172},"H. Fernandez",{"url":1156,"publisher":1174,"properties":1182},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":1175,"slug":662,"properties":1176,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1179,"manageAffiliations":1180,"indexDatabases":1181,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":1177,"title":1178},{"VOID":665},{"EN":667},[],[],[],{"volume":1183,"pages":1185},{"VOID":1184},"38",{"VOID":876},"2002-01-01",2002,{"id":1189,"createTime":1190,"updateTime":1191,"relativeEntities":1192,"slug":1193,"properties":1194,"entityType":688,"verifyStatus":28,"verifyTime":1191,"verifyNote":1201,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1202,"fullTextUrl":26,"authors":1203,"publicationType":747,"publisherRelationship":1232,"citationCount":26,"citationInfo":26,"publishDate":1246,"publishYear":1247,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"83ee17d2-6508-46b2-8348-f1e481b0c9c0","2024-01-11T03:23:13.763+00:00","2024-12-05T17:40:40.930+00:00",[],"Cirug%C3%ADa-m%C3%ADnimamente-invasiva-de-la-incontinencia-urinaria-de-esfuerzo",{"references":1195,"title":1197,"doi":1199},{"VOID":1196},"Minaire, 1992, The prevalence of female urinary incontinence in general practice, J. Gynecol. Obstet. Biol. Reprod. (Paris), 21, 731\nJacquetin, 1998, Can a very simple test justify using a new intervention in stress urinary incontinence? The Ulmsten prosthetic sub-urethral support, J. Gynecol. Obstet. Biol. Reprod. (Paris), 27, 215\nAmarenco, 2004, The ANAES Recommendations for good practice: management of female urinary incontinence in general medicine (May 2003), Gynecol. Obstet. Fertil., 32, 1082, 10.1016\u002Fj.gyobfe.2004.10.013\nNilsson, 2004, Seven-year follow-up of the tension-free vaginal tape procedure for treatment of urinary incontinence, Obstet. Gynecol., 104, 1259, 10.1097\u002F01.AOG.0000146639.62563.e5\nJacquetin, 2000, Use of \"TVT\" in surgery for female urinary incontinence, J. Gynecol. Obstet. Biol. Reprod. (Paris), 29, 242\nMeltomaa, 2004, Concomitant vaginal surgery did not affect outcome of the tension-free vaginal tape operation during a prospective 3-year follow-up study, J. Urol., 172, 222, 10.1097\u002F01.ju.0000128679.18540.20\nHolmgren, 2005, Long-term results with tension-free vaginal tape on mixed and stress urinary incontinence, Obstet. Gynecol., 106, 38, 10.1097\u002F01.AOG.0000167393.95817.dc\nSergent, 2004, Does tension-free vaginal tape (TVT) have a place in the treatment of sphincter incompetence?, J. Gynecol. Obstet. Biol. Reprod. (Paris), 33, 210, 10.1016\u002FS0368-2315(04)96441-1\nRezapour, 2001, Tension-Free vaginal tape (TVT) in stress incontinent women with intrinsic sphincter deficiency (ISD)--a long-term follow-up, Int. Urogynecol. J. Pelvic Floor Dysfunct., 12, S12, 10.1007\u002Fs001920170005\nRezapour, 2001, Tension-Free vaginal tape (TVT) in women with recurrent stress urinary incontinence--a long-term follow up, Int. Urogynecol. J. Pelvic Floor Dysfunct., 12, S9, 10.1007\u002Fs001920170004\nEnhorning, 1960, Functional sphincterometry-a test for stress incontinence, Urol. Int., 10, 129, 10.1159\u002F000277492\nDeLancey, 1994, Structural support of the urethra as it relates to stress urinary incontinence: the hammock hypothesis, Am. J. Obstet. Gynecol., 170, 1713, 10.1016\u002FS0002-9378(12)91840-2\nPetros, 1990, An integral theory of female urinary incontinence. Experimental and clinical considerations, Acta Obstet. Gynecol. Scand., 153, 7, 10.1111\u002Fj.1600-0412.1990.tb08027.x\nPetros, 1997, Role of the pelvic floor in bladder neck opening and closure I: muscle forces, Int. Urogynecol. J. Pelvic Floor Dysfunct., 8, 74, 10.1007\u002FBF02764822\nBerkow, 1955, Paraurethral fixation for stress incontinence; re-examination of its rationale, indications, and technic, Obstet. Gynecol., 5, 74\nHodgkinson, 1957, Urinary stress incontinence in the female. III. Round-ligament technic for retropubic suspension of the urethra, Obstet. Gynecol., 10, 493\nIngelman-Sundberg, 1957, A vaginal sling operation; for cases of stress incontinence and for women who cannot use a diaphragm due to prolapse of the anterior vaginal wall, J. Obstet. Gynaecol. Br. Emp., 64, 849, 10.1111\u002Fj.1471-0528.1957.tb08488.x\nGranjon, 1965, Retropubic suspension of the urethra and bladder neck in women. (Marshall-Marchetti-Krantz operation), Gynecol. Obstet. (Paris), 64, 581\nBurch, 1968, Cooper's ligament urethrovesical suspension for stress incontinence. Nine years' experience--results, complications, technique, Am. J. Obstet. Gynecol., 100, 764, 10.1016\u002FS0002-9378(15)33576-6\nPereyra, 1959, A simplified surgical procedure for the correction of stress incontinence in women, West. J. Surg. Obstet. Gynecol., 67, 223\nRaz, 1989, Four-corner bladder and urethral suspension for moderate cystocele, J. Urol., 142, 712, 10.1016\u002FS0022-5347(17)38863-8\nStamey, 1973, Endoscopic suspension of the vesical neck for urinary incontinence, Surg. Gynecol. Obstet., 136, 547\nBologna, 1973, Surgical methods for the treatment of stress urinary incontinence, Minerva Ginecol., 25, 413\nSalomonson, 1951, Stress incontinence; review of sixty cases operated on by the Goebell-Stoeckel method, Brux. Med., 31, 687\nMubiayi, 2002, Surgical cure of stress urinary incontinence with vaginal tissue sling: technique, results, indications, Prog. Urol., 12, 60\nLiu, 1993, Laparoscopic retropubic colposuspension (Burch procedure), J. Am. Assoc. Gynecol. Laparosc., 1, 31, 10.1016\u002FS1074-3804(05)80755-8\nPolascik, 1995, Comparison of laparoscopic and open retropubic urethropexy for treatment of stress urinary incontinence, Urology, 45, 647, 10.1016\u002FS0090-4295(99)80057-0\nUlmsten, 1995, Intravaginal slingplasty (IVS): an ambulatory surgical procedure for treatment of female urinary incontinence, Scand. J. Urol. Nephrol., 29, 75, 10.3109\u002F00365599509180543\nVierhout, 2001, Severe hemorrhage complicating tension-free vaginal tape (TVT): a case report, Int. Urogynecol. J. Pelvic Floor Dysfunct., 12, 139, 10.1007\u002Fs001920170080\nde Tayrac, 2004, Evolution of surgical routes in female stress urinary incontinence, Gynecol. Obstet. Fertil., 32, 1031, 10.1016\u002Fj.gyobfe.2004.10.019\nPeyrat, 2001, Intestinal perforation as a complication of tension-free vaginal tape procedure for urinary incontinence, Eur. Urol., 39, 603, 10.1159\u002F000052511\nDaher, 2003, Pre-pubic TVT. an alternative to classic TVT in selected patients with urinary stress incontinence, Eur. J. Obstet. Gynecol. Reprod. Biol., 107, 205, 10.1016\u002FS0301-2115(03)00051-4\nDelorme, 2001, Transobturator urethral suspension: mini-invasive procedure in the treatment of stress urinary incontinence in women, Prog. Urol., 11, 1306\nHermieu, 2005, Suburethral bands in women urinary stress incontinence: a review of the various techniques, Ann. Urol. (Paris), 39, 124, 10.1016\u002Fj.anuro.2005.08.001\nCosson, 2003, Mechanical properties of biological or synthetic implants used to treat genital prolapse and stress incontinence in women: what is the ideal material?, J. Gynecol. Obstet. Biol. Reprod. (Paris), 32, 321\nCosson, 2003, Mechanical properties of synthetic implants used in the repair of prolapse and urinary incontinence in women: which is the ideal material?, Int. Urogynecol. J. Pelvic Floor Dysfunct., 14, 169, 10.1007\u002Fs00192-003-1066-z\nDebodinance, 2004, Changing attitudes on the surgical treatment of urogenital prolapse: birth of the tension-free vaginal mesh, J. Gynecol. Obstet. Biol. Reprod. (Paris), 33, 577, 10.1016\u002FS0368-2315(04)96598-2\nConnolly, 2004, Necrotizing surgical site infection after tension-free vaginal tape, Obstet. Gynecol., 104, 1275, 10.1097\u002F01.AOG.0000146284.62793.8f\nJohnson, 2003, EL OB-B, Miller HJ, Fine PM. Necrotizing fasciitis after tension-free vaginal tape (TVT) placement, Int. Urogynecol. J. Pelvic Floor Dysfunct., 14, 291, 10.1007\u002Fs00192-003-1064-1\n2003, Evaluation of TVT in feminine urinary stress incontinence (March 2002), Gynecol. Obstet. Fertil., 31, 91\nUstun, 2003, Tension-free vaginal tape compared with laparoscopic Burch urethropexy, J. Am. Assoc. Gynecol. Laparosc., 10, 386, 10.1016\u002FS1074-3804(05)60268-X\nParaiso, 2004, Laparoscopic Burch colposuspension versus tension-free vaginal tape: a randomized trial, Obstet. Gynecol., 104, 1249, 10.1097\u002F01.AOG.0000146290.10472.b3\nValpas, 2004, Tension-free vaginal tape and laparoscopic mesh colposuspension for stress urinary incontinence, Obstet. Gynecol., 104, 42, 10.1097\u002F01.AOG.0000128904.40103.e8\nNilsson, 2004, Latest advances in TVT tension-free support for urinary incontinence, Surg. Technol. Int., 12, 171\nTsivian, 2004, Tension-free vaginal tape procedure for the treatment of female stress urinary incontinence: long-term results, J. Urol., 172, 998, 10.1097\u002F01.ju.0000135072.27734.4a\nGutierrez Banos, 2003, Treatment of urinary stress incontinence using suburethral implantation of tension-free vaginal tape (TVT). 4 years' experience, Arch. Esp. Urol., 56, 885\nJeffry, 2001, Objective and subjective cure rates after tension-free vaginal tape for treatment of urinary incontinence, Urology, 58, 702, 10.1016\u002FS0090-4295(01)01340-1\nKuuva, 2002, A nationwide analysis of complications associated with the tension-free vaginal tape (TVT) procedure, Acta Obstet. Gynecol. Scand., 81, 72, 10.1034\u002Fj.1600-0412.2002.810113.x\nAbouassaly, 2004, Complications of tension-free vaginal tape surgery: a multi-institutional review, BJU Int., 94, 110, 10.1111\u002Fj.1464-410X.2004.04910.x\nDuckett, 2004, Tension-free vaginal tape (TVT) in the United Kingdom, J. Obstet. Gynaecol., 24, 794, 10.1080\u002F01443610400009535\nAgostini, 2006, Immediate complications of tension-free vaginal tape (TVT): Results of a french survey, Eur. J. Obstet. Gynecol. Reprod. Biol., 124, 237, 10.1016\u002Fj.ejogrb.2005.06.035\nNovak, 1977\nde Leval, 2003, Novel surgical technique for the treatment of female stress urinary incontinence: transobturator vaginal tape inside-out, Eur. Urol., 44, 724, 10.1016\u002Fj.eururo.2003.09.003\nBonnet, 2005, Transobturator vaginal tape inside out for the surgical treatment of female stress urinary incontinence: anatomical considerations, J. Urol., 173, 1223, 10.1097\u002F01.ju.0000148364.13525.7b\nReisenauer, 2005, Transobturator vaginal tape inside-out A minimally invasive treatment of stress urinary incontinence: Surgical procedure and anatomical conditions, Eur. J. Obstet. Gynecol. Reprod. Biol., 26\nDelorme, 2004, Transobturator tape (Uratape): a new minimally-invasive procedure to treat female urinary incontinence, Eur. Urol., 45, 203, 10.1016\u002Fj.eururo.2003.12.001\nCindolo, 2004, Tension-free transobturator approach for female stress urinary incontinence, Minerva Urol. Nefrol., 56, 89\nDavila, 2005, Multicenter experience with the Monarc transobturator sling system to treat stress urinary incontinence, Int. Urogynecol. J. Pelvic. Floor. Dysfunct., 29, 1\nDeval, 2005, Objective and subjective cure rates after trans-obturator tape (Obtape®) treatment of female urinary incontinence, Eur. Urol., 20\nWang, 2005, Prospective randomized comparison of transobturator suburethral sling (Monarc) vs suprapubic arc (Sparc) sling procedures for female urodynamic stress incontinence, Int. Urogynecol. J. Pelvic Floor Dysfunct., 3, 1\nFischer, 2005, Comparison of retropubic and outside-in transobturator sling systems for the cure of female genuine stress urinary incontinence, Eur. Urol., 48, 799, 10.1016\u002Fj.eururo.2005.07.019\nDavid-Montefiore, 2006, Peri-operative complications and pain after the suburethral sling procedure for urinary stress incontinence: a French prospective randomised multicentre study comparing the retropubic and transobturator routes, Eur. Urol., 49, 133, 10.1016\u002Fj.eururo.2005.09.019\nMinaglia, 2004, Bladder injury during transobturator sling, Urology, 64, 376, 10.1016\u002Fj.urology.2004.04.030\nBut, 2005, Vaginal wall erosion after transobturator tape procedure, Int. Urogynecol. J. Pelvic Floor Dysfunct., 16, 506, 10.1007\u002Fs00192-004-1266-1\nGame, 2004, Obturator infected hematoma and urethral erosion following transobturator tape implantation, J. Urol., 171, 1629, 10.1097\u002F01.ju.0000115881.28311.f8\nAlbouy, 2004, Can transobturator tape for urinary incontinence cause complete urinary retention?, Prog. Urol., 14, 189\nPolitano, 1973, Periurethral Teflon® injection for urinary incontinence, Trans. Am. Assoc. Genitourin. Surg., 65, 54\nFerro, 1988, Periurethral granuloma: unusual complication of Teflon® periurethral injection, Urology, 31, 422, 10.1016\u002F0090-4295(88)90740-6\nKiilholma, 1993, Complications of Teflon® injection for stress urinary incontinence, Neurourol. Urodyn., 12, 131, 10.1002\u002Fnau.1930120206\nPifarotti, 2003, The injectables in urogynecology, Minerva Ginecol., 55, 99\nBarranger, 2000, Results of transurethral injection of silicone micro-implants for females with intrinsic sphincter deficiency, J. Urol., 164, 1619, 10.1016\u002FS0022-5347(05)67042-5\nMadjar, 2003, New periurethral bulking agent for stress urinary incontinence: modified technique and early results, J. Urol., 170, 2327, 10.1097\u002F01.ju.0000090968.85279.84\nvan Kerrebroeck, 2004, Treatment of stress urinary incontinence using a copolymer system: impact on quality of life, BJU Int., 94, 1040, 10.1111\u002Fj.1464-410X.2004.05101.x\nMazouni, 2004, Minimally invasive surgery for female urinary incontinence: experience with periurethral microballoon implantation, J. Endourol., 18, 901, 10.1089\u002Fend.2004.18.901\nMcCormack, 2004, Duloxetine: in stress urinary incontinence, Drugs, 64, 2567, 10.2165\u002F00003495-200464220-00005\nSchulz, 2004, Bulking agents for stress urinary incontinence: short-term results and complications in a randomized comparison of periurethral and transurethral injections, Int. Urogynecol. J. Pelvic Floor Dysfunct., 15, 261\nPickard, 2003, N'Dow J. Periurethral injection therapy for urinary incontinence in women, Cochrane Database Syst. Rev., 2, 10.1002\u002F14651858.CD003881\nCure d'incontinence urinaire, fiche d'information aux patientes (éditée par le CNGOF), août-septembre 1999. www.cngof.asso.fr\n1998\nKamina, 2000\nCosson, 2004\nVillet, 2005\nFernandez, 2005",{"ES":1198},"Cirugía mínimamente invasiva de la incontinencia urinaria de esfuerzo",{"VOID":1200},"10.1016\u002Fs1283-081x(07)70828-7","Author affiliation is blank","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X07708287",[1204,1211,1218,1225],{"id":1205,"sortIndex":115,"researcher":26,"roles":1206,"affiliations":1207,"properties":1208},"9b39df1a-f727-4657-9733-5b3fc7afb388",[696],[],{"title":1209},{"VI":1210},"B. Fatton",{"id":1212,"sortIndex":114,"researcher":26,"roles":1213,"affiliations":1214,"properties":1215},"51a70d06-e5e3-4d0b-952e-de7178631e36",[696],[],{"title":1216},{"VI":1217},"G. Chene",{"id":1219,"sortIndex":59,"researcher":26,"roles":1220,"affiliations":1221,"properties":1222},"35e3eb21-86a7-4456-af21-28a92aacb1b9",[696],[],{"title":1223},{"VI":1224},"B. Jacquetin",{"id":1226,"sortIndex":36,"researcher":26,"roles":1227,"affiliations":1228,"properties":1229},"921608b6-9fb8-42ca-9d4e-500fcea94259",[696],[],{"title":1230},{"VI":1231},"J. Amblard",{"url":1202,"publisher":1233,"properties":1241},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":1234,"slug":662,"properties":1235,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1238,"manageAffiliations":1239,"indexDatabases":1240,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":1236,"title":1237},{"VOID":665},{"EN":667},[],[],[],{"volume":1242,"pages":1244},{"VOID":1243},"43",{"VOID":1245},"1-13","2007-01-01",2007,{"id":1249,"createTime":1250,"updateTime":1251,"relativeEntities":1252,"slug":1253,"properties":1254,"entityType":688,"verifyStatus":25,"verifyTime":1251,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1261,"fullTextUrl":26,"authors":1262,"publicationType":747,"publisherRelationship":1320,"citationCount":26,"citationInfo":26,"publishDate":1141,"publishYear":1142,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"6295d359-68af-4766-aaf7-4883bc9227ad","2023-12-28T21:25:20.387+00:00","2025-02-09T18:50:52.785+00:00",[],"C%C3%A1ncer-de-endometrio",{"references":1255,"title":1257,"doi":1259},{"VOID":1256},"Jemal, 2005, Cancer statistics, 2005, CA Cancer J. Clin., 55, 10, 10.3322\u002Fcanjclin.55.1.10\nMadison, 2004, Endometrial cancer: socioeconomic status and racial\u002Fethnic differences in stage at diagnosis, treatment, and survival, Am. J. Public Health, 94, 2104, 10.2105\u002FAJPH.94.12.2104\nGershenson, 2004\nCalle, 2003, Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults, N. Engl. J. Med., 348, 1625, 10.1056\u002FNEJMoa021423\nSwanson, 1993, Relation of endometrial cancer risk to past and contemporary body size and body fat distribution, Cancer Epidemiol. Biomarkers Prev., 2, 321\nPotischman, 1996, Case-control study of endogenoussteroid hormones and endometrial cancer, J. Natl. Cancer Inst., 88, 1127, 10.1093\u002Fjnci\u002F88.16.1127\nRichelson, 1984, Relative contributions of aging and estrogen deficiency to post-menopausal bone loss, N. Engl. J. Med., 311, 1273, 10.1056\u002FNEJM198411153112002\nKlip, 2000, Cancer risk associated with subfertility and ovulation induction: a review, Cancer Causes Control, 11, 319, 10.1023\u002FA:1008921211309\nLambe, 1999, Childbearing at older age and endometrial cancer risk, Cancer Causes Control, 10, 43, 10.1023\u002FA:1008860615584\nPetrakis, 1987, Influence of pregnancy and lactation on serum and breast fluid estrogen level: implications for breast cancer risk, Int. J. Cancer, 40, 587, 10.1002\u002Fijc.2910400502\nSalerno, 1962, Feminizing mesenchymomas of the ovary: an analysis of 28 granulosa-theca cell tumors and their relationshipto co-existent carcinoma, Am. J. Obstet. Gynecol., 84, 731, 10.1016\u002F0002-9378(62)90022-4\nSpeert, 1949, Endometrial cancer and hepatic cirrhosis, Cancer, 2, 597, 10.1002\u002F1097-0142(194907)2:4\u003C597::AID-CNCR2820020407>3.0.CO;2-0\nDeligeoroglou, 2003, Oral contraceptives and reproductive system cancer, Ann. N. Y. Acad. Sci., 997, 199, 10.1196\u002Fannals.1290.023\n1983, Oral contraceptive use and the risk of endometrial cancer, JAMA, 249, 1600, 10.1001\u002Fjama.1983.03330360040033\nWeiderpass, 1999, Use of oral contraceptives and endometrial cancer risk (Sweden), Cancer Causes Control, 10, 277, 10.1023\u002FA:1008945721786\nLawrence, 1987, Smoking, body weight, and early-stage endometrial cancer, Cancer, 59, 1665, 10.1002\u002F1097-0142(19870501)59:9\u003C1665::AID-CNCR2820590924>3.0.CO;2-2\nHemminki, 2004, Familial clustering of ovarian and endometrial cancers, Eur. J. Cancer, 40, 90, 10.1016\u002FS0959-8049(03)00627-0\nUmar, 2004, Testing guidelines for hereditary non-polyposis colorectal cancer, Nat. Rev. Cancer, 4, 153, 10.1038\u002Fnrc1278\nGehrig, 2004, Association between uterine serous carcinoma and breast cancer, Gynecol. Oncol., 94, 208, 10.1016\u002Fj.ygyno.2004.04.009\nLanger, 1997, Transvaginal ultrasonography comprared with endometrial biopsy for the detection of endometrial disease\u002F Post menopausal estrogen\u002Fprogestin interventions trial, N. Engl. J. Med., 337, 1792, 10.1056\u002FNEJM199712183372502\nRobertson, 2003, Screening for endometrial cancer, Med. J. Aust., 178, 657, 10.5694\u002Fj.1326-5377.2003.tb05400.x\nGerber, 2001, Ultrasonographic detection of asymptomatic endometrial cancer in post menopausal patients offers no pronostic advantage over symptomatic disease discovered by uterine bleeding, Eur. J. Cancer, 37, 64, 10.1016\u002FS0959-8049(00)00356-7\nKim, 1998, Diagnostic and therapeutic advances in gynecology oncology: screening for gynecologic cancer, Cancer Treat. Res., 95, 253, 10.1007\u002F978-1-4615-5447-9_9\nLhomme, 2003, Endometrial surveillance of women on tamoxifen, Gynecol. Obstet. Fertil., 31, 647\nNeven, 1998, Should tamoxifen users be screened for endometrial lesions?, Lancet, 351, 155, 10.1016\u002FS0140-6736(05)78216-7\nLu, 2005, Gynecologic cancer as a \"sentinel cancer\" for women with hereditary non polyposis colorectal cancer syndrome, Obstet. Gynecol., 105, 569, 10.1097\u002F01.AOG.0000154885.44002.ae\nStefansson, 2004, Pronostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type, Histopathology, 44, 472, 10.1111\u002Fj.1365-2559.2004.01882.x\nLax, 2000, A binary architectural grading system for uterine endometrioid carcinoma has superior reproductibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis, Am. J. Surg. Pathol., 24, 1201, 10.1097\u002F00000478-200009000-00002\nZaino, 1988, Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma, Semin. Diagn. Pathol., 5, 154\nSlomovitz, 2003, Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases, Gynecol. Oncol., 91, 463, 10.1016\u002Fj.ygyno.2003.08.018\nWheeler, 2000, Minimal uterine serous carcinoma diagnosis and clinicopathologic correlation, Am. J. Surg. Pathol., 24, 797, 10.1097\u002F00000478-200006000-00004\nGoff, 2005, Uterine papillary serous carcinoma: what have we learned over the past quarter century?, Gynecol. Oncol., 98, 341, 10.1016\u002Fj.ygyno.2005.07.006\nSherman, 1992, Uterine serous carcinoma: a morphologically diverse neoplasm with unifying clinicopathologic features, Am. J. Surg. Pathol., 16, 600, 10.1097\u002F00000478-199206000-00008\nAmant, 2005, Endometrial cancer, Lancet, 366, 491, 10.1016\u002FS0140-6736(05)67063-8\nAmbros, 1995, Endometrial intraepithelial carcinoma: a distinctive lesion speciffically associated with tumors displaying serous differentiation, Hum. Pathol., 26, 1260, 10.1016\u002F0046-8177(95)90203-1\nCarcangiu, 1997, Stage IA uterine serous carcinoma: a study of 13 cases, Am. J. Surg. Pathol., 21, 1507, 10.1097\u002F00000478-199712000-00015\nSoslow, 2000, Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis, Am. J. Surg. Pathol., 24, 726, 10.1097\u002F00000478-200005000-00012\nEifel, 1982, Simultaneous presentation of carcinoma involving the ovary and the uterine corpus, Cancer, 50, 163, 10.1002\u002F1097-0142(19820701)50:1\u003C163::AID-CNCR2820500131>3.0.CO;2-K\nBrinkmann, 2004, A molecular genetic and statistical approach for the diagnosisof dual-site cancers, J. Natl. Cancer Inst., 96, 1441, 10.1093\u002Fjnci\u002Fdjh272\nBokhman, 1983, Two pathogenetic types of endometrial carcinoma, Gynecol. Oncol., 15, 10, 10.1016\u002F0090-8258(83)90111-7\nGupta, 2002, Ultrasonographic endometrial thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: a meta-analysis, Acta Obstet. Gynecol. Scand., 81, 799, 10.1034\u002Fj.1600-0412.2001.810902.x\nSmith-Bindman, 1998, Endovaginal ultrasound to exclude endometrial cancer and other endometrial abnormalities, JAMA, 280, 1510, 10.1001\u002Fjama.280.17.1510\nTabor, 2002, Endometrial thickness as a test for endometrial cancer in women with postmenopausal vaginal bleeding, Obstet. Gynecol., 99, 663\nTrimble, 2005, Atypical endometrial hyperplasia: a tough call, Int. J. Gynecol. Cancer, 15, 401, 10.1111\u002Fj.1525-1438.2005.t01-1-abst_5.x\nEddy, 1997, Papanicolaou smears by the Bethesda system in endometrial malignancy: utility and pronostic importance, Obstet. Gynecol., 90, 999, 10.1016\u002FS0029-7844(97)00548-6\nFukuda, 1999, Preoperative cervical cytology in endometrial carcinoma and its clinicopathologic relevance, Gynecol. Oncol., 72, 273, 10.1006\u002Fgyno.1998.5244\nLarson, 1994, Pronostic significance of malignant cervical cytology in patient with endometrial cancer, Obstet. Gynecol., 84, 399\nGoff, 1994, Surgical stage IV endometrial carcinoma: a study of 47 cases, Gynecol. Oncol., 52, 237, 10.1006\u002Fgyno.1994.1038\nHricak, 1987, Endometrial carcinoma staging by MR imaging, Radiology, 162, 297, 10.1148\u002Fradiology.162.2.3797641\nDubinsky, 1997, The role of transvaginal sonography and endometrial biopsy in the evaluation of peri and postmenopausal bleeding, Am. J. Roentgenol., 169, 145, 10.2214\u002Fajr.169.1.9207515\nGoldstein, 2001, Evaluation of the woman with postmenopausal bleeding: Society of Radiologists in Ultrasound-Sponsored Concensus Conference statement, J. Ultrasound. Med., 20, 1025, 10.7863\u002Fjum.2001.20.10.1025\nGull, 2003, Can ultrasound replace dilatation and curettag? A longitudinal evaluation of postmenopausal bleeding and transvaginal sonographic measurement of the endometrium as predictors of endometrial cancer, Am. J. Obstet. Gynecol., 188, 401, 10.1067\u002Fmob.2003.154\nGrasel, 2000, Endometrial polyps: MR imaging features and distinction from endometrial carcinoma, Radiology, 214, 47, 10.1148\u002Fradiology.214.1.r00ja3647\nWeber, 1997, Vaginal ultrasonography versus endometrial biopsy in women with postmenopausal bleeding, Am. J. Obstet. Gynecol., 177, 924, 10.1016\u002FS0002-9378(97)70295-3\nFerrazzi, 1996, Sonographic endometrial thickness: a useful test to predict atrophy in patients with post menopausal bleeding. An italian multicenter study, Ultrasound Obstet. Gynecol., 7, 315, 10.1046\u002Fj.1469-0705.1996.07050315.x\nDijkhuizen, 2000, The accuracy of endometrial sampling in the diagnosis of patients with endometrial cancer: a systematic quantitative review, Cancer, 89, 1765, 10.1002\u002F1097-0142(20001015)89:8\u003C1765::AID-CNCR17>3.0.CO;2-F\nKarlsson, 1995, Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding: A Nordic Multicenter Study, Am. J. Obstet. Gynecol., 172, 1488, 10.1016\u002F0002-9378(95)90483-2\nPhillip, 2004, Correlation between transvaginal ultrasound measured endometrial thickness and histopathologic findings in Afro-Carrbean Jamaican women with postmenopausal bleeding, J. Obstet. Gynecol., 24, 568, 10.1080\u002F01443610410001722671\nvan Doorn, 2004, Accuracy of transvaginal ultrasonography in diabetic or obese women with post menopausal bleeding, Obstet. Gynecol., 104, 571, 10.1097\u002F01.AOG.0000136080.55874.7f\nWang, 2006, Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers, Gynecol. Oncol., 101, 120, 10.1016\u002Fj.ygyno.2005.09.042\nSchwarzler, 1998, An evaluation of sonohysterography and diagnostic hysteroscopy for the assessment of intrauterine pathology, Ultrasound Obstet. Gynecol., 11, 337, 10.1046\u002Fj.1469-0705.1998.11050337.x\nGoldstein, 1997, Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding, Am. J. Obstet. Gynecol., 177, 102, 10.1016\u002FS0002-9378(97)70446-0\nAyhan, 1994, Correlation between clinical and histopathologic risk factors and lymph node metastases in early endometrial cancer (a multivariate analysis of 183 cases), Int. J. Gynecol. Cancer, 4, 306, 10.1046\u002Fj.1525-1438.1994.04050306.x\nBradley, 2004, Hysteroscopy and cytology in endometrial cancer, Obstet. Gynecol., 104, 1030, 10.1097\u002F01.AOG.0000143263.19732.18\nNarducci, 2006, What is new in the surgical treatment of pelvic gynecologic cancers?, Bull. Cancer, 93, 43\nDessole, 2006, Risks and usefulness of sonohysterography in patients with endometrial carcinoma, Am. J. Obstet. Gynecol., 194, 362, 10.1016\u002Fj.ajog.2005.08.036\nValenzano, 2001, The role of transvaginal ultrasound and sonohysterography in the diagnosis and staging of endometrial adenocarcinoma, Radiol. Med. (Torino), 101, 365\nClark, 2002, Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review, BJOG, 109, 313, 10.1111\u002Fj.1471-0528.2002.01088.x\nKoss, 1981, Screening of asymptomatic women for endometrial cancer, Obstet. Gynecol., 57, 681\nGarcia, 2003, Thin-layer cytology and histopathology in the evaluation of abnormal uterine bleeding, J. Reprod. Med., 48, 882\nEpstein, 2001, Dilatation and curettage fails to detect most focal lésions in the uterine cavity in women with post menopausal bleeding, Acta Obstet. Gynecol. Scand., 80, 1121, 10.1034\u002Fj.1600-0412.2001.801210.x\nObermair, 1999, Endometrial cancer accuracy of the finding of a well-differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy, Int. J. Gynecol. Cancer, 9, 383, 10.1046\u002Fj.1525-1438.1999.99050.x\nDaniel, 1988, Accuracy of office and operating room curretage in the grading of endometrial carcininoma, Obstet. Gynecol., 71, 612\nDijkhuizen, 2003, Cost-effectiveness of the use of transvaginal sonography in the evaluation of post menopausal bleeding, Maturitas, 45, 275, 10.1016\u002FS0378-5122(03)00152-X\nClark, 2006, Investigating postmenopausal bleeding for endometrial cancer: cost-effectiveness of initial diagnostic strategies, BJOG, 113, 502, 10.1111\u002Fj.1471-0528.2006.00914.x\nCreasman, 1989, FIGO stage 1988 revision, Gynecol. Oncol., 35, 125\nCreutzberg, 2000, Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma, Lancet, 355, 1404, 10.1016\u002FS0140-6736(00)02139-5\nZuurendonk, 2006, Routine pelvic lymphadenectomy in apparently early stage endometrial cancer, Eur. J. Surg. Oncol., 32, 450, 10.1016\u002Fj.ejso.2006.02.008\nKinkel, 1999, Radiologic staging in patients with endometrial cancer: a meta-analysis, Radiology, 212, 711, 10.1148\u002Fradiology.212.3.r99au29711\nBoronow, 1984, Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study, Obstet. Gynecol., 63, 825\nCreasman, 1987, Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study, Cancer, 60, 2035, 10.1002\u002F1097-0142(19901015)60:8+\u003C2035::AID-CNCR2820601515>3.0.CO;2-8\nPiver, 1982, Paraaortic lymph node evaluation in stage I endometrial carcinoma, Obstet. Gynecol., 59, 97\nSironi, 1992, Myometrialinvasion by endometrial carcinoma: assessment with plain and galodinium-enhanced MR imaging, Radiology, 185, 207, 10.1148\u002Fradiology.185.1.1523309\nGoff, 1990, Assessment of depth of myometrial invasion in endometrial adenocarcinoma, Gynecol. Oncol., 38, 46, 10.1016\u002F0090-8258(90)90009-A\nDoering, 1989, Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma, Obstet. Gynecol., 74, 930\nQuinlivan, 2001, Accuracy of frozen section for the operative management of endometrial cancer, BJOG, 108, 798\nFrumovitz, 2004, Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer, J. Am. Coll. Surg., 199, 388, 10.1016\u002Fj.jamcollsurg.2004.05.258\nOlaya, 1998, Transvaginal sonography in endometrial carcinoma: preoperative assessment of the depth of myometrial invasion in 50 cases, Eur. J. Radiol., 26, 274, 10.1016\u002FS0720-048X(96)01129-1\nTeefey, 1996, Local staging of endometrial carcinoma:comparison of transvaginal and intraoperative sonography and gross visual inspection, AJR Am. J. Roentgenol., 166, 547, 10.2214\u002Fajr.166.3.8623626\nYamashita, 1993, Assessment of myometrial invasion by endometrial carcinoma: transvaginal sonography vs contrast-enhanced MR imaging, AJR Am. J. Roentgenol., 161, 595, 10.2214\u002Fajr.161.3.8352114\nBalfe, 1983, Computed tomography in malignant endometrial neoplasms, J. Comput. Assist. Tomogr., 7, 677, 10.1097\u002F00004728-198308000-00018\nDore, 1987, CT evaluation of myometrium invasion in endometrial carcinoma, J. Comput. Assist. Tomogr., 11, 282, 10.1097\u002F00004728-198703000-00018\nKim, 1995, Detection of deep myometrial invasion in endometrial carcinoma:comparison of transvaginal ultrasound, CT, and MRI, J. Comput. Assist. Tomogr., 19, 766, 10.1097\u002F00004728-199509000-00013\nWalsh, 1982, Computed tomography of primary persistent, and recurrent endometrial malignancy, Am. J. Roentgenol., 139, 1149, 10.2214\u002Fajr.139.6.1149\nConnor, 2000, Computed tomography in endometrial carcinoma, Obstet. Gynecol., 95, 692\nJoja, 1996, Endometrial carcinoma: dynamic MRI with turbo-FLASH technique, J. Comput. Assist. Tomogr., 20, 878, 10.1097\u002F00004728-199611000-00003\nManfredi, 2005, Endometrial cancer: magnetic resonance imaging, Abdom. Imaging, 30, 626, 10.1007\u002Fs00261-004-0298-9\nSavci, 1998, Assessment of depth of myometrial carcinoma:comparison of T2-weighted SE and contrast-enhanced dynamic GRE MR imaging, Eur. Radiol., 8, 218, 10.1007\u002Fs003300050365\nIto, 2004, Endometrial cancer diagnosis by MR imaging, Nippon Rinsho, 62, 313\nSeki, 2000, Value of dynamic MR imaging in assessing endometrial carcinoma involvement of the cervix, Am. J. Roentgenol., 175, 171, 10.2214\u002Fajr.175.1.1750171\nToki, 1998, A comparative study of pre-operative procedures to assess cervical invasion by endometril carcinoma, Br. J. Obstet. Gynaecol., 105, 512, 10.1111\u002Fj.1471-0528.1998.tb10151.x\nBurghardt, 1978, Local spread and lymph node involvement in cervical cancer, Obstet. Gynecol., 52, 138\nTrattner, 2001, Prognostic factors in surgically treated stage Ib-IIb cervical carcinomas with special emphasis on the importance of tumor volume, Gynecol. Oncol., 82, 11, 10.1006\u002Fgyno.2001.6252\nMeroni, 2004, T2 weighted MRI in the pre-operative assessment of myometrial and cervical invasions in endometrial carcinoma, Br J Radiol Congress Series, 30, 6\nO'Connel, 1998, Triage of abnormal postmenopausal bleeding: a comparaison of endometrial biopsy and transvaginal sonohysterography versus fractional curettage with hysteroscopy, Am. J. Obstet. Gynecol., 178, 956, 10.1016\u002FS0002-9378(98)70530-7\nKim, 1994, Uterine cervical carcinoma: evaluation of pelvic lymph node metastasis with MR imaging, Radiology, 190, 807, 10.1148\u002Fradiology.190.3.8115631\nBipat, 2003, Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review, Gynecol. Oncol., 91, 59, 10.1016\u002FS0090-8258(03)00409-8\nRockall, 2005, Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer, J. Clin. Oncol., 23, 2813, 10.1200\u002FJCO.2005.07.166\nManfredi, 2004, Local-regional staging of endometrial carcinoma: role of MR imaging in surgical planning, Radiology, 231, 372, 10.1148\u002Fradiol.2312021184\nAscher, 2002, Imaging of cancer of the endometrium, Radiol. Clin. North Am., 40, 563, 10.1016\u002FS0033-8389(01)00013-6\nBerman, 1980, Prognosis and treatment of endometrial cancer, Am. J. Obstet. Gynecol., 136, 679, 10.1016\u002F0002-9378(80)91024-8\nChao, 2006, 18F-FDG PET in the management of endometrial cancer, Eur. J. Nucl. Med. Mol. Imaging, 33, 36, 10.1007\u002Fs00259-005-1876-y\nHorowitz, 2004, Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer, Gynecol. Oncol., 95, 546, 10.1016\u002Fj.ygyno.2004.08.009\nSood, 1997, Value of preoperative CA125 level in the management of uterine cancer and prediction of clinical outcome, Obstet. Gynecol., 90, 441, 10.1016\u002FS0029-7844(97)00286-X\nDotters, 2000, Preoperative CA125 in endometrial cancer: is it useful?, Am. J. Obstet. Gynecol., 182, 1328, 10.1067\u002Fmob.2000.106251\nMorrow, 1991, Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study, Gynecol. Oncol., 40, 55, 10.1016\u002F0090-8258(91)90086-K\nCreasman, 1981, Pronostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals, Am. J. Obstet. Gynecol., 141, 921, 10.1016\u002FS0002-9378(16)32684-9\nSaga, 2006, Is peritoneal cytology a prognostic factor of endometrial cancer confined to the uterus?, Gynecol. Oncol., 103, 277, 10.1016\u002Fj.ygyno.2006.03.003\nTurner, 1989, The pronostic significance of peritonel cytology for stage I endometrial cancer, Obstet. Gynecol., 74, 775\nObermair, 2000, Peritoneal cytology: impact on disease-free survival in clinical stage I endometrioïd adenocarcinoma of the uterus, Cancer Lett., 164, 105, 10.1016\u002FS0304-3835(00)00722-9\nKasamatsu, 2003, Pronostic significance of peritoneal cytology in endometrial carcinoma confined to the uterus, Br. J. Cancer, 88, 245, 10.1038\u002Fsj.bjc.6600698\nTebeu, 2004, Positive peritoneal cytology in early-stage endometrial cancer does not influence prognosis, Br. J. Cancer, 91, 720, 10.1038\u002Fsj.bjc.6602035",{"ES":1258},"Cáncer de endometrio",{"VOID":1260},"10.1016\u002Fs1283-081x(09)70794-5","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X09707945",[1263,1278,1293,1308],{"id":1264,"sortIndex":59,"researcher":26,"roles":1265,"affiliations":1266,"properties":1275},"cef910cc-fa95-4bae-8172-8046433edf2f",[696],[1267],{"id":26,"sortIndex":36,"affiliation":1268,"properties":26},{"id":1269,"createTime":1270,"updateTime":1270,"relativeEntities":1271,"slug":26,"properties":1272,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"790aef77-2587-4290-96a5-b3728d6154d7","2023-12-28T21:25:20.452+00:00",[],{"title":1273},{"VI":1274},"Service d'anatomie pathologique, Hôpital Jeanne de Flandre, Centre hospitalier régional universitaire de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France",{"title":1276},{"VI":1277},"M.-O. Farine",{"id":1279,"sortIndex":114,"researcher":26,"roles":1280,"affiliations":1281,"properties":1290},"d31b973b-ee99-47cf-ae97-31689369e959",[696],[1282],{"id":26,"sortIndex":36,"affiliation":1283,"properties":26},{"id":1284,"createTime":1285,"updateTime":1285,"relativeEntities":1286,"slug":26,"properties":1287,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"cecee8a2-37a4-4d94-9091-7ab927f86a9f","2023-12-28T21:25:20.437+00:00",[],{"title":1288},{"VI":1289},"Service de radiologie, Hôpital Jeanne de Flandre, Centre hospitalier régional universitaire de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France",{"title":1291},{"VI":1292},"E. Poncelet",{"id":1294,"sortIndex":115,"researcher":26,"roles":1295,"affiliations":1296,"properties":1305},"84006b33-c306-4c93-9b75-ac620154bf45",[696],[1297],{"id":26,"sortIndex":36,"affiliation":1298,"properties":26},{"id":1299,"createTime":1300,"updateTime":1300,"relativeEntities":1301,"slug":26,"properties":1302,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6c25f16e-a544-4f68-9f28-7f0cc22dbc6a","2023-12-28T21:25:20.402+00:00",[],{"title":1303},{"VI":1304},"Service de chirurgie gynécologique, Hôpital Jeanne de Flandre, Centre hospitalier régional universitaire de Lille, 2, avenue Oscar-Lambret, 59037 Lille cedex, France",{"title":1306},{"VI":1307},"P. Collinet",{"id":1309,"sortIndex":36,"researcher":26,"roles":1310,"affiliations":1311,"properties":1317},"4789b1fe-417d-4eb8-a059-6833ff9b4245",[696],[1312],{"id":26,"sortIndex":36,"affiliation":1313,"properties":26},{"id":1299,"createTime":1300,"updateTime":1300,"relativeEntities":1314,"slug":26,"properties":1315,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1316},{"VI":1304},{"title":1318},{"VI":1319},"D. Vinatier",{"url":1261,"publisher":1321,"properties":1329},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":1322,"slug":662,"properties":1323,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1326,"manageAffiliations":1327,"indexDatabases":1328,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":1324,"title":1325},{"VOID":665},{"EN":667},[],[],[],{"volume":1330,"pages":1331},{"VOID":1138},{"VOID":1245},{"id":1333,"createTime":1334,"updateTime":1335,"relativeEntities":1336,"slug":1337,"properties":1338,"entityType":688,"verifyStatus":25,"verifyTime":1335,"verifyNote":690,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1345,"fullTextUrl":26,"authors":1346,"publicationType":747,"publisherRelationship":1410,"citationCount":26,"citationInfo":26,"publishDate":1424,"publishYear":1425,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"95c1d447-6c9b-413a-ab19-a2d1b3795194","2023-12-05T11:51:49.537+00:00","2025-02-10T04:17:31.296+00:00",[],"Adenomiosis-tratamiento",{"references":1339,"title":1341,"doi":1343},{"VOID":1340},"Mori, 1991, Animal model of uterine adenomyosis: is prolactin a potent inducer of adenomyosis in mice?, Am J Obstet Gynecol, 165, 232, 10.1016\u002F0002-9378(91)90258-S\nUeki, 2004, Expression of apoptotisis-related proteins in adenomyotic uteri treated with danazol and GnRH agonists, Int J Gynecol Pathol, 23, 248, 10.1097\u002F01.pgp.0000130109.80359.57\nMaia, 2005, Effect of menstrual cycle and hormonal treatment on ki-67 and bcl-2 expression and adenomyosis, Gynecol Endocrinol, 20, 127, 10.1080\u002F09513590400021086\nRoman, 2008, Hiérarchisation des stratégies thérapeutiques pour ménométrorragies avec ou sans désir de grossesse, J Gynecol Obstet Biol Reprod, 37, S405, 10.1016\u002FS0368-2315(08)74781-1\nFalk, 1989, Exacerbation of adenomyosis symptomatology by estrogen-progestin therapy: a case report and histopathological observations, Int J Fertil, 34, 386\nNegami, 1993, Therapeutic effects of Danazol on endometrial cells may be activated by the presence of extracellular matrix, Am J Obstet Gynecol, 169, 739, 10.1016\u002F0002-9378(93)90655-3\nTanaka, 1999, Danazol effects on human endometrial cells in vitro, Clin Exp Obstet Gynecol, 26, 67\nLuisi, 2009, Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age, Fertil Steril, 92, 1351, 10.1016\u002Fj.fertnstert.2008.08.017\nNelson, 1993, Long-term management of adenomyosis with a gonadotropin-releasing hormone agonist: a case report, Fertil Steril, 59, 444, 10.1016\u002FS0015-0282(16)55704-5\nLin, 2000, Gonadotropin-releasing hormone agonist and laparoscopy in treatment of adenomyosis with infertility, Chin Med J Engl, 113, 442\nHuang, 1999, Effects of short-course buserelin therapy on adenomyosis with infertility, J Reprod Med, 44, 741\nBadawy, 2012, Aromatase inhibitors or gonadotropin-releasing hormone agonists for the management of uterine adenomyosis: a randomized controlled trial, Acta Obstet Gynecol Scand, 91, 489, 10.1111\u002Fj.1600-0412.2012.01350.x\nMorelli, 2013, Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study, Gynecol Endocrinol, 29, 305, 10.3109\u002F09513590.2012.743017\nAkira, 2009, Efficacy of long-term, low-dose gonadotropin-releasing hormone agonist therapy (draw-back therapy) for adenomyosis, Med Sci Monit, 15, CR1\nKang, 2010, Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis, Gynecol Obstet Invest, 69, 73, 10.1159\u002F000258683\nFriedman, 1993, Gonadotrophin releasing hormone agonist plus estrogen progestin « add-back » therapy for endometriosis related pelvic pain, Fertil Steril, 60, 236, 10.1016\u002FS0015-0282(16)56090-7\nFedele, 1997, Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device, Fertil Steril, 68, 426, 10.1016\u002FS0015-0282(97)00245-8\nFong, 1999, Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system, Contraception, 60, 173, 10.1016\u002FS0010-7824(99)00075-X\nIgarashi, 2000, Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device, Fertil Steril, 74, 412, 10.1016\u002FS0015-0282(00)00624-5\nLaoag-Fernandez, 2003, Effects of levonorgestrel-releasing intra-uterine system on the expression of vascular endothelial growth factor and adrenomedullin in the endometrium in adenomyosis, Hum Reprod, 18, 694, 10.1093\u002Fhumrep\u002Fdeg179\nHe, 2005, Effect of levonorgestrel-releasing intrauterine system in the treatment of adenomyosis, Zhonghua Fu Chan Ke Za Zhi, 40, 536\nOzdegirmenci, 2011, Comparison of levonorgestrel intrauterine system versus hysterectomy on efficacy and quality of life in patients with adenomyosis, Fertil Steril, 95, 497, 10.1016\u002Fj.fertnstert.2010.10.009\nSheng, 2009, The LNG-IUS study on adenomyosis: a 3-year follow-up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis, Contraception, 79, 189, 10.1016\u002Fj.contraception.2008.11.004\nCho, 2008, Clinical effects of the levonorgestrel-releasing intrauterine device in patients with adenomyosis, Am J Obstet Gynecol, 198, 10.1016\u002Fj.ajog.2007.10.798\nKelekci, 2012, Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis, Contraception, 86, 458, 10.1016\u002Fj.contraception.2012.04.001\nPeng, 2010, Insertion of the Mirena intrauterine system for treatment of adenomyosis-associated menorrhagia: a novel method, Taiwan J Obstet Gynecol, 49, 160, 10.1016\u002FS1028-4559(10)60034-4\nZhang, 2013, Efficacy of combined levonorgestrel-releasing intrauterine system with gonadotropin-releasing hormone analog for the treatment of adenomyosis, Med Princ Pract, 22, 480, 10.1159\u002F000351431\nZhang, 2008, Evaluation of the efficacy of a danazol-loaded intrauterine contraceptive device on adenomyosis in an ICR mouse model, Hum Reprod, 23, 2024, 10.1093\u002Fhumrep\u002Fden208\nZhou, 2000, Effects of mifepristone (RU486) treatment on the development of uterine adenomyosis induced by pituitary grafting in mice, Life Sci, 67, 2713, 10.1016\u002FS0024-3205(00)00850-X\nNagasawa, 1989, Stimulation of mammary tumourigenesis and inhibition of uterine adenomyosis by suppressed progesterone effects in SHN mice, Anticancer Res, 9, 827\nFerrero, 2008, Deep dyspareunia: causes, treatments, and results, Curr Opin Obstet Gynecol, 20, 394, 10.1097\u002FGCO.0b013e328305b9ca\nXue, 2013, Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis, Reproduction, 146, 397, 10.1530\u002FREP-13-0135\nLiu, 2011, Valproic acid alleviates generalized hyperalgesia in mice with induced adenomyosis, J Obstet Gynaecol Res, 37, 696, 10.1111\u002Fj.1447-0756.2011.01655.x\nLiu, 2010, Valproic acid as a therapy for adenomyosis: a comparative case series, Reprod Sci, 17, 904, 10.1177\u002F1933719110373807\nBrun, 1997, Results and factors influencing the outcome of 203 transcervical endometrial resections, J Gynecol Surg, 13, 57, 10.1089\u002Fgyn.1997.13.57\nMergui, 1995, Adénomyose : place du traitement hystéroscopique, Contracept Fertil Sex, 23, 590\nTresserra, 1999, Morphological changes in hysterectomies after endometrial ablation, Hum Reprod, 14, 1473, 10.1093\u002Fhumrep\u002F14.6.1473\nRaiga, 1994, Facteurs d’échec d’endométrectomie : à propos d’une série de 196 cas, J Gynecol Obstet Biol Reprod, 23, 274\nPreutthipan, 2010, Hysteroscopic rollerball endometrial ablation as an alternative treatment for adenomyosis with menorrhagia and\u002For dysmenorrhea, J Obstet Gynaecol Res, 36, 1031, 10.1111\u002Fj.1447-0756.2010.01251.x\nMcCausland, 1996, Depth of endometrial penetration in adenomyosis helps determine outcome of rollerball ablation, Am J Obstet Gynecol, 174, 1786, 10.1016\u002FS0002-9378(96)70211-9\nMaia, 2003, Insertion of Mirena® after endometrial resection in patients with adenomyosis, J Am Assoc Gynecol Laparosc, 10, 512, 10.1016\u002FS1074-3804(05)60158-2\nMaia, 2012, Effect of a hormone-releasing intrauterine system (Mirena®) on aromatase and Cox-2 expression in patients with adenomyosis submitted or not to endometrial resection, Int J Womens Health, 4, 175, 10.2147\u002FIJWH.S30087\nAbbott, 2003, A double-blind randomised trial comparing the Cavaterm™ and the NovaSure endometrial ablation systems for the treatment of dysfunctional uterine bleeding, Fertil Steril, 80, 203, 10.1016\u002FS0015-0282(03)00549-1\nGoldrath, 2003, Evaluation of HydroThermAblator and rollerball endometrial ablation for menorrhagia 3 years after treatment, J Am Assoc Gynecol Laparosc, 10, 505, 10.1016\u002FS1074-3804(05)60157-0\nAmso, 2003, Uterine endometrial thermal balloon therapy for the treatment of menorrhagia: long-term multicentre follow-up study, Hum Reprod, 18, 1082, 10.1093\u002Fhumrep\u002Fdeg206\nBrun, 2008, Modalités et efficacité des traitements médicaux et chirurgicaux devant des ménométrorragies organiques, J Gynecol Obstet Biol Reprod, 37, S368, 10.1016\u002FS0368-2315(08)74778-1\nMaillet, 2013, Evaluation de l’endométrectomie par radiofréquence chez les femmes préménopausiques : étude rétrospective sur 90 cas, J Gynecol Obstet Biol Reprod, 42, 458, 10.1016\u002Fj.jgyn.2013.05.001\nMiddleton, 2010, Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patients, Br Med J, 341, c3929, 10.1136\u002Fbmj.c3929\nDaniels, 2012, Second generation endometrial ablation techniques for heavy menstrual bleeding: network meta-analysis, Br Med J, 344, e2564, 10.1136\u002Fbmj.e2564\nMartyn, 1998, Long-term follow-up of endometrial ablation, J Am Assoc Gynecol Laparosc, 5, 115, 10.1016\u002FS1074-3804(98)80075-3\nWood, 1998, Surgical and medical treatment of adenomyosis, Hum Reprod Update, 4, 323, 10.1093\u002Fhumupd\u002F4.4.323\nOsada, 2011, Surgical procedure to conserve the uterus for future pregnancy in patients suffering from massive adenomyosis, Reprod Biomed Online, 22, 94, 10.1016\u002Fj.rbmo.2010.09.014\nWang, 2009, Safety and efficacy of high intensity focused ultrasound ablation therapy for adenomyosis, Acad Radiol, 16, 1416, 10.1016\u002Fj.acra.2009.06.005\nFan, 2012, Feasibility of MRI-guided high intensity focused ultrasound treatment for adenomyosis, Eur J Radiol, 81, 3624, 10.1016\u002Fj.ejrad.2011.05.036\nHuang, 2003, Incomplete vaginal expulsion of pyoadenomyoma with sepsis and focal bladder necrosis after uterine artery embolization for symptomatic adenomyosis: case report, Hum Reprod, 18, 167, 10.1093\u002Fhumrep\u002Fdeg035\nKim, 2004, Uterine artery embolization for adenomyosis without fibroids, Clin Radiol, 59, 520, 10.1016\u002Fj.crad.2003.11.018\nPelage, 2005, Midterm results of uterine artery embolisation for symptomatic adenomyosis, Radiology, 234, 948, 10.1148\u002Fradiol.2343031697\nBratby, 2009, Uterine artery embolisation for symptomatic adenomyosis–mid-term results, Eur J Radiol, 70, 128, 10.1016\u002Fj.ejrad.2007.12.009\nPopovic, 2011, Uterine artery embolization for the treatment of adenomyosis: a review, J Vasc Interv Radiol, 22, 901, 10.1016\u002Fj.jvir.2011.03.013\nKim, 2011, Uterine artery embolization for symptomatic adenomyosis: a new technical development of the 1-2-3 protocol and predictive factors of MR imaging affecting outcomes, J Vasc Interv Radiol, 22, 497, 10.1016\u002Fj.jvir.2011.01.426\nJung, 2012, Prediction of early response to uterine arterial embolisation of adenomyosis: value of T2 signal intensity ratio of adenomyosis, Eur Radiol, 22, 2044, 10.1007\u002Fs00330-012-2436-z\nWang, 2002, Laparoscopic uterine artery ligation for treatment of symptomatic adenomyosis, J Am Assoc Gynecol Laparosc, 9, 293, 10.1016\u002FS1074-3804(05)60407-0\nBrun, 2006, Cavaterm thermal balloon endometrial ablation versus hysteroscopic endometrial resection to treat menorrhagia: the French, multicenter, randomized study, J Min Inv Gynecol, 13, 424, 10.1016\u002Fj.jmig.2006.05.006\nHuang, 2012, Fertility outcome of infertile women with adenomyosis treated with the combination of a conservative microsurgical technique and GnRH agonist: long-term follow-up in a series of nine patients, Taiwan J Obstet Gynecol, 51, 212, 10.1016\u002Fj.tjog.2012.04.008\nCampo, 2012, Adenomyosis and infertility, Reprod Biomed Online, 24, 35, 10.1016\u002Fj.rbmo.2011.10.003\nSalim, 2012, Adenomyosis reduces pregnancy rates in infertile women undergoing IVF, Reprod Biomed Online, 25, 273, 10.1016\u002Fj.rbmo.2012.05.003\nZhou, 2013, Study on leuprorelin acetate in treatment of uterine adenomyosis with infertility, Zhonghua Fu Chan Ke Za Zhi, 48, 334\nNiu, 2013, Long-term pituitary downregulation before frozen embryo transfer could improve pregnancy outcomes in women with adenomyosis, Gynecol Endocrinol, 29, 1026, 10.3109\u002F09513590.2013.824960\nMijatovic, 2010, Adenomyosis has no adverse effects on IVF\u002FICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF\u002FICSI, Eur J Obstet Gynecol Reprod Biol, 151, 62, 10.1016\u002Fj.ejogrb.2010.02.047",{"ES":1342},"Adenomiosis: tratamiento",{"VOID":1344},"10.1016\u002Fs1283-081x(15)72833-x","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X1572833X",[1347,1361,1386,1398],{"id":1348,"sortIndex":59,"researcher":26,"roles":1349,"affiliations":1350,"properties":1359},"5147470d-7b0a-4c54-89d6-0791a1c58201",[696],[1351],{"id":26,"sortIndex":36,"affiliation":1352,"properties":26},{"id":1353,"createTime":1354,"updateTime":1354,"relativeEntities":1355,"slug":26,"properties":1356,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"4373c3ed-ad1f-49ac-84a5-de6ab27f5377","2023-12-05T11:51:49.642+00:00",[],{"title":1357},{"VI":1358},"Service de gynécologie obstétrique, Hôpital de Bicêtre, 94275 Le Kremlin-Bicêtre, France",{"title":1360},{"VI":1172},{"id":1362,"sortIndex":36,"researcher":26,"roles":1363,"affiliations":1364,"properties":1383},"901df3cb-be85-456e-b3e6-5705e93efde9",[696],[1365,1375],{"id":1366,"sortIndex":115,"affiliation":1367,"properties":1374},"c29f74df-5a9e-4f71-a632-cd91593f6a2d",{"id":1368,"createTime":1369,"updateTime":1369,"relativeEntities":1370,"slug":26,"properties":1371,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"6f5613bd-a25e-4556-8950-c808d0f9c436","2023-12-05T11:51:19.502+00:00",[],{"title":1372},{"VI":1373},"UMR 5234, Microbiologie fondamentale et pathogénicité, Université Bordeaux Segalen, 33076 Bordeaux, France",{},{"id":26,"sortIndex":36,"affiliation":1376,"properties":26},{"id":1377,"createTime":1378,"updateTime":1378,"relativeEntities":1379,"slug":26,"properties":1380,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},"52d5e5ce-39bb-4da1-a6fe-6627d3ea0134","2023-12-05T11:51:19.498+00:00",[],{"title":1381},{"VI":1382},"Pôle d’obstétrique reproduction gynécologie, Centre Aliénor d’Aquitaine, Hôpital Pellegrin, 33076 Bordeaux, France",{"title":1384},{"VI":1385},"J.-L. Brun",{"id":1387,"sortIndex":114,"researcher":26,"roles":1388,"affiliations":1389,"properties":1395},"454cd9e7-a252-454b-9b52-42c51c283d00",[696],[1390],{"id":26,"sortIndex":36,"affiliation":1391,"properties":26},{"id":1353,"createTime":1354,"updateTime":1354,"relativeEntities":1392,"slug":26,"properties":1393,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1394},{"VI":1358},{"title":1396},{"VI":1397},"L. Pelage",{"id":1399,"sortIndex":115,"researcher":26,"roles":1400,"affiliations":1401,"properties":1407},"63eb1bb8-fb4c-48c0-92c8-65bf9e0c66cb",[696],[1402],{"id":26,"sortIndex":36,"affiliation":1403,"properties":26},{"id":1377,"createTime":1378,"updateTime":1378,"relativeEntities":1404,"slug":26,"properties":1405,"entityType":98,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36},[],{"title":1406},{"VI":1382},{"title":1408},{"VI":1409},"S. Fenomanana",{"url":1345,"publisher":1411,"properties":1419},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":1412,"slug":662,"properties":1413,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1416,"manageAffiliations":1417,"indexDatabases":1418,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":1414,"title":1415},{"VOID":665},{"EN":667},[],[],[],{"volume":1420,"pages":1422},{"VOID":1421},"51",{"VOID":1423},"1-10","2015-09-01",2015,{"id":1427,"createTime":1428,"updateTime":1428,"relativeEntities":1429,"slug":26,"properties":1430,"entityType":688,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"primaryUrl":1437,"fullTextUrl":26,"authors":1438,"publicationType":747,"publisherRelationship":1446,"citationCount":26,"citationInfo":26,"publishDate":1459,"publishYear":1460,"citationAnalyzeStatus":28,"lastCitationAnalyze":26,"indexDatabases":26,"openAccess":26,"references":26,"isForceReanalyzing":772},"31a7f9d6-93d1-402c-be84-14a37a565937","2023-12-12T01:24:20.491+00:00",[],{"references":1431,"title":1433,"doi":1435},{"VOID":1432},"Lacroix, 2000, Prescription of drugs during pregnancy in France, Lancet, 356, 1735, 10.1016\u002FS0140-6736(00)03209-8\nGarcia, 2000, Prescription médicamenteuse chez la femme enceinte dans le département de la Loire, Therapie, 55, 605\nBeyens, 2003, Prescription of drugs to pregnant women in France: the HIMAGE study, Therapie, 58, 505, 10.2515\u002Ftherapie:2003082\nOlesen, 2006, Associations between socio-economic factors and the use of prescription medication during pregnancy: a population-based study among 19,874 Danish women, Eur. J. Clin. Pharmacol., 62, 547, 10.1007\u002Fs00228-006-0119-x\nEgen-Lappe, 2004, Drug prescription in pregnancy: analysis of a large statutory sickness fund population, Eur. J. Clin. Pharmacol., 60, 659, 10.1007\u002Fs00228-004-0817-1\nAndrade, 2004, Prescription drug use in pregnancy, Am. J. Obstet. Gynecol., 191, 398, 10.1016\u002Fj.ajog.2004.04.025\nLee, 2006, National patterns of medication use during pregnancy, Pharmacoepidemiol. Drug Saf., 15, 537, 10.1002\u002Fpds.1241\nMattison, 2006, Gaps in knowledge in treating pregnant women, Gend Med, 3, 169, 10.1016\u002FS1550-8579(06)80205-6\nGlover, 2003, Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population, Am. J. Obstet. Gynecol., 188, 1039, 10.1067\u002Fmob.2003.223\nNordeng, 2004, Use of herbal drugs in pregnancy: A survey among 400 Norwegian women, Pharmacoepidemiol Drug Sail, 13, 371, 10.1002\u002Fpds.945\nSchirm, 2004, Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system, Eur. J. Obstet. Gynecol. Reprod. Biol., 114, 182, 10.1016\u002Fj.ejogrb.2003.10.024\nHeadley, 2004, Medication use during pregnancy: data from the Avon Longitudinal Study of Parents and Children, Eur. J. Clin. Pharmacol., 60, 355, 10.1007\u002Fs00228-004-0775-7\nCzeizel, 2009, The estimation of human teratogenic\u002Ffetotoxic risk of exposures to drugs on the basis of Hungarian experience: a critical evaluation of clinical and epidemiological models of human teratology, Expert Opin. Drug Saf., 8, 283, 10.1517\u002F14740330902916459\nBuhimschi, 2009, Medications in pregnancy and lactation: part 1. Teratology, Obstet. Gynecol., 113, 166, 10.1097\u002FAOG.0b013e31818d6788\nAugustine-Rauch, 2007, Alternative experimental approaches for interpreting skeletal findings in safety studies, Birth Defects Res B Dev Reprod Toxicol, 80, 497, 10.1002\u002Fbdrb.20132\nAugustine-Rauch, 2008, Predictive teratology: teratogenic risk-hazard identification partnered in the discovery process, Curr. Drug Metab., 9, 971, 10.2174\u002F138920008786485137\nMohan, 2007, Computer-assisted methods in chemical toxicity prediction, Mini Rev. Med. Chem., 7, 499, 10.2174\u002F138955707780619554\nØstensen, 2009, Management of RA medications in pregnant patients, Nat Rev Rheumatol, 5, 382, 10.1038\u002Fnrrheum.2009.103\nMir, 2010, Taxanes for breast cancer during pregnancy: a systematic review, Ann. Oncol., 21, 425, 10.1093\u002Fannonc\u002Fmdp517\nMawer, 2010, Pregnancy with epilepsy: obstetric and neonatal outcome of a controlled study, Seizure, 19, 112, 10.1016\u002Fj.seizure.2009.11.008\n2007, Prakash, Prabhu LV, Nasar MA, Rai R, Madhyastha S, Singh G. Lamotrigine in pregnancy: safety profile and the risk of malformations, Singapore Med. J., 48, 880\nNguyen, 2009, Teratogenesis associated with antibipolar agents, Adv. Ther., 26, 281, 10.1007\u002Fs12325-009-0011-z\nSerreau, 2006, Placental transfer of drugs, 285\nJacqz Aigrain E, Serreau R. Pharmacologie fœto-maternelle : risques des médicaments en cours de grossesse, traitements médicamenteux du fœtus. EMC (Elsevier Masson SAS, Paris), Pédiatrie, 4-002-M-10, 2002 : 7p.\nMenon, 2008, Psychotropic medication during pregnancy and lactation, Arch. Gynecol. Obstet., 277, 1, 10.1007\u002Fs00404-007-0433-2\nWatts, 2007, Teratogenicity risk of antiretroviral therapy in pregnancy, Curr HIV\u002FAIDS Rep, 4, 135, 10.1007\u002Fs11904-007-0020-y\nSoldin, 2008, Triptans in pregnancy, Ther. Drug Monit., 30, 5, 10.1097\u002FFTD.0b013e318162c89b\nKlieger, 2008, Treating the mother--protecting the unborn: the safety of hypoglycemic drugs in pregnancy, J. Matern. Fetal Neonatal Med., 21, 191, 10.1080\u002F14767050801929653\nMir, 2008, Use of platinum derivatives during pregnancy, Cancer, 113, 3069, 10.1002\u002Fcncr.23935\nSchinkel, 1997, The physiological function of drug-transporting pglycoproteins, Semin. Cancer Biol., 8, 161, 10.1006\u002Fscbi.1997.0068\nTanabe, 2001, Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene, J. Pharmacol. Exp. Ther., 297, 1137\nLankas, 1997, P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances vermectin induced neurotoxicity, Toxicol. Appl. Pharmacol., 143, 357, 10.1006\u002Ftaap.1996.8086\nMolsa, 2005, Functional role of P-glycoprotein in the human blood-placental barrier, Clin. Pharmacol. Ther., 78, 123, 10.1016\u002Fj.clpt.2005.04.014\nSmit, 1999, Absence or pharmacological blocking of placental Pglycoprotein profoundly increases fetal drug exposure, J. Clin. Invest., 104, 1441, 10.1172\u002FJCI7963\nAtkinson, 2003, Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer, Am. J. Physiol. Cell Physiol., 285, C584, 10.1152\u002Fajpcell.00418.2002\nNagashige, 2003, Basal membrane localization of MRP1 in human placental trophoblast, Placenta, 24, 951, 10.1016\u002FS0143-4004(03)00170-X\nHooijberg, 2004, Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1), Biochem. Pharmacol., 67, 1541, 10.1016\u002Fj.bcp.2003.12.022\nIfergan, 2004, Folate deprivation results in the loss of breast cancer resistance protein (BCRP\u002FABCG2) expression: a role for BCRP in cellular folate homeostasis, J. Biol. Chem., 279, 25527, 10.1074\u002Fjbc.M401725200\nGennuso, 2004, Bilirubin protects astrocytes from its own toxicity by inducing up-regulation and translocation of multidrug resistance-associated protein 1 (Mrp1), Proc. Natl. Acad. Sci. USA, 101, 2470, 10.1073\u002Fpnas.0308452100\nMadon, 2000, Transport function and hepatocellular localization of mrp6 in rat liver, Mol. Pharmacol., 57, 634, 10.1124\u002Fmol.57.3.634\nSt-Pierre, 2000, Expression of members of the multidrug resistance protein family in human term placenta, Am. J. Physiol. Regul. Integr. Comp. Physiol., 279, R1495, 10.1152\u002Fajpregu.2000.279.4.R1495\nGunshin, 1997, Cloning and characterization of a mammalian proton-coupled metal-ion transporter, Nature, 388, 482, 10.1038\u002F41343\nAllikmets, 1998, A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance, Cancer Res., 58, 5337\nMiyake, 1998, Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone- resistant cells: 7 breast cancer cells, Proc. Natl. Acad. Sci. USA, 95, 15665\nAFSSAPS. Rappel sur la contre-indication des antagonistes des récepteurs à l'angiotensine II au cours des 2es et 3es trimestres de grossesse, lettre aux prescripteurs, juin 2003, agmed.sante.gouv.fr\u002Fhtm\u002F10\u002Ffilltrpsc\u002Flp030602.htm.\nSerreau, 1999, Developmental toxicity of the angiotensine II type 1 receptor antagonists human demonstration of homology to ABC transport genes, Cancer Res., 59, 8\nDoyle, 2005, A multidrug resistance transporter from human MCF- pregnancy a report of 10 cases, BJOG, 112, 710\nMartinovic, 2001, Fetal toxic effects and angiotensin-II-receptor antagonists, Lancet, 358, 241, 10.1016\u002FS0140-6736(01)05426-5\nRamasubbu, 2004, Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review, J. Clin. Psychiatry, 65, 1642, 10.4088\u002FJCP.v65n1209\nGuittin, 2002, Future improvements and implementation of animal care practices within the animal testing regulatory environment, ILAR J., 43, S80, 10.1093\u002Filar.43.Suppl_1.S80\n2005, Prescrire. « Éviter les rétinoïdes en application cutanée pendant la grossesse, Rev Prescrire, 25, 106\nRecommandations médicaments et grossesse du dictionnaire Vidal® (accès libre ; mise à jour : 12 novembre 2009) avec les références et sites internationaux ; arbre décisionnel.\nwww.vidalrecos.fr\u002Fpages\u002Findex.php?idannexe=2585&titre=Prescription_et_populations_particulieres_Medicaments_et_grossesse&prov=acc.\nAfssaps – octobre 2009 – actualité thalidomide et plan de gestion de risque www.afssaps.fr\u002Fvar\u002Fafssaps_site\u002Fstorage\u002Foriginal\u002Fapplication\u002F47fdcdc60cd555fe67ba5ba652a36495.pdf.\nCentre de références sur les agents tératogènes (CRAT) www.lecrat.org\u002F.\nIconographie d'un hypocalvaria fœtal après une exposition in utero aux IEC : http:\u002F\u002Fjasn.asnjournals.org\u002Fcgi\u002Freprint\u002F3\u002F9\u002F1575.\nDysgénésie rénale après exposition IEC ou sartans : www.humpath.com\u002Frenal-tubular-dysgenesis.",{"ES":1434},"Teratología y uso de medicamentos durante el embarazo",{"VOID":1436},"10.1016\u002Fs1283-081x(11)71084-0","https:\u002F\u002Fwww.sciencedirect.com\u002Fscience\u002Farticle\u002Fpii\u002FS1283081X11710840",[1439],{"id":1440,"sortIndex":36,"researcher":26,"roles":1441,"affiliations":1442,"properties":1443},"1a90059d-f00e-4d93-b772-61e905070016",[696],[],{"title":1444},{"VI":1445},"R. Serreau",{"url":1437,"publisher":1447,"properties":1455},{"id":659,"createTime":660,"updateTime":660,"relativeEntities":1448,"slug":662,"properties":1449,"entityType":24,"verifyStatus":28,"verifyTime":26,"verifyNote":26,"syncStatus":28,"languages":26,"translateLanguages":26,"viewCount":36,"subjectFields":1452,"manageAffiliations":1453,"indexDatabases":1454,"url":26,"thumbnailPath":26,"statistic":26,"gsStatistic":26,"type":26,"analyzePriority":26},[],{"issn":1450,"title":1451},{"VOID":665},{"EN":667},[],[],[],{"volume":1456,"pages":1458},{"VOID":1457},"47",{"VOID":1423},"2011-01-01",2011]